Note: Descriptions are shown in the official language in which they were submitted.
CA 02341777 2001-03-02
NEUTRAL AMINO ACID TRANSPORTER AND GENE THEREOF
Field of the Invention
The present invention relates to an amino acid transporter protein or a
part thereof, DNA coding for the protein or a part thereof, RNA coding for the
protein or a part thereof, DNA hybridizing to the DNA, an expression vector
containing the DNA, a transformed cell transformed by the DNA or by the
vector, a
cell in which the RNA is introduced, an antibody or a part thereof having a
reactivity with the protein or a part thereof, a cell which produces the
antibody, a
labeled DNA in which a part of the DNA is radiolabeled, a labeled RNA in which
a
part of the RNA is radiolabeled, a labeled antibody in which the antibody or a
part
of the antibody is labeled, a kit comprising the labeled DNA, a kit comprising
the
labeled RNA, a kit comprising the labeled antibody, a pharmaceutical
composition
containing a part of the DNA, a pharmaceutical composition containing a part
of
the RNA, a pharmaceutical composition containing the antibody or a part of the
antibody, a method for determining whether the protein is expressed or for
measuring the expressed amount thereof, a method for identifying a substance
having an ability of inhibiting the biological activity of the protein, a
method for
identifying the substance having an ability of inhibiting the transcription of
DNA
coding for the protein into mRNA, a method for identifying the substance
having
an ability of inhibiting the expression of the protein, a substance which is
identified by the identifying method and a transgenic mouse into which the DNA
coding for the protein of the present invention is introduced.
1
CA 02341777 2001-03-02
Background Art
Amino acids play a very important role not only as a substrate for protein
synthesis but also as a precursor in gluconeogenesis and in biosynthesis of
many
biomolecules such as porphyrin, purine and pyrimidine.
Most of such a biosynthesis reaction is carried out in cells and, therefore,
in the cells, various proteins which are generally called amino acid
transporters for
incorporating amino acid into the cells from outside of the cells are
contained in
cell membrane.
The amino acid transporter not only functions for supplying amino acids to
each cell but also is incorporated into tissues playing a role of an
epithelial
transport of amino acids in small intestine and renal tubule and a resorption
of
neurotransmitter in nervous tissue whereby it is oriented at an important
position
for the expression of a specific function of tissues.
With regard to an amino acid transport mechanism (an amino acid
transport system mediated by amino acid transporter), its identification and
classification have been carried out using cultured cells and cell membrane
samples since about 1960's and, reflecting the diversity of amino acid
molecules,
there have been identified amino acid transport systems mediated by various
amino acid transporters having different substrate specificity (Physiol. Rev.
Vol. 70,
p. 43-77, 1990).
However, such a transport system does not independently function to each
amino acid but each amino acid bears an intracellular transport for more than
one
amino acids using the more than one amino acids as substrates.
Amino acids are classified into basic amino acids (diamino/monocarboxylic
acids) having positive charge, acidic amino acids (monoamino/dicarboxylic
acids)
2
CA 02341777 2001-03-02
having negative charge and neutral amino acids (monoamino/monocarboxylic
acids; or those excluding basic amino acids or acidic amino acids). Because of
such a charge of amino acid, when a neutral amino acid or an acidic amino acid
having negative charge, for example, is transported into cells having negative
electric potential against the concentration gradient, it is necessary to
carry out an
active transport associated with some energy consumption.
From such a viewpoint, in amino acid transporters, that which shows a
dependency on sodium (Na') and that which shows an independency on Na' are
present like in the case of a sugar transport system. The Na+-dependent
transporter has a big concentrating ability since it is able to transport the
amino
acid against the concentration gradient by coupling amino acid transport with
Na'
transport and, therefore, it plays an important role in the site in a living
body
where formation of a big concentration difference mediated by cell membrane is
requested (Annual Rev Kidney "Structure and Function of Kidney-Specific
Organic Solute Transporters", p. 91-100, 1995, published by Chugai Igakusha).
Such a Na+-dependent transporter can be further classified into two families,
i.e.
an Na/Cl--dependent transporter family and an Na+/K--dependent transporter
family (Annual Rev. Neurosci., Vol. 16, p. 73-93, 1993 and FASEB J., Vol. 7,
p.
1450-1459, 1993).
Further, in combination of such a charge property, amino acid transporters
can be classified, in view of the substrate specificity, into molecule where
basic
amino acid (diamino/monocarboxylic acid) is a substrate, molecule where acidic
amino acid (monoamino/dicarboxylic acid) is a substrate and molecule where
neutral amino acid (monoamino/monocarboxylic acid; or that excluding basic
amino acid or acidic amino acid) is a substrate.
3
CA 02341777 2001-03-02
It has been known that, for example, a basic amino acid having amino
group or imidazole group on the side chain such as arginine, lysine and
histidine
(basic amino acid which is nearly neutral) is transported mostly by an Na+-
independent amino acid transporter y+ (J. Membrane Biol., Vol. 66, p. 213-225,
1982). It has been known that an acidic amino acid having carboxyl group on
the
side chain such as glutamic acid and aspartic acid is transported by an Na+-
dependent amino acid transporter X-A,G (Biochim. Biophys. Acta, Vol. 732, p.
24-31,
1983). In the case of transport of a neutral amino acid to which many amino
acids
belong, it has been known that an Na `-independent amino acid transporter L
(Ann.
Rev. Physiol., Vol. 46, p. 417-433, 1984) and Na+-dependent amino acid
transporters A and ASC (Ann. Rev. Physiol., Vol. 46, p. 417-433, 1984 and J.
Membrane Biol., Vol. 52, p. 83-92, 1980) play an important role (Physiol.
Rev., Vol.
70, p. 43-77, 1990 and Saishin Igaku, Vol. 50, p. 1997-2004, 1995).
As mentioned already, amino acids play a very important role as materials
in biosynthesis of various biocomponents taking place in cells and, therefore,
it is
presumed that abnormal transport of the amino acid into cell participates in
various symptoms.
It has been known from the studies up to now that the symptoms in which
abnormal transport mechanism of the amino acid into cells are participated are
aminoaciduia where disorder of amino acid resorption from renal tubule occurs
and amyotrophic lateral sclerosis, etc. in which disorder of glutamic acid
incorporation and nerve cell death are participated (Annual Rev. Kidney
"Structure and Function of Kidney-Specific Organic Solute Transporters", p. 91-
100, 1995, published by Chugai Igakusha; Saishin Igaku, Vol. 50, p. 1997-2004,
1995; and Saishin Igaku, Vol. 51, p. 64-70, 1996).
4
CA 02341777 2001-03-02
Amino acid transporters play an essential and very important role in
incorporation of amino acids necessary for generation, differentiation,
proliferation
and maintenance of all cells and, therefore, they are believed to participate
not
only in the above-mentioned symptoms but also in onset of many other symptoms.
In addition, when the indispensability of amino acid transporter in living
body is
taken into consideration, it is hardly concluded that incorporation of various
amino
acids is not mediated by several already-identified transporters only but it
is
believed that many other unknown amino acid transporters will be present.
Identification of such unknown amino acid transporters which play a role
essential for existence and maintenance of cells, tissues, organs and living
body
has a possibility of clarification of causes for onset of various diseases for
which the
causes have not been clarified yet. In addition, if the relation between such
amino acid transporters and various diseases is made clear, an effective
treatment
of such diseases will become possible by regulation of biological function or
expression of the amino acid transporters. Accordingly, it is a pressing need
to
identify new amino acid transporter and to clarify the relation between the
transporter molecule and a symptom.
However, in spite of medical and social needs as such, it is a current state
that there has been little progress in identification of an amino acid
transporter
and clarification of an amino acid transport mechanism.
Thus, in order to identify an amino acid transporter molecule, it is
necessary to purify the molecule and, in order to analyze the activity of the
purified substance, it is necessary to reconstitute the purified substance to
cell
membrane so that an amino acid transport activity is regenerated. However, an
amino acid transporter molecule has a relatively little expression amount as a
CA 02341777 2001-03-02
membrane protein and has a relatively small regenerating efficiency and,
therefore, there is a difficulty in the technique in the identification of new
molecules.
In addition, identification of an amino acid transporter which is
specifically expressed in abnormal cells directly participating in the symptom
such
as cancer cells (tumor cells) and plays a role of supplying an amino acid to
the
abnormal cells has a very important significance in the clarification of
existence
and proliferation of such symptom-related cells and also in the development of
therapeutic methods for cancer, etc. However, an amino acid transporter is
inherently a molecule essential for the existence of normal cells and is
believed to
be present in a wide range of cell species and, accordingly, it is not easy to
identify
an amino acid transporter molecule which is expressed specifically in such
abnormal cells.
As a neutral amino acid transporter, ASCT1 and ASCT2 have been cloned
as sodium-dependent transporters (Kanai, Curr. Opin. Cell Biol., 9, 565
(1997)).
However, the main substrates thereof are alanine, serine, cysteine, threonine
and
glutamine and their substrate specificity is different from a neutral amino
acid
transporting system L. Further, glycine transporter and proline transporter
have
been cloned but their substrate specificity is different from neutral amino
acid
transport system L (Amara and Kuhar, Annu. Rev. Neurosci., 16, 73 (1993)).
Although not a transporter per se, cDNAs of rBAT and 4F2hc which are a
type II membrane glycoprotein having only one transmembrane structure believed
to be an activating factor for an amino acid transporter have been cloned and
it has
been known that, when they are expressed in oocytes of Xenopus laevis, uptake
of
a basic amino acid is activated together with that of a neutral amino acid
(Palacin,
6
CA 02341777 2001-03-02
J Exp. Biol., 196, 123 (1994)).
Accordingly, it is an effective key for providing a therapeutic method for
the symptom and disease that an amino acid transporter molecule which has not
been identified yet and is specifically expressed in abnormal cells deeply
associated
with such a symptom is identified and that the relation between the molecule
and
existence/proliferation of the abnormal cells is clarified.
Thus, when the biological activity of the amino acid transporter molecule
or the expression of the molecule is controlled, it is now possible to treat
the
diseases.
The present inventors have paid their attention to the already-known cell
membrane surface molecule 4F2 (CD98) which is believed to be essential for the
proliferation of tumor cells in order to investigate a novel amino acid
transporter
which is specifically expressed in such symptom-related abnormal cells or,
particularly, tumor cells and have succeeded in identifying a novel amino acid
transporter molecule named LAT1 (L-type amino acid transporter-1) which is
particularly significantly expressed in tumor cells as compared with the
expression
in normal cells.
Thus, for a quick cell division and continuous growth and proliferation, the
tumor cells are to be provided with nutrients such as amino acids and
saccharides
thereinto and it is believed that such a providing is carried out by means of
an up-
regulation of an amino acid transporter which is specific to the nutrients
(Physiol.
Rev, Vol. 70, p. 43-77, 1990). For growth, proliferation and maintenance of
the
tumor cells, a protein biosynthesis is to be carried out in the cells and,
therefore,
incorporation of the essential amino acids into the cells (transport from
outside of
the cells to inside of the cells) is particularly important.
7
CA 02341777 2001-03-02
From the studies up to now, it has been believed that, for the proliferation
of tumor cells, a known cell membrane surface antigen named 4F2 (CD98)
classified into a type II membrane glycoprotein believed to have a function of
activating the amino acid transporter which has not been identified yet will
play
an important role (J. Immunol., Vol. 126, p. 1409-1414, 1981; J. Immunol.,
Vol. 129,
p. 623-628, 1982; Proc. Nat]. Acad. Sci. USA., Vol. 84, p. 6526-6530, 1987;
Cancer
Res., Vol. 46, p. 1478-1484, 1986; J. Biol. Chem., Vol. 267, p. 15285-15288,
1992;
Proc. Natl. Acad. Sci. USA, Vol. 89, p. 5606-5610, 1992; Biochem. J., Vol.
324, p.
535-541, 1997; and J. Exp. Biol., Vol. 196, p. 123-137, 1994).
Under such circumstances, the present inventors have carried out an
intensive investigation for identification of human tumor cell membrane
surface
molecule which conjugates or interacts with a 4F2 molecule and found a gene
coding for a novel amino acid transporter LATl having the following
characteristics whereupon the present invention has been accomplished.
Disclosure of the Invention
The amino acid transporter LAT1 or, particularly, the amino acid
transporter LAT1 derived from human being in accordance with the present
invention has the following characteristics.
(1) As a result of a northern blotting using tumor cells derived from human
being and mRNA derived from human normal tissues, its expression is noted as a
band of about 4.8 kb in tumor cells derived from human being of a wide range
including stomach signet ring cell carcinoma (KATO III), malignant melanoma (G-
361) and lung small cell carcinoma (RERF-LC-MA). In the human normal tissues,
its expression is similarly confirmed as a band of about 4.8 kb only in
specific and
8
CA 02341777 2001-03-02
limited tissues where neogenesis and proliferation of cells are vigorous
(placenta,
liver of fetus, bone marrow, testicle, brain and peripheral leukocytes).
(2) Open reading frame (ORF; including termination codon) has a base
sequence comprising 1,524 bases (a base sequence from 66th to 1589th bases in
the
base sequence mentioned in SEQ ID NO: I) and the ORF codes for an amino acid
sequence comprising 507 amino acids as a whole and has a molecular weight of
about 55 kDa (calculated value) (SEQ ID NO:2).
(3) As a result of a hydrophobic plot analysis, human LAT1 has 12
transmembrane regions and is identified as a membrane surface molecule having
a
phosphorylated site by tyrosine protein kinase (119th Tyr in an amino acid
sequence of SEQ ID NO:2) and a phosphorylated site by protein kinase C (189th
Ser and 346th Ser in an amino acid sequence of SEQ ID NO:2) in an
intracellular
region.
(4) In a cell in which human LAT1 and human 4F2hc (4F2 heavy chain)
are co-expressed, a very strong incorporation of leucine (Leu), isoleucine
(Ile),
phenylalanine (Phe), methionine (Met), tyrosine (Tyr), tryptophan (Trp) and
valine
(Val) which are neutral amino acids and histidine (His) which is a nearly
neutral
basic amino acid is confirmed. In addition, significant incorporation of
threonine,
cysteine, asparagine and glutamine which are other neutral amino acids is
confirmed as well.
(5) In a cell in which human LAT1 and human 4F2hc are co-expressed, not
only the incorporation of the above-mentioned amino acids but also known
incorporation of pharmaceuticals such as L-DOPA which is a remedy for
Parkinson's disease and physiologically active substance such as
triiodothyronine
(thyroid hormone) are confirmed. In addition, incorporation of BCH (2-amino-2-
9
CA 02341777 2001-03-02
norbornane-carboxylic acid) known as an inhibitor for incorporation of neutral
amino acids is confirmed as well.
(6) In a Michaelis-Menten kinetic test, a Km value showing the affinity of
the human LAT1 with the above-mentioned various substrates is about 21 VM.
(7) The above-mentioned incorporation of various amino acids,
pharmaceuticals and physiologically active substances mediated by LAT1 into
the
cells is not dependent upon Na' ion and Cl- ion.
Thus, the present invention discloses, for the first time in the world, an
amino acid transporter in which a specific expression is noted in tumor cells
of a
wide range as compared with normal cells and which is believed to be essential
for
existence and proliferation of various tumor cells having a wide substrate
specificity.
From the above-mentioned characteristics of the amino acid transporter
molecule of the present invention, the molecule is quite hopeful as a target
in the
development of an antitumor agent (anticancer agent) for example. Thus, when a
pharmaceutical agent having an activity of suppressing the biological activity
of
the molecule or the expression of the molecule (such as antisense DNA
pharmaceuticals, antisense RNA pharmaceuticals, antibody pharmaceuticals,
antibody fragment pharmaceuticals, peptide antagonist pharmaceuticals and non-
peptide antagonist pharmaceuticals including low-molecular compounds) is used
so as to suppress the incorporation of nutrients (various amino acids and
physiologically active substance) into tumor cells mediated by the molecule,
it is
now possible that the tumor cells are made in a hungry state and that
existence
and proliferation of the tumor cells are suppressed.
Accordingly, the protein of the present invention or a part thereof, DNA
CA 02341777 2003-09-12
coding for the protein or a part thereof, RNA coding for the protein or a part
thereof,
DNA hybridizing to the DNA, expression vector containing the DNA, transformed
cell transformed by the DNA or by the vector, a cell in which the RNA is
introduced,
antibody or a part thereof having a reactivity with the protein or a part
thereof, a cell
which produces the antibody, a labeled DNA in which a part of the DNA is
radiolabeled, a labeled RNA in which it part of the RNA is radiolabeled, a
labeled
antibody in which the antibody or a part of the antibody is labeled, a kit
comprising
the labeled DNA, a kit comprising the labeled RNA and a kit comprising the
labeled
antibody are quite useful as a pharmaceutical agent having such an antitumor
effect
and/or as a reagent in the development of such pharmaceuticals.
In addition, when the above-mentioned DNA, RNA or various substances of
the present invention such as transformed cell are used, it is also possible
to provide
various identifying methods (or assay methods) for such various
pharmaceuticals.
Brief Description of the drawings
Fig. 1 shows a homology in amino acid sequence of a human amino acid
transporter LAT1 with that of a rat amino acid transporter LAT1 wherein the
top row
of sequence corresponds with the human amino acid transporter LATI and the
bottom
row of sequence corresponds with the rat amino acid transporter LATI.
Fig. 2 shows hydrophilic and hydrophobic regions of a human amino acid
transporter LAT1 by a hydrophobic plot analysis. Numbers 1 to 12 identify the
transmembrane regions of LAT I.
Fig. 3 shows an expressed state of mRNA of a human amino acid transporter
LAT1 in various human tissues by a northern blotting.
Fig. 4 shows an incorporation activity of leucine into the cells of Xenopus
laevis oocytes wherein a human amino acid transporter LAT 1 and a human cell
11
CA 02341777 2001-03-02
membrane surface molecule 4F2hc are co-expressed.
Fig. 5 shows the amount of leucine incorporated into the cells when
Xenopus laevis oocytes wherein a human amino acid transporter LAT1 and a
human cell membrane surface molecule 4F2hc are co-expressed are incubated in
the presence of various salts.
Fig. 6 shows an affinity of a human amino acid transporter LAT1 to the
substrate in a Michaelis-Menten kinetic test.
Fig. 7 shows the amount of radiolabeled leucine as a substrate
incorporated into the cells when Xenopus laevis oocytes wherein a human amino
acid transporter LAT1 and a human cell membrane surface molecule 4F2hc are
co-expressed are incubated in the presence of various amino acids.
Fig. 8 shows the amount of radiolabeled phenylalanine as a substrate
incorporated into the cells when Xenopus laevis oocytes wherein a human amino
acid transporter LAT1 and a human cell membrane surface molecule 4F2hc are
co-expressed are incubated in the presence of amino acid or a pharmaceutical
agent.
Fig. 9 shows the amount of radiolabeled leucine as a substrate
incorporated into the cells when Xenopus laevis oocytes wherein a human amino
acid transporter LAT1 and a human cell membrane surface molecule 4F2hc are
co-expressed are incubated in the presence of amino acid or physiologically
active
substance.
Fig. 10 shows the amount of various radiolabeled amino acids as
substrates incorporated into the cells of Xenopus laevis oocytes wherein a
human
amino acid transporter LAT1 and a human cell membrane surface molecule 4F2hc
are co-expressed.
12
CA 02341777 2003-09-12
Fig. 11 shows the result the experiment of leucine incorporation by oocytes
into which mRNA derived from rat C6 glioma and/or cRNA of rat 4F2hc gene
are/is
injected.
Fig. 12 shows hydrophobic plots of a rat neutral amino acid transporter LATI.
Numbers 1-12 indicate the transmembrane regions of LAT I. Tyr-P indicates a
tyrosine phosphorylation site. PKC indicates a protein kinase C dependent
phosphorylation site.
Fig. 13 is a photograph as a substitute for a drawing which shows the result
of
analysis of expression of LATI gene mRNA in various organ tissues of rat by a
northern blotting.
Fig. 14 is a photograph as a substitute for a drawing which shows the result
of
comparison of expression of LATI gene mRNA in each culture cell line of rat
with
expression of LATI gene mRNA in the liver of rat by a northern blotting.
Fig. 15 is a photograph as a substitute for a thawing which shows the result
of
analysis of expression of LAT1 gene mRNA in each culture cell line of human
being
by northern blotting.
Fig. 16 shows the result where an experiment of incorporation of leucine using
oocytes into which rat LATI gene cRNA and/or rat 4F2hc gene cRNA are/is
injected
is carried out after 2 or 5 days after injection of cRNA.
Fig. 17 shows the result of testing the influence of added salt in an
experiment
of incorporation of leucine using oocytes into which rat LAT I gene cRNA and
rat
4F2hc gene cRNA are injected.
Fig. 18 shows the result of testing the influence of concentration of the
substrate leucine in an experiment of incorporation of leucine using oocytes
into
which rat LAT l gene cRNA and rat 4F2hc gene cRNA are injected.
Fig. 19 shows the result of testing the influence of addition of various amino
acids or similar compounds thereto on the system in an experiment of
13
CA 02341777 2001-03-02
incorporation of leucine using oocytes into which rat LAT1 gene cRNA and rat
4F2hc gene cRNA are injected.
Fig. 20 shows the result of testing the influence of addition of D-leucine or
BCH to a medium on cell proliferation in an cultured rat liver cell line.
Fig. 21 is a photograph as a substitute for a drawing which shows the
result of analysis of expression of LAT1 gene mRNA and 4F2hc gene mRNA in
cultured human tumor cell line by a northern blotting.
Fig. 22 is a photograph as a substitute for a drawing which shows the
result of analysis of expression of LAT1 gene mRNA and 4F2hc gene mRNA in
cultured human tumor cell line (leukemia cells) by a northern blotting.
Fig. 23 shows the result of Na` dependency of leucine incorporation of T24
cells.
Fig. 24. Upper graph shows the concentration dependency of T24 cells for
a leucine incorporation (Michaelis-Menten kinetic test); lower graph shows the
result of analysis of concentration dependency of T24 cells for a leucine
incorporation by Eadie-Hoffstee plots.
Fig. 25 shows the result of influence of addition of various amino acids or
similar compounds to the system in the leucine incorporation experiment by T24
cells.
Fig. 26 shows the result of analysis of the effect of BCH using double
reciprocal plots in a leucine incorporation experiment by T24 cells.
Fig. 27 shows the effect of BCH on the growth of T24 cells (A) and Daudi
cells (B).
Fig. 28 shows the result of investigation of survival effect by BCH, D-Leu
and D-Ala after intraperitoneal transplantation of mouse sarcoma 180 cells to
ICR
14
CA 02341777 2001-03-02
mouse.
Description of the Preferred Embodiments
Each of the various inventions in the present application specifically has
the following usefulness.
DNA, RNA and transformed cell of the present invention are useful not
only in the manufacture of the protein of the present invention as a
recombined
protein using a gene recombination technique but also as a reagent (tool) for
drug
design, screening and identification such as for a pharmaceutical agent for
controlling (activating, suppressing and inhibiting) the biological activity
of the
protein of the present invention, a pharmaceutical agent for inhibiting the
transcription of the protein of the present invention into mRNA, a
pharmaceutical
agent for inhibiting the translation of the mRNA into the protein of the
present
invention, a pharmaceutical agent for inhibiting the interaction of the
protein with
other molecule, etc.
To be more specific, DNA of the present invention can be used not only in
an assay for the identification of a pharmaceutical agent controlling the
biological
activity of the protein of the present invention but also in an assay for the
identification of a pharmaceutical agent controlling the expression of the
protein of
the present invention.
In the former assay, cells of mammals, etc. are transformed by DNA coding
for the amino acid transporter molecule of the present invention to express
the
molecule in the cells, the transformed cells are incubated in the coexistence
of the
test substance and the substrate (such as amino acid) for the molecule, the
numbers of the substrate incorporated into the cells thereby are compared with
the
CA 02341777 2001-03-02
incorporation in the control cells and the activity of the test substance to
the
control of the biological activity of the amino acid transporter of the
present
invention is evaluated.
The latter assay is represented by the so-called reporter gene assay which
is commonly used in the assay, screening and the identification of such a
pharmaceutical agent and by the so-called high through put screening where the
reporter gene assay is a principle and the screening is carried out by a
machine
(robot) (Soshiki Baiyo Kogaku, Vol. 23, No. 13, p. 521-524; and U. S. Patent
5, 670,113).
In the present invention, DNA coding for the amino acid transporter
molecule of the present invention, DNA coding for the expression regulation
control region of the DNA and DNA coding for a reporter protein molecule
emitting
the fluorescence such as luciferase are inserted in such a manner that,
depending
upon the expression of the transporter molecule, the reporter protein molecule
is
able to be expressed, the resulting expression vector is used for
transformation of
the cells which are commonly used in the manufacture of gene recombinant
protein,
the resulting transformed cells are contacted to the test compound, and the
amount of the transporter molecule which is expressed depending upon the
action
of the compound is indirectly measured by measuring the amount of the
fluorescence emitted from the reporter protein which is expressed together
with
the expression of the molecule whereupon it is analyzed whether the compound
affects the expression of the transporter molecule (U.S. Patent No. 5,436,128
and
U. S. Patent No. 5,401,629).
Moreover, the RNA of the present invention is able to be used for an assay
for the identification of a pharmaceutical agent which controls the biological
16
CA 02341777 2001-03-02
activity of the amino acid transporter protein molecule of the present
invention.
Thus, the present assay is that the RNA coding for the amino acid
transporter molecule of the present invention is injected into oocytes of
Xenopus
laevis for example to express the transporter molecule in the cells, an
incubation is
carried out in the coexistence of the test substance and the substrate (amino
acid,
etc.) of the molecule and the amount of the substrate incorporated into the
cells is
compared with the incorporation into the control cells whereupon the activity
of
the test substance to the control of the biological activity of the amino acid
transporter of the present invention is evaluated.
A part of the DNA of the present invention and a part of the RNA thereof
may be used as a probe in the case of identification of DNA or RNA which is
hybridized in a colony hybridization method or a plaque hybridization method.
In
addition, a part of the DNA of the present invention may be used as a primer
for
the amplification of the gene coding for the DNA of the present invention or
the
transporter molecule of the present invention using a PCR (polymerase chain
reaction).
Further, a part of the DNA of the present invention, the DNA which is
complementary to the DNA and a part of the RNA of the present invention are
not
only useful as the reagent as mentioned above but also useful as the so-called
antisense DNA pharmaceutical agent or antisense RNA pharmaceutical agent.
Thus, antisense pharmaceutical agent is an agent according to a
mechanism of inhibiting the transcription from DNA to mRNA or the translation
from the mRNA to protein utilizing the nature of bonding a part of base
sequence
of DNA, a part of base sequence complementary to the base sequence of the
DNAor
a part of base sequence of RNA to DNA or RNA having a sequence complementary
17
CA 02341777 2001-03-02
to the base sequence thereof. When a part of the antisense sequence in the
antisense pharmaceutical agent is subjected to a chemical modification, it is
possible to modify the properties such as increase in a half life in blood,
permeability into cells, targeting efficiency to disease target site, etc.
In the protein of the present invention, the state where the protein
molecule is expressed on the cell surface is utilized whereby it is possible
as
mentioned above to identify the pharmaceutical agent which controls the
biological
activity of the protein of the present invention or the expression of the
protein. In
addition, based upon the amino acid sequence of the protein, it is also
possible to
design a peptide antagonist having an ability of inhibiting the biological
activity of
the protein. The peptide antagonist designed as such is useful as a
pharmaceutical agent where binding of the amino acid transporter which is a
protein of the present invention to a substrate or binding of a protein of the
present
invention to other molecule is competitively inhibited so that the biological
function of the protein of the present invention is not achieved.
The protein of the present invention or a part thereof and the cells such as
transformed cell expressing the protein are useful as an immunosensitized
antigen
in the preparation of antibody (antiserum, monoclonal antibody) to the protein
of
the present invention.
Antiserum (polyclonal antibody) having a reactivity with the amino acid
transporter molecule which is a protein of the present invention and a
monoclonal
antibody are useful as antibody pharmaceutical agents by inhibiting
(neutralizing)
the achievement of biological activity of the molecule by binding to the
molecule.
In addition, the antibody is useful as a reagent in the analysis
(immunohistological staining, western blotting, ELISA, etc.) of expressed
state of
18
CA 02341777 2001-03-02
the protein of the present invention in various biosamples (cells, tissues,
organs or
body fluids) by labeling with various substances which are able to achieve a
detectable signal.
Like in such a labeled antibody, the labeled DNA where the DNA of the
present invention or a part thereof is labeled with various substances which
are
able to achieve a detectable signal is useful as a reagent in a test (such as
southern
blotting, FISH, etc.) in the identification of the gene coding for the protein
of the
present invention.
In addition, a radiolabeled RNA where the RNA of the present invention or
a part thereof is similarly labeled with radioisotope is useful as a reagent
in an
analysis (such as northern blotting) of expressed state of mRNA coding for the
protein of the present invention in cells, tissues or organs.
Further, with regard to the DNA of the present invention, when the DNA
of an amino acid transporter derived from human being which is an embodiment
of
the present invention is introduced into mammals other than human being such
as
mouse, it is possible to prepare a transgenic animal as a model animal.
It is furthermore possible that a gene coding for the amino acid
transporter of the present invention derived from human being is used as a
probe
to clone a gene coding for a homologue protein derived from rabbit or mouse
and,
based upon the resulting genetic information, the intrinsic gene coding for
the
homologue protein of mouse or rabbit is destroyed (inactivated) to prepare a
model
animal (knockout animal). When physical, biological, pathological and genetic
characteristics of such a model animal are analyzed, functions of the amino
acid
transporter according to the present invention can be clarified in more
detail.
In addition, when the model animal where the intrinsic gene is destroyed
19
CA 02341777 2001-03-02
as such is crossed with the transgenic animal, it is possible to prepare a
model
animal having only the gene (DNA) which codes for the amino acid transporter
of
the present invention derived from human being. When the above-mentioned
pharmaceutical agent (antisense pharmaceutical agent, peptide antagonist, low-
molecular non-peptide compound, antibody, etc.) which controls the biological
activity of the amino acid transporter molecule of the present invention or
the
expression of the molecule is administered to this model animal, it is
possible to
evaluate the therapeutic effect of the pharmaceutical agent.
Thus, the present invention is to provide the substance, the drug, the
reagent and the method having a very high utility in industry as mentioned
above
which is described in each of the following <1> to <55>.
<1> Protein which is a cell surface protein having an ability of mediating
the transport of amino acid into cell and having an ability of mediating the
incorporation of at least one amino acid selected from a group consisting of
leucine
(Leu), isoleucine (Ile), phenylalanine (Phe), methionine (Met), tyrosine
(Tyr),
tryptophan (Trp), valine (Val) and histidine (His) into the cell in an Na+-
independent manner.
<2> The protein according to <1>, wherein, when it coexists with a 4F2hc
protein classified under a type II membrane glycoprotein or a part thereof, it
has
an ability of transportation of neutral amino acid and substances similar
thereto.
<3> The protein according to <2>, wherein the 4F2hc protein classified
under a type II membrane glycoprotein is a protein having an amino acid
sequence
mentioned in SEQ ID NO:6 or NO:8 or an amino acid sequence where a part of
amino acids thereof is deleted, substituted or added.
<4> The protein according to any of <1> to <3>, wherein it is a protein
CA 02341777 2001-03-02
derived from human being or rat.
<5> The protein according to any of <1> to <4>, wherein it has an amino
acid sequence of any of the following (1) and (2).
(1): an amino acid sequence mentioned in SEQ ID NO: 2 or NO:4
(2): an amino acid sequence mentioned in SEQ ID NO:2 or NO:4 where one
or more amino acid(s) is/are deleted, substituted or added.
<6> A polypeptide containing a partial amino acid sequence in the amino
acid sequence mentioned in SEQ ID NO:2 or NO:4 and having an antigenicity.
<7> DNA coding for any of the protein mentioned in <1> to <5>.
<8> The DNA according to <7>, wherein it is a DNA derived from human
being or rat.
<9> DNA coding for a cell surface protein which hybridizes under a
stringent condition to the DNA having a base sequence of from 66th to 1586th
bases mentioned in SEQ ID NO:1 or having a base sequence of from 64th to
1599th
bases mentioned in SEQ ID NO:3 and has an ability of mediating the
incorporation
of at least one kind of amino acid into cell.
<10> The DNA according to <9>, wherein it codes for a cell surface protein
where incorporation of amino acid into the cell is mediated by the coexistence
of a
4F2hc protein classified under the type II membrane glycoprotein or a part
thereof.
<11> The DNA according to <10>, wherein the 4F2hc protein classified
under the type II membrane glycoprotein has an amino acid sequence mentioned
in SEQ ID NO:6 or NO:8 or an amino acid sequence where a part of amino acids
is
deleted, substituted or added.
<12> RNA which is able to be derived from the DNA mentioned in <7> to
<11>.
21
CA 02341777 2001-03-02
<13> The RNA according to <12>, wherein it is an RNA having a base
sequence mentioned in SEQ ID NO:26 or NO:27.
<14> An expression vector containing the DNA mentioned in any of the
above <7> to <11>.
<15> A transformant cell which is transformed by the expression vector
mentioned in the above <14>.
<16> The transformant cell according to <14> or <15>, wherein the
transformant cell is further transformed by a DNA containing a base sequence
comprising a base sequence of from 110th to 1696th bases in the base sequence
mentioned in SEQ ID NO:5 and any one of nonsense base sequence represented by
TAG, TGA or TAA adjacent to the 1696th base.
<17> The transformant cell according to any of the above <14> to <16>,
wherein the transformant cell is further transformed by a DNA coding for a
reporter protein.
<18> A cell which is not derived from human being into which the RNA
mentioned in the above <12> or <13> is introduced.
<19> The cell according to <18>, wherein the cell is an oocyte of Xenopus
laevis.
<20> An antiserum or a polyclonal antibody having a reactivity with the
protein mentioned in any of the above <1> to <5> or to the polypeptide
mentioned
in the above <6>.
<21> A monoclonal antibody having a reactivity with the protein
mentioned in any of the above <1> to <5> or to the polypeptide mentioned in
the
above <6> or a part of the monoclonal antibody.
<22> The monoclonal antibody or a part of the monoclonal antibody
22
CA 02341777 2001-03-02
according to <21>, wherein the monoclonal antibody is a recombined chimera
monoclonal antibody comprising a variable region of immunoglobulin derived
from
mammals except human being and a constant region of immunoglobulin derived
from human being.
<23> The monoclonal antibody or a part of the monoclonal antibody
according to <21>, wherein the monoclonal antibody is a recombined human type
monoclonal antibody comprising all or a part of a complementarity-determining
region of a hypervariable region of immunoglobulin derived from mammals except
human being, a frame region of a hypervariable region of immunoglobulin
derived
from human being and a constant region of immunoglobulin derived from human
being.
<24> The monoclonal antibody or a part of the monoclonal antibody
according to any of the above <21> to <23>, wherein the monoclonal antibody is
a
human monoclonal antibody.
<25> A cell which produces the monoclonal antibody mentioned in any of
the above <21> to <24>.
<26> The cell according to the above <25>, wherein the cell is a fused cell
prepared by a fusion of a B cell derived from non-human mammals having an
ability of producing the monoclonal antibody with a myeloma cell derived from
mammals.
<27> The cell according to the above <25>, wherein the cell is a genetically
recombined cell transformed by introduction of DNA coding for heavy chain of
the
monoclonal antibody, DNA coding for light chain thereof or both of the DNA
into
the cell.
<28> A pharmaceutical composition containing the DNA mentioned in any
23
CA 02341777 2001-03-02
of the above <7> to <11> and a pharmaceutically acceptable carrier.
<29> The pharmaceutical composition according to <28>, wherein the
pharmaceutical composition is used for suppressing the growth of the tumor
cells.
<30> A pharmaceutical composition containing the RNA
mentioned in the above <12> or <13> and a pharmaceutically acceptable carrier.
<31> The pharmaceutical composition according to <30>, wherein the
pharmaceutical composition is used for suppressing the growth of the tumor
cells.
<32> A pharmaceutical composition containing the antiserum or the
polyclonal antibody mentioned in the above <20> and a pharmaceutically
acceptable carrier.
<33> The pharmaceutical composition according to <32>, wherein the
pharmaceutical composition is used for suppressing the growth of the tumor
cells.
<34> A pharmaceutical composition containing the monoclonal antibody
mentioned in any of the above claims <21> to <24> or a part of the monoclonal
antibody and a pharmaceutically acceptable carrier.
<35> The pharmaceutical composition according to <34>, wherein the
pharmaceutical composition is used for suppressing the growth of the tumor
cells.
<36> A labeled monoclonal antibody in which the monoclonal antibody
mentioned in any of the above <21> to <24> is labeled with a labeling
substance
which is able to give a detectable signal either solely or by the reaction
with other
substance.
<37> The labeled monoclonal antibody according to the above <36>,
wherein the labeling substance is enzyme, fluorescent substance,
chemiluminescent substance, biotin, avidin or radioisotope.
<38> A kit which is to detect the protein having the amino acid sequence
24
CA 02341777 2001-03-02
mentioned in SEQ ID NO:2 or a fragment where the kit comprises the labeled
monoclonal antibody mentioned in the above <36> or <37>.
<39> A method for the examination whether protein is expressed in a
sample or for the examination of the expressed amount, characterized in that,
the
method comprises:
(1) a step where the sample is contacted to the labeled monoclonal
antibody mentioned in the above <36> and <37> and
(2) a step where the amount of the labeled monoclonal antibody bonded to
the sample is measured by detecting fluorescence, chemiluminescence or
radioactivity depending upon the type of the labeling substance bonded to the
labeled monoclonal antibody.
<40> The method according to the above <39>, wherein the sample is
tumor cell, tumor tissue, tumor-having organ or a part thereof.
<41> A labeled DNA in which the DNA mentioned in any of the above <7>
to <11> or a fragment thereof is labeled with enzyme, fluorescent substance,
chemiluminescent substance, biotin, avidin or radioisotope.
<42> A radiolabeled RNA in which the RNA mentioned in the above <12>
or <13> is labeled with a radioisotope.
<43> A kit for detecting the gene coding for the protein mentioned in any
of the above <1> to <5>, characterized in that, the kit comprises the labeled
DNA
mentioned in the above <41> or the radioactive RNA mentioned in the above
<42>.
To be more precise, a kit for detecting the gene coding for the protein having
an
amino acid sequence mentioned in SEQ ID NO:2, characterized in that, the kit
comprise the labeled DNA mentioned in the above <41> or the radioactive RNA
mentioned in the above <42>.
CA 02341777 2001-03-02
<44> A method for detecting the action as a substrate of a test substance
to the ability for transporting the neutral amino acids of the protein using
the
protein mentioned in any of <1> to <5>.
<45> The method according to the above <44>, wherein the cell
transformed by the DNA mentioned in any of the above <7> to <11> is used.
<46> The method according to the above <44>, wherein an oocyte of
Xenopus laevis is used.
<47> The method according to any of the above <44> to <46>, wherein the
test substance is a substance other than an amino acid.
<48> A method for screening the test substance having an action of
suppressing the ability for transport of neutral amino acid and similar
substance
thereto of the protein using the protein mentioned in any of the above <1> to
<5>.
To be more precise, a method for identification of a substance having an
ability of
inhibiting the ability of mediating the incorporation of any one amino acid
selected
from a group consisting of leucine (Leu), isoleucine (Ile), phenylalanine
(Phe),
methionine (Met), tyrosine (Tyr), histidine (His), tryptophan (Trp) and valine
(Val)
into cells which is a biological function of the protein having an amino acid
sequence mentioned in SEQ ID NO:2, characterized in that, the method comprises
the steps of the following (1) and (2).
(1) a step in which any of the cells mentioned in the following (a) to (d) is
incubated in the coexistence of the substance and a radiolabeled amino acid
where
any one amino acid selected from a group consisting of leucine (Leu),
isoleucine
(Ile), phenylalanine (Phe), methionine (Met), tyrosine (Tyr), histidine (His),
tryptophan (`Irp) and valine (Val) is labeled with a radioisotope or in the
presence
of the radiolabeled amino acid only:
26
CA 02341777 2001-03-02
(a) a naturally-occurring cell in which a protein having an amino acid
sequence mentioned in SEQ ID NO:2 and a protein having an amino acid sequence
mentioned in SEQ ID NO:6 are co-expressed;
(b) a recombinant cell in which a protein having an amino acid sequence
mentioned in SEQ ID NO:2 and a protein having an amino acid sequence
mentioned in SEQ ID NO:6 are co-expressed by a co-transformation using a DNA
containing a base sequence of 66th to 1586th bases in the base sequence
mentioned
in SEQ ID NO:1 and a base sequence comprising any one nonsense base sequence
represented by TAG, TGA or TAA adjacent to the 1586th base and a DNA
containing a base sequence of 110th to 1696th bases in the base sequence
mentioned in SEQ ID NO:5 and a base sequence comprising any one nonsense base
sequence represented by TAG, TGA or TAA adjacent to the 1696th base;
(c) a non-human-derived recombinant cell in which a protein having an
amino acid sequence mentioned in SEQ ID NO:2 and a protein having an amino
acid sequence mentioned in SEQ ID NO:6 are co-expressed by a co-introduction
of
an RNA containing a base sequence of 1st to 1521st bases in the base sequence
mentioned in SEQ ID NO:26 and a base sequence comprising any one nonsense
base sequence represented by UAG, UGA or UAA adjacent to the 1521st base and
an RNA containing a base sequence of 1st to 1587th bases in the base sequence
mentioned in SEQ ID NO:27 and a base sequence comprising any one nonsense
base sequence represented by UAG, UGA or UAA adjacent to the 1587th base; or
(d) a tumor cell derived from human being; and
(2) a step in which the radioactivity of the cell incubated in the coexistence
of the substance and the radiolabeled amino acid and the radioactivity of the
cell
incubated in the presence of the radiolabeled amino acid only are measured and
27
CA 02341777 2001-03-02
the difference between them is compared.
<49> The method according to <48>, wherein the cell which is transformed
by the DNA mentioned in any of the above <7> to <11> is used.
<50> The method according to <48>, wherein an oocyte of Xenopus laevis
is used.
<51> A method for the identification of a substance having an ability of
inhibiting the transcription of the DNA mentioned in any of the above <7> to
<11>
to mRNA or the expression of the protein mentioned in any of the above <1> to
<5>.
<52> A substance which is detected, screened or identified by a method
mentioned in any of the above <44> to <51>.
<53> The substance according to <52>, wherein the substance is a
substance having an ability of inhibiting the growth of tumor cell.
<54> A transgenic mouse having an extrinsic gene, characterized in that, a
DNA coding for a protein having an amino acid sequence mentioned in SEQ ID
NO:2 or NO:4 is incorporated on an intrinsic gene of the mouse whereupon the
mouse has a cell expressing the protein in its body.
<55> The transgenic mouse according to <54>, wherein the DNA is a DNA
which contains a base sequence comprising a base sequence of from 66th to
1586th
bases in the base sequence mentioned in SEQ ID NO: 1 and any one nonsense base
sequence represented by TAG, TGA or TAA adjacent to the 1586th base or a base
sequence comprising a base sequence of from 64th to 1599th bases in the base
sequence mentioned in SEQ ID NO:3 and any one nonsense base sequence
represented by TAG, TGA or TAA adjacent to the 1599th base.
The present invention will now be illustrated in detail as hereunder by
28
CA 02341777 2003-09-12
clarifying the meanings of the terms used in the present invention and also
the general
method for the manufacture of DNA, proteins, antibodies, cells produced by the
antibody, transformants, labeled DNA, labeled RNA, labeled antibodies,
pharmaceutical compositions, transgenic mice, etc. of the present invention.
The term "mammals" used in the present invention means all mammals such
as human being, cattle, horse, pig, goat, sheep, dog, cat, rabbit, rat,
hamster, guinea
pig and mouse; preferably, human being, cattle, horse, pig, goat, sheep, dog,
cat,
rabbit, rat, hamster, guinea pig and mouse; and, particularly preferably,
human being,
rat, hamster, guinea pig and mouse.
The terms "mammals except human being" and "non-human mammals" used
in the present invention have the same meaning and stand for all mammals
except
human being in the above-defined mammals.
"Amino acid" used in the present invention means all amino acids present in
nature and, preferably, it is the amino acid represented as follows in
accordance with
the three-letter notation or one-letter notation by alphabets used for
representing the
amino acid.
Thus, glycine (Gly/G), alanine (Ala/A), valine (Val/V), leucine (Leu/L),
isoleucine (Ile/1), serine (Ser/S), threonine (Thr/T), aspartic acid (Asp/D),
glutamic
acid (G1u/E), asparagine (AsnIN), glutamine (Gln/Q), lysine (Lys/K), arginine
(ArgfR), cysteine (Cys/C), methionine (Met/M), phenylalanine (Phe/F), tyrosine
(Tyr/Y), tryptophan (Trp/W), histidine (His/H) and proline (Pro/P).
Amino acids are classified into acidic, basic and neutral amino acids
according
to the state of polarity and charge of the amino acid. When the above-
mentioned
amino acids are classified according to such a classification, they are
classified as
follows and, when the degree of polarity and charge are more finely
29
CA 02341777 2001-03-02
classified or a classification is carried out by taking other parameters into
consideration, there are amino acids which are not always suitable for the
following classification.
(Acidic amino acids)
Aspartic acid (Asp/D) and glutamic acid (Glu/E).
(Basic amino acids)
Lysine (Lys/K), arginine (Arg/R) and histidine (His/H).
(Neutral amino acids)
Leucine (Leu/L), isoleucine (Ile/1), phenylalanine (Phe/F), methionine
(Met/M), tyrosine (Fyr/Y), tryptophan (Trp/W), valine (Val/V), histidine
(His/H),
threonine (Thr/T), cysteine (Cys/C), asparagine (Asn/N), glutamine (Gln/Q),
glycine (Gly/G), alanine (Ala/A), serine (Ser/S) and proline (Pro/P).
The term "protein" used in the present invention means a molecule being
derived from the above-mentioned mammals and having a specific amino acid
sequence comprising the above-mentioned amino acids.
The "protein" of the present invention is a protein which is mentioned in
any of the above-mentioned <1> to <5>. To be more specific, it is
"a cell surface protein having an ability of mediating the transport of an
amino acid into cell and the protein has an ability of mediating an
incorporation of
any one amino acid selected from a group consisting of leucine (Leu),
isoleucine
(Ile), phenylalanine (Phe), methionine (Met), tyrosine (Tyr), histidine (His),
tryptophan (Trp) and valine (Val) in the cell in which the protein of the
following
(1) or (2) is expressed:
(1) a protein having an amino acid sequence mentioned in SEQ ID NO:6 or
NO:8; or
CA 02341777 2001-03-02
(2) a homologous protein to the protein having an amino acid sequence
mentioned in SEQ ID NO:6 or NO:8 and being coded by DNA which hybridizes to
DNA containing a base sequence mentioned in SEQ ID NO:5 or NO:7 under a
stringent condition"
The above-mentioned protein of the present invention therefore means a
protein which, when the protein of the present invention is co-expressed on a
cell
membrane where a human-derived cell membrane surface molecule 4F2hc having
an amino acid sequence mentioned in SEQ ID NO:6 or a homologous protein
thereto derived from non-human animal is expressed, is able to give a property
of
inducing the incorporation of any one of the above-mentioned amino acids into
the
cell.
Here, the "homologous protein" means a protein derived from animal
species except human being having a sequence homology to the amino acid
sequence (SEQ ID NO:6) of human-derived cell membrane surface molecule 4F2hc,
being believed to be derived from the common ancestor protein in terms of
evolution and having the same physiological function as that of the human-
derived
4F2hc.
Preferably, the protein of the present invention is any of the proteins of the
following (1) and (2).
(1) a protein having an amino acid sequence mentioned in SEQ ID NO:2;
or
(2) a protein having an amino acid sequence where one or more amino
acid(s) in the amino acid sequence mentioned in SEQ ID NO:2 is/are deleted,
substituted or added and the protein is characterized in having an ability of
mediating the incorporation of any one of amino acids selected from a group
31
CA 02341777 2001-03-02
consisting of leucine (Leu), isoleucine (Ile), phenylalanine (Phe), methionine
(Met),
tyrosine (Tyr), histidine (His), tryptophan (r1'rp) and valine (Val) in the
cell in which
the protein having the amino acid sequence mentioned in SEQ ID NO:6 is
expressed.
Here "more amino acids" means plural amino acids. To be more specific,
that is 1 to 40 amino acid(s), preferably 1 to 30 amino acid(s), more
preferably 1 to
20 amino acid(s) and, particularly preferably, 1 to 10 amino acid(s).
A partial modification (deletion, substitution, insertion and addition) of
the amino acid in the amino acid sequence of the protein of the present
invention
as mentioned above can be introduced by a partial modification of the base
sequence coding for the protein. The partial modification of the base sequence
can be introduced by a common method using a known site-specific mutagenesis
(Prot. Natl. Acad. Sci., USA, Vol. 81, p. 5662-5666, 1984).
The "partial amino acid sequence" in the present invention is an
embodiment of the protein of the present invention as mentioned above and it
means any partial amino acid sequence (protein fragment) in the amino acid
sequence. Preferably, it is a partial sequence containing a site which is
necessary
for the protein of the present invention to achieve its biological function or
a site
where the protein of the present invention bonds to or interact with other
protein
molecule (receptor or ligand).
In addition, "polypeptide containing a partial amino acid sequence and
having an antigenicity" in the present invention means a polypeptide
containing
the above-mentioned partial amino acid sequence and being recognized as a not-
one's-own substance or a foreign substance due to the immune response
mechanism of the mammal when the polypeptide is administered into the body of
32
CA 02341777 2001-03-02
the above-mentioned mammal whereby production of an antibody to the
polypeptide in the body of the mammal is possible.
The polypeptide containing the protein of the present invention or the
partial amino acids in the amino acid sequence of the protein of the present
invention can be expressed by an appropriate use of a method known in the
technical field such as a chemical synthesis or a cell incubation method or a
modified method thereof in addition to the genetic recombination technique
which
will be mentioned later.
It is also possible that the protein of the present invention is expressed by
an injection of the RNA of the present invention which will be mentioned later
into
various cells such as oocytes of Xenopus laevis whereupon a direct translation
of
the RNA infused into the cells to the protein takes place without the
transcription
from DNA to mRNA (Special Issue of Jikken Igaku, "Method of Experiments of
Biosignals", Vol. 11, No. 3, p. 30-38, 1993).
"DNA" of the present invention is that which is mentioned any of the
above <7> to <11>. A preferred embodiment is the DNA which codes for the
protein or the polypeptide of the present invention. DNA having any base
sequence such as cDNA, DNA which is complementary to the cDNA and genomic
DNA is covered as well so far as it is a DNA being able to code for the
protein of the
present invention. The DNA of the present invention further covers any DNA
composed of any codon so far as the codon codes for the same amino acid.
Further,
one preferred embodiment of the DNA of the present invention is a DNA coding
for
the human-derived protein of the present invention.
More particularly, the DNA of the present invention is a DNA which is
mentioned in any of the following (1) to (3).
33
CA 02341777 2001-03-02
(1) DNA which codes for the protein mentioned in any of the above <1> to
<5>. Here, the DNA covers a DNA having any base sequence such as cDNA, DNA
which is complementary to the cDNA and genomic DNA so far as it is a DNA
coding
for the protein such as a protein comprising the amino acid sequence mentioned
in
SEQ ID NO:2 or No:4.
(2) DNA which contains a base sequence comprising the base sequence
which comprises a base sequence of 66th to 1586th bases in the base sequence
mentioned in SEQ ID NO:1 and any one nonsense base sequence represented by
TAG, TGA or TAA adjacent to the 1586th base or the base sequence of 64th to
1599th bases in the base sequence mentioned in SEQ ID NO:3 and any one
nonsense base sequence represented by TAG, TGA or TAA adjacent to the 1599th
base .
Here, "nonsense base sequence" is any of the base sequence of TAG, TGA
or TAA which is also called termination codon, stop codon, nonsense codon,
termination codon or termination signal and is a base sequence which codes for
the
termination point of the synthesis of protein.
(3) DNA which codes for the cell surface protein having an ability of
mediating the incorporation of at least one amino acid into cell by
hybridizing,
under a stringent condition, to a DNA having a base sequence which comprises a
base sequence of 66th to 1586th bases of the base sequence of SEQ ID NO:1 or a
base sequence of 64th to 1599th bases of the base sequence of SEQ ID NO:3 and
at
least any one nonsense base sequence represented by TAG, TGA or TAA adjacent
to
the 1599th base where incorporation of the amino acid into cell is mediated
without dependent upon the coexistence of any of the proteins of the following
(a)
and (b).
34
CA 02341777 2001-03-02
(a) protein having an amino acid sequence mentioned in SEQ ID NO:6 or
NO:8; and
(b) protein having an amino acid sequence mentioned in SEQ ID NO:6 or
NO:8 where one or more amino acid(s) is/are deleted, substituted or added.
The term "more amino acids" used here has the same meaning as defined
already.
The term "under a stringent condition" used here means a condition for
carrying out the hybridization and, to be more specific, it means temperature
and
salt concentration. The temperature is usually about 36 C to about 42 C and,
depending upon the length and the degree of complementarily of the probe used,
it
may be also set as follows.
For example, when a probe having 50 or more bases is used and a
hybridization is carried out under 0.9% NaCl, the aim of the temperature (Tm)
giving a dissociation of 50% is calculated from the following formula and the
temperature of hybridization can be set as shown in the following formula.
Tin = 82.3 C + 0.41 x (G + C)% - 500/n - 0.61 x (formamide)%
(n is a base number of the probe)
Temperature = Tin - 25 C
When a probe having 100 or more bases (G + C = 40 to 50%) is used, the
aim is that Tin changes according to the following (1) and (2).
(1) Tm lowers about 1 C per 1% mismatch.
(2) Tin lowers at the rate of 0.6 to 0.7 C per 1% formamide.
Accordingly, the temperature condition in the case of a combination of a
completely complemented chains may be made as follows.
(A) 65 to 75 C (when no formamide added)
CA 02341777 2001-03-02
(B) 35 to 45 C (in the presence of 50% formamide)
The temperature condition in the case of a combination of incompletely
complemented chains may be made as follows.
(A) 45 to 55 C (when no formamide added)
(B) 35 to 42 C (in the presence of 30% formamide)
The temperature condition when a probe having 23 or less bases may be
made 37 C or the following formula may be an aim.
Temperature = 2 C x (numbers of T + A) + 4 C x (numbers of G + C) - 5 C
With regard to a salt concentration, 5 x SSC or equivalent thereto may be
usually set.
Accordingly, the temperature in a hybridization in the present invention
may, for example, be set at about 37 C while the salt concentration may be set
at 5
x SSC or equivalent thereto.
The above-mentioned DNA of the present invention may be that which is
prepared by any method. For example, complementary DNA (cDNA) prepared
from mRNA, DNA prepared from genomic DNA, DNA obtained by chemical
synthesis, DNA obtained by amplification by means of a PCR using RNA or DNA as
a template and DNA which is constituted by an appropriate combination of those
methods are included in the DNA of the present invention.
DNA which codes for the protein of the present invention may be prepared
by a method where cDNA is cloned from mRNA of the protein of the present
invention by a conventional method, a method where genomic DNA is isolated and
subjected to splicing treatment, a chemical synthetic method, etc.
(1) For example, with regard to a method of cloning of cDNA from mRNA of
the protein of the present invention, the following method is exemplified.
36
CA 02341777 2003-09-12
First, from the above-mentioned tissue or cell wherefrom the protein of the
present invention is generated/produced, mRNA which codes for the protein of
the
present invention is prepared. Preparation of mRNA is carried out, for
example, by a
method where a whole RNA prepared by a known method such as a guanidine
thiocyanate method (Chirgwin, et al., Biochemistry, Vol. 18, p. 5294, 1979), a
hot
phenol method or an AGPC method is subjected to an affinity chromatography
using
oligo(dT)cellulose or poly-U-Sepharose TM
Then cDNA chain is synthesized by, for example, a known method such as
that using a reverse transcriptase, e.g. a method by Okayama (Mol. Cell Biol.,
Vol. 2,
p. 161, 1982; and ibid, Vol. 3, p. 280, 1.983), a method by Hoffman, et al.
(Gene, Vol.
25, p. 263, 1983), etc. using the above-prepared mRNA as a template whereupon
the
eDNA is converted to a double-stranded cDNA. The resulting cDNA is integrated
into a plasmid vector or a phage vector and, after Escherichia coil is
transformed or
subjected to an in vitro packaging, it is transfected into E. coil whereupon a
cDNA
library is prepared.
With regard to the plasmid vector used here there is no particular limitation
so
far as it is duplicated and held in a host and, with regard to the phage
vector used,
anything which is able to proliferate in the host may be used. Examples of the
vector
for cloning which is usually applied are a,ZipLox TM, pUC19, Xgt10 and a,gtll.
However, when subjecting to an immunological screening which will be mentioned
later, a vector having a promoter which is able to express a gene coding for
the
protein of the present invention in a host is preferred.
With regard to a method for integration of eDNA into plasmid, an example is
a method by Maniatis, et al. which is mentioned in Molecular Cloning, A
Laboratory
Manual, second edition, Cold Spring Harbor Laboratory, No. 1, p. 53,
37
CA 02341777 2001-03-02
1989. With regard to a method for integration of cDNA into phage vector, an
example is a method by Hyunh, et al., DNA Cloning, a Practical Approach, Vol.
1, p.
49, 1985. To be more simple, a commercially available cloning kit (such as
that
manufactured by Gibco or Takara Shuzo) may be used as well. The recombined
plasmid or phage vector prepared as such is introduced into an appropriate
host in
prokaryotic cells (such as E. coli:HB101, DH5a or MC1061/P3, etc.).
With regard to a method for the introduction of plasmid into a host, a
calcium chloride method or a calcium chloride/rubidium chloride method
mentioned in Molecular Cloning, a Laboratory Manual, second edition, Cold
Spring Harbor Laboratory, No. 1, p. 74, 1989), an electroporation method, etc.
may
be exemplified. With regard to a method for the introduction of phage vector
into
a host, a method where phage DNA is subjected to an in vitro packaging and
then
introduced into a proliferated host may be exemplified. The in vitro packaging
method may be easily carried out using a commercially available in vitro
packaging kit (such as that manufactured by Stratagene, Amersham, etc.).
A method for the isolation of cDNA coding for the protein of the present
invention from the cDNA library prepared by the above-mentioned method is
carried out by a combination of common cDNA screening methods.
For example, a method where DNA which contains a part of or all of the
base sequence coding for the amino acid sequence of the protein of the present
invention or DNA which has a homology to the base sequence is prepared
separately, this is labeled with 32P or [a-32P]dCTP to prepare a probe and
then a
clone which contains the desired cDNA is screened by a known colony
hybridization method (Crunstein, et al., Proc. Natl. Acad. Sci. USA, Vol. 72,
p. 3961,
1975) or a plaque hybridization method (Molecular Cloning, A Laboratory
Manual,
38
CA 02341777 2001-03-02
second edition, Cold Spring Harbor Laboratory, No. 2, p. 108, 1.989) and a
method
where a PCR primer is prepared, the specific region of the protein of the
present
invention is amplified by a PCR and the clone which has a DNA fragment coding
for the region is selected, etc. may be exemplified.
When a cDNA library prepared by the vector which is able to express the
cDNA (such as ).ZipLox or ?gtll phage vector) is used, a desired clone can be
selected utilizing an antigen-antibody reaction using an antibody which has a
reactivity with the protein of the present invention. When clone is treated in
a
large scale, it is preferred to use a screening method utilizing a PCR.
The base sequence of the DNA prepared as such can be determined by a
method by Maxam-Gilbert (Maxam, et al., Proc. Nat]. Acad. Sci. USA, Vol. 74,
p.
560, 1977), a method where dideoxynucleotide synthetic chain is stopped using
phage M13 (Sanger, et al., Proc. Nat]. Acad. Sci. USA, Vol. 74, p.5463-5467,
1977)
or a diterminator cycle sequencing method (manufactured by Applied
Biosystems).
The gene coding for the protein of the present invention can be prepared by a
method where all or a part thereof is excised from the above-prepared clone
using a
restriction enzyme, etc.
(2) With regard to a method of preparation by isolating the DNA coding for
the protein of the present invention from the genomic DNA derived from the
cell
expressing the protein of the present invention as mentioned above, the
following
method will be exemplified. Thus, the cell is dissolved preferably using SDS
or
protenase K, etc. and extraction with phenol is repeated whereby protein is
removed from DNA. RNA is digested preferably by ribonuclease. The resulting
DNA is partially digested by an appropriate restriction enzyme and the
resulting
DNA fragment is amplified by an appropriate phage or cosmid to prepare a
library.
39
CA 02341777 2001-03-02
A clone having a desired sequence is detected, for example, by a method where
a
radiolabeled DNA probe is used and all or a part of the gene coding for the
protein
of the present invention is excised from the clone by a restriction enzyme or
the
like and is collected.
(3) Manufacture of the cDNA coding for the protein having the amino acid
sequence mentioned in SEQ ID NO:2 which is an embodiment of the DNA of the
present invention can be carried out by a conventional method based upon a
base
sequence mentioned in SEQ ID NO:1.
For example, a rat C6 glioma cell is used as a gene source and mRNA
(poly(A) RNA) is prepared therefrom. This is fractionated and each fraction is
introduced into oocytes of Xenopus laevis together with the cRNA of 4F2hc.
Since cDNA of gene of 4F2hc has been reported already [Broer, et. al,
Biochem. J., Vol. 312, p. 863, 1995], it is possible to easily prepare the
gene of
4F2hc from this sequence information using a PCR, etc. From the resulting
cDNA of 4F2hc, it is possible to synthesize an RNA which is complementary
thereto (cRNA) (capped one) using T3 or T7 RNA polymerase, etc.
With regard to the oocyte into which cRNA of 4F2hc and mRNA are
introduced, transport (incorporation) of the substrate into the cell is
measured
using leucine or the like as a substrate and an mRNA fraction showing a high
incorporation activity is selected whereby the mRNA of LAT1 can be
concentrated.
A cDNA library is prepared using this concentrated mRNA as a base. From the
cDNA of the library, cRNA (capped one) is prepared where one group consists of
about 500 clones and each group is introduced into oocytes together with cRNA
of
4F2hc and, using the incorporation activity of the substrate as an index, a
positive
group is selected. When a positive group is found, it is further classified
into
CA 02341777 2001-03-02
subgroups and the same operation is repeated whereupon clones containing cDNA
of LAT1 gene can be obtained.
With regard to the resulting cDNA, its base sequence is determined by a
common method and a translation region is analyzed whereby the protein coded
thereby or, in other words, the amino acid sequence of LAT1 can be determined.
The fact that the resulting cDNA is a cDNA of a neutral amino acid
transporter gene or, in the other words, that the genetic product coded by the
cDNA is a neutral amino acid transporter can, for example, be ascertained as
follows. Thus, the cRNA prepared from the resulting cDNA of LAT1 gene is
expressed by introducing into oocytes together with the cRNA of 4F2hc and the
ability of transport (incorporation) of the neutral amino acid into the
oocytes can
be confirmed in the same manner as mentioned above by measuring the
incorporation of the substrate into the oocytes according to a conventional
incorporation test (Kanai and Hediger, Nature, 360, 467-471 (1992)) using an
appropriate neutral amino acid as a substrate.
The same incorporation experiment is applied to the expressed cell
whereby it is possible to investigate the characteristic of LAT1 such as the
characteristic that LAT1 carries out an exchange of amino acids, a substrate
specificity of LAT1, etc.
When the resulting cDNA of LAT1 gene is used and an appropriate cDNA
library or genomic DNA library prepared from different gene sources is
screened, it
is possible to isolate the homologous gene, chromosomal gene, etc. derived
from
different tissues and different organisms.
Further, when a common PCR (polymerase chain reaction) is carried out
using a synthetic primer designed based upon the information of the disclosed
base
41
CA 02341777 2001-03-02
sequence of the gene of the present invention (a base sequence shown in SEQ ID
NO:1 or a part thereof), it is possible to isolate a gene from a cDNA library
or a
genomic DNA library.
SEQ ID NO:3 of the Sequence Listing which will be mentioned later shows
a full-length cDNA base sequence (about 3.5 kbp) of gene of a neutral amino
acid
transporter (rat LAT1) derived from a rat C6 glioma cell line and an amino
acid
sequence (512 amino acids) of the protein coded to the translation region
thereof.
SEQ ID NO:4 of the Sequence Listing shows an amino acid sequence (512 amino
acids) of a neutral amino acid transporter (rat LAT1) derived from a rat C6
glioma
cell line.
A DNA library such as a cDNA library or a genomic DNA library can be
prepared by a method mentioned, for example, in Molecular Cloning (by
Sambrook,
J., Fritsh, E. F. and Maniatis, T., published by Cold Spring Harbor Press in
1989).
Alternatively, a commercially available library may be used if available.
In the preparation of a cDNA coding for the protein derived from human
being, it can be also prepared by the following manner that a cosmid library
into
which human genomic DNA (chromosomal DNA, genomic DNA) is further
introduced (Laboratory Manual Human Genome Mapping, edited by Masaaki Hori
and Yusuke Nakamura, published by Maruzen) is prepared, then the cosmid
library is screened to give a positive clone containing the DNA of the coding
region
of the desired protein and a coding DNA excised from the positive clone is
used as a
probe for carrying out a screening of the above-mentioned cDNA library.
SEQ ID NO:1 of the Sequence Listing which will be mentioned later shows
a full-length cDNA base sequence (about 4.5 kbp) of the gene of a neutral
amino
acid transporter (human LAT1) derived from human being and an amino acid
42
CA 02341777 2001-03-02
sequence (507 amino acids) of the protein coded to the translation region
thereof.
SEQ ID NO:2 of the Sequence Listing shows an amino acid sequence (507 amino
acids) of a neutral amino acid transporter (human LAT1) derived from human
being.
SEQ ID NO:5 of the Sequence Listing shows a full-length cDNA base
sequence (about 1.8 kbp) of the gene of 4F2hc protein derived from human being
and an amino acid sequence (529 amino acids) of the protein coded to the
translation region thereof and SEQ ID NO:6 of the Sequence Listing shows an
amino acid sequence (529 amino acids) of the 4F2hc protein derived from human
being. SEQ ID NO:7 of the Sequence Listing shows a full-length cDNA base
sequence (about 1.8 kbp) of the gene of 4F2hc protein derived from rat and an
amino acid sequence (527 amino acids) of the protein coded to the translation
region thereof and SEQ ID NO:8 of the Sequence Listing shows an amino acid
sequence (527 amino acids) of the 4F2hc protein derived from rat.
"Expression vector" of the present invention means a recombinant vector
containing the DNA of the present invention. There is no particular limitation
for
the recombinant vector of the present invention so far as it is able to
conduct a
self-multiplication in various hosts such as prokaryotic cells and/or
eukaryotic cell
including plasmid vector and phage vector.
In a simple manner, the recombinant vector can be prepared by linking the
DNA of the present invention by a common method to a vector for recombination
available in the art (plasmid DNA and bacteriophage DNA). Specific examples of
the applicable vector for recombination in the case of plasmid derived from
Escherichia coli are pBR322, pBR325, pUC12, pUC13 and pUC19; in the case of
plasmid derived from yeast are pSH19 and pSH15; and in the case of plasmid
43
CA 02341777 2001-03-02
derived from Bacillus subtilis are pUB110, pTP5 and pC194. Examples of the
phage are bacteriophage such as ? phage and also animal and insect virus such
as
retrovirus, vaccinia virus and nuclear polyhedrosis virus (pVL 1393
manufactured
by Invitrogen). Further example is pZL1.
For an object of expression of the protein of the present invention,
expression vector is useful. With regard to an expression vector, there is no
particular limitation therefor so far as it has an ability of expressing the
protein of
the present invention in various host cells of prokaryotic cells and/or
eukaryotic
cells. For example, pMAL C2, pEF-BOS (Nucleic Acid Research, Vol. 18, p. 5322,
1990; etc.) or pME18S (Handbook of Genetic Engineering, Supplementary Issue of
Jikken Igaku, 1992; etc.) may be exemplified.
When bacteria, particularly Escherichia coli, are used as a host cell, an
expression vector is usually constituted at least from promoter-operator
region,
initiation codon, DNA coding for the protein of the present invention,
termination
codon, terminator region and replicable unit.
When yeast, animal cell or insect cell is used as a host, it is preferred that
an expression vector contains at least promoter, initiation codon, DNA coding
for
the protein of the present invention and termination codon. It may further
contain DNA coding for a signal peptide, enhancer sequence, non-translated
region
on 5'- and 3'-sides of the gene coding for the protein of the present
invention,
splicing conjugated part, polyadenylation site, selective marker region or
duplicable unit. Depending upon an object, it may also contain gene for gene
amplification (marker) which is commonly used.
Promoter-operator region for expressing the protein of the present
invention in bacteria contains promoter, operator and Shine-Dalgarno (SD)
44
CA 02341777 2001-03-02
sequence (such as AAGG). When the host is a bacterium of genus Escherichia,
appropriate examples are those which contain Trp promoter, lac promoter, rec A
promoter, XPL promoter, lpp promoter and tac promoter. Examples of the
promoter for expressing the protein of the present invention in yeast are PH05
promoter, PGK promoter, GAP promoter and ADH promoter and, when the host
belongs to genus Bacillus, the examples are SLO1 promoter, SP02 promoter and
penP promoter. When the host is a eukaryotic cell such as a mammalian cell,
its
examples are promoter derived from SV40, promoter for retrovirus and heat
shock
promoter. Preferred examples are SV-40 and retrovirus. However, there is no
particular limitation to the above. Utilization of enhancer is an effective
method
for the expression as well.
With regard to the suitable initiation codon, methionine codon (ATG) is
exemplified.
With regard to the termination codon, commonly used termination codons
(such as TAG, TGA and TAA) are exemplified.
With regard to the terminator region, commonly used natural or synthetic
terminator may be used.
Duplicable unit means the DNA having an ability of being able to
duplicate its total DNA sequence in host cells and includes natural plasmid,
artificially modified plasmid (DNA fragment prepared from natural plasmid) and
synthetic plasmid. With regard to a suitable plasmid, plasmid pBR322 or
artificially modified product thereof (DNA fragment obtained by treating
pBR322
with an appropriate restriction enzyme) in the case of E. coli; yeast 21i
plasmid or
yeast chromosomal DNA in the case of yeast; and plasmid pRSVneo (ATCC 37198),
plasmid pSV2dhfr (ATCC 37145), plasmid pdBPV-MMTneo (ATCC 37224),
CA 02341777 2001-03-02
plasmid pSV2neo (ATCC 37149), etc. in the case of mammalian cells.
With regard to the enhancer sequence, polyadenylation site and splicing
combination site, those which are commonly used by the persons skilled in the
art
such as each of those derived from SV40 may be used.
With regard to the selective marker, those which are commonly used may
be used by a conventional method. For example, gene which is resistant to
antibiotics such as tetracycline, ampicillin, neomycin or kanamycin is
exemplified.
With regard to the gene for a gene amplification, dihydrofolic acid
reductase (DHFR) gene, thymidinekinase gene, neomycin-resistant gene, glutamic
acid-synthetic enzyme gene, adenosinedeaminase gene, ornithinedecarboxylase
gene, hygromycin B phosphotransferase gene, aspartate transcarbamylase, etc.
are exemplified.
The expression vector of the present invention can be prepared by
continuously and cyclically linking at least the above-mentioned promoter,
initiation codon, DNA coding for the protein of the present invention,
termination
codon and terminator region to an appropriately duplicable unit. If necessary
in
that case, it is also possible to use an appropriate DNA fragment (such as
linker,
other restriction site, etc.) by a common method such as digestion with a
restriction enzyme or ligation using a T4 DNA ligase.
The "transformed cell" of the present invention is a cell which is
transformed by the above-mentioned expression vector or DNA of the present
invention and can be prepared by introducing the DNA or expression vector into
prokaryotic cell or eukaryotic cell as a host cell.
With regard to the host cell used in the present invention, there is no
particular limitation so far as it is adapted to the above-mentioned
expression
46
CA 02341777 2001-03-02
vector and is able to be transformed and its examples are various cells such
as
natural cell or artificially established recombinant cell which are commonly
used
in the technical field of the present invention such as bacteria (belonging to
genus
Escherichia and genus Bacillus), yeast (belonging to genus Saccharomyces,
genus
Pichia, etc.), animal cells and insect cells.
Preferably, it is Escherichia coli or animal cells and, to be more specific,
E.
coil (DH5a, TBl, HB101, etc.), mouse-derived cells (COP, L, C127, Sp2/0, NS-1
and
NIH3T3, etc.), rat-derived cells (PC12, PC12h, etc.), hamster-derived cells
(BHK
and CHO, etc.), monkey-derived cells (COS I, COS3, COST, CV1 and Velo, etc.)
and
human-derived cells (HeLa, cells derived from diploid fibroblast, HEK293
cells,
myeloma cells and Namalwa, etc.) may be exemplified.
Introduction of expression vector into host cells (transformation (character
transfer)) may be carried out by a method which has been known already.
Thus, the transformation can be carried out, for example, by a method of
Cohen, et al. (Proc. Nat]. Acad. Sci. USA, Vol. 69, p. 2110, 1972), a
protoplast
method (Mol. Gen. Genet., Vol. 168, p. 111, 1979) and a competent method (J
Mol.
Biol., Vol. 56, p. 209, 1971) in the case of bacteria (Escherichia coli,
Bacillus
subtilis, etc.); for example, by a method of Hinnen, et al. (Proc. Natl. Acad.
Sci.
USA, Vol. 75, p. 1927, 1978) and a lithium method (J. Bacteriol., Vol. 153, p.
163,
1983) in the case of Saccharomyces cerevisiae; for example, by a method of
Graham
(Virology, Vol. 52, p. 456, 1973) in the case of animal cells; and, for
example, by a
method of Summers, et al. (Mol. Cell. Biol., Vol. 3, p. 2156-2165, 1983) in
the case
of insect cell; respectively.
The "protein" of the present invention can be expressed by incubation of
the above-prepared transformant cell (hereinafter, this will be used in a
sense of
47
CA 02341777 2001-03-02
covering the substance into which the character is transferred) containing the
expression vector in a nutritive medium.
It is preferred that the nutritive medium contains carbon source, inorganic
nitrogen source or organic nitrogen source necessary for the growth of the
host cell
(transformant). With regard to the carbon source, glucose, dextran, soluble
starch, sucrose, etc. may be exemplified; and with regard to the inorganic
nitrogen
source or an organic nitrogen source, ammonium salts, nitrates, amino acid,
corn
steep liquor, peptone, casein, meat extract, soybean cake, potato extract,
etc. may
be exemplified. If desired, other nutrients (such as inorganic salt [e.g.,
calcium
chloride, sodium dihydrogen phosphate and magnesium chloride], vitamins,
antibiotic substances [e.g., tetracycline, neomycin, ampicillin and
kanamycin],
etc.) may be contained therein.
The incubation may be carried out by a method which has been known in
the art. The incubating conditions such as temperature, pH of the medium and
incubating time may be appropriately selected so as to abundantly express the
protein of the present invention.
As hereunder, the specific media and incubating conditions which are used
depending upon the host cell will be exemplified although the present
invention is
not limited thereto at all.
When the host is bacteria, Actinomyces, yeast or filamentous fungi, a
liquid medium containing the above-mentioned nutrients is appropriate for
example. Preferably, it is a medium where the pH is 5-8.
When the host is E. cola, examples of the preferred medium are LB
medium, M9 medium (Miller, et al., Exp. Mol. Genet., Cold Spring Harbor
Laboratory, p. 431, 1972), etc. In that case, the incubation may be carried
out
48
CA 02341777 2001-03-02
usually at 14-43 C for about 3-24 hours together, if necessary, with aeration
and
stirring.
When the host is genus Bacillus, the incubation may be carried out usually
at 30-40 C for about 16-96 hours, if necessary, with aeration and stirring.
When the host is yeast, it is preferred that the medium is, for example, a
Burkholder minimum medium (Bostian, Proc. Nat]. Acad. Sci. USA, Vol. 77, p.
4505, 1980) and the pH is preferably 5-8. Incubation is carried out usually at
about 20-35 C for about 14-144 hours and, if necessary, aeration and stirring
may
be conducted.
When the host is animal cells, MEM medium containing about 5-20% of
bovine fetus serum (Science, Vol. 122, p. 501, 1952), DMEM medium (Virology,
Vol.
8, p. 396, 1959), RPMI 1640 medium (J. Am. Med. Assoc., Vol. 199, p. 519,
1967),
199 medium (Proc. Soc. Exp. Biol. Med., Vol. 73, p.1, 1950), etc. may be used
as a
medium. The pH of the medium is preferably about 6-8 and the incubation is
carried out usually at about 30-40 C for about 15-72 hours. If necessary,
aeration
and stirring may be conducted as well.
When the host is insect cells, Grace's medium containing bovine fetus
serum (Proc. Nat]. Acad. Sci. USA, Vol. 82, p. 8404, 1985), etc. may be used
for
example and its pH is preferably about 5-8. The incubation is carried out
usually
at about 20-40 C for about 15-100 hours and, if necessary, aeration and
stirring
may be conducted as well.
The protein of the present invention can be expressed by such a manner
that the transformant which is prepared as above using the expression vector
or
the DNA of the present invention as mentioned above is incubated under the
above-mentioned incubating condition.
49
CA 02341777 2003-09-12
When the protein of the present invention is prepared as a soluble protein,
the
cells are collected after the cell incubation and suspended in an appropriate
buffer
solution and, after the cell walls and/or cell membranes of the cell, etc. are
destroyed
by, for example, means of ultrasonic wave, lysozyme, freeze-thaw, etc., a
method
such as centrifugation, filtration, etc. is carried out whereupon the membrane
fraction
containing the protein of the present invention is obtained. The membrane
fraction is
solubilized using a surface-active agent such as Triton-X 100 TM to give a
crude
solution. The crude solution is subjected to a commonly used purifying method
so as
to purify and isolate the protein whereupon the protein of the present
invention can be
isolated as a soluble protein.
With regard to a method for isolation and for purification, there may be
exemplified a method where the solubility is utilized such as salting-out and
solvent
precipitation methods; a method where the difference in molecular weights is
utilized
such as dialysis, ultrafiltration, gel filtration and a sodium dodecylsulfate-
polyacrylamide gel electrophoresis method; a method where the charge is
utilized
such as ion exchange chromatography and hydroxylapatite chromatography; a
method
where the specific affinity is utilized such as affinity chromatography; a
method
where the difference in hydrophobicity is utilized such as a reversed phase
high-
performance chromatography; and a method where the difference in isoelectric
points
is utilized such as isoelectric focusing.
The "RNA" of the present invention is an RNA which is mentioned in the
above <5> and will be mentioned later.
"an RNA which contains a base sequence of base numbers of from I st to
1521st of the base sequence mentioned in SEQ ID NO:26 and a base sequence
comprising any of one nonsense base sequence represented by UAG, UGA or UAA
CA 02341777 2001-03-02
adjacent to the base of the base number of 1521st"
Here, the term "nonsense base sequence" means any of the base sequences
of UAG, UGA and UAA which is also called termination codon, stop codon,
nonsense codon, termination codon or termination signal and is a base sequence
coding for the termination point of the translation to the protein.
The RNA of the present invention can be prepared by a common method
using a commercially available RNA polymerase (such as T7 RNA polymerase)
using a DNA sequence complementary to the DNA mentioned in the above <1>, i.e.
"DNA which contains a base sequence of from 66th to 1586th bases of the base
sequence mentioned in SEQ ID NO:1 and any one of the nonsense base sequences
of TAG, TGA and TAA adjacent to the 1586th base" as a template.
The RNA of the present invention can be used for expressing the protein of
the present invention in various cells. Thus, when the RNA of the present
invention is injected into oocytes of Xenopus laevis, it is possible to
directly express
the protein of the present invention in the cells from the injected RNA
without a
transcription from DNA to mRNA (Special Issue of Jikken Igaku, "Method of
Experiments of Biosignals", Vol. 11, No. 3, p. 30-38, 1993).
Another feature of the present invention is the DNA as mentioned in the
above <4> which will be given as follows.
"DNA which contains a partial base sequence in the base sequence
mentioned in SEQ ID NO:1 or DNA where a part of the DNA is chemically
modified,
or DNA which contains a base sequence which is complementary to the partial
base sequence or DNA where a part of the DNA is chemically modified and has
the
following characteristics (1) and (2).
(1) the partial base sequence is a base sequence which is not so completely
51
CA 02341777 2001-03-02
identical with the partial base sequence of the base sequence mentioned in SEQ
ID
NO:3; and
(2) the DNA or the chemically modified DNA hybridizes to the gene coding
for the protein having an amino acid sequence mentioned in SEQ ID NO:2.
Here, "a partial base sequence in the base sequence mentioned in SEQ ID
NO: I" means a partial base sequence comprising optional numbers of base in
any
site contained in the base sequence mentioned in SEQ ID NO: I".
The DNA is useful as a probe in an operation of a DNA hybridization or an
RNA hybridization. In an object of using the DNA as a probe, there may be
exemplified a partial base sequence of continuous 20 or more bases, preferably
a
partial base sequence of continuous 50 or more bases, more preferably a
partial
base sequence of continuous 100 or more bases, still more preferably a partial
base
sequence of continuous 200 or more bases and, particularly preferably, a
partial
base sequence of continuous 300 or more bases as the partial base sequence.
The above-mentioned DNA is also useful as a primer in a PCR. In an
object of using the DNA as a primer in a PCR, there may be exemplified a
partial
base sequence of continuous 5 to 100 bases, preferably a partial base sequence
of
continuous 5 to 70 bases, more preferably a partial base sequence of
continuous 5
to 50 bases and, still more preferably, a partial base sequence of continuous
5 to 30
bases as the partial base sequence.
Further, the above-mentioned DNA is useful as an antisense
pharmaceutical agent as well. Thus, the DNA hybridizes to the RNA or the DNA
coding for the protein having an amino acid sequence mentioned in SEQ ID NO:2
whereby transcription of the DNA to mRNA or translation of the mRNA to protein
can be inhibited as well.
52
CA 02341777 2001-03-02
In an object of using the above DNA as an antisense pharmaceutical agent,
there may be exemplified a partial base sequence of continuous 5 to 100 bases,
preferably a partial base sequence of continuous 5 to 70 bases, more
preferably a
partial base sequence of continuous 5 to 50 bases and, still more preferably,
a
partial base sequence of continuous 5 to 30 bases as the partial base
sequence.
When the DNA is used as an antisense pharmaceutical, it is possible to
subject a part of the base sequence of the DNA to a chemical modification so
as to
increase its half life (stability) in blood when the DNA is administered into
the
body of a patient, to increase a permeability in the intracellular membrane,
to
increase the resistance to decomposition in or the absorption with a digestive
organs in the case of an oral administration, etc. With regard to the chemical
modification, that of a phosphoric acid bond in the oligonucleotide structure,
ribose,
nucleic acid base, saccharide site, 3'- and/or 5'-terminal(s), etc. maybe
exemplified.
With regard to a modification of the phosphoric acid bond, a change of one
or more the bond(s) to any of phosphodiester bond (D-oligo), phosphorothioate
bond,
phosphorodithioate bond (S-oligo), methyl phosphate bond (MP-oligo),
phosphoroamidate bond, non-phosphoric acid bond and methyl phosphonothioate
or to a combination thereof may be given. With regard to a modification of
ribose,
a change to 2'-fluororibose, to 2'-O-methylribose, etc. may be given. With
regard
to a modification of nucleic acid base, a change to 5-propynyluracil, to 2-
aminoadenine, etc. may be given.
Another feature of the present invention is the RNA mentioned in the
above <6> which will be as follows.
"an RNA containing a partial base sequence in the base sequence of RNA
having a base sequence complementary to the base sequence mentioned in SEQ ID
53
CA 02341777 2001-03-02
NO:26 or an RNA in which a part of the RNA is chemically modified, wherein the
RNA or the chemically modified RNA is characterized in hybridizing to an RNA
which codes for the protein having an amino acid sequence mentioned in SEQ ID
NO:2"
Here, "partial base sequence" means a partial base sequence comprising
any numbers of bases at any site.
The above-mentioned RNA is useful as an antisense pharmaceutical agent
as well. Thus, the RNA hybridizes to the RNA or the DNA coding for the protein
having an amino acid sequence mentioned in SEQ ID NO:2 whereby transcription
of the DNA to mRNA or translation of the mRNA to protein can be inhibited.
In an object of using the above RNA as an antisense pharmaceutical agent,
there may be exemplified a partial base sequence of continuous 5 to 100 bases,
preferably a partial base sequence of continuous 5 to 70 bases, more
preferably a
partial base sequence of continuous 5 to 50 bases and, still more preferably,
a
partial base sequence of continuous 5 to 30 bases as the partial base
sequence.
When the RNA is used as an antisense pharmaceutical agent, it is possible
to subject a part of the base sequence of the RNA to a chemical modification
so as
to increase its half life in blood when the RNA is administered into the body
of a
patient, to increase a permeability in the intracellular membrane, to increase
the
resistance to decomposition in or the absorption with a digestive organs in
the case
of an oral administration, etc. With regard to the chemical modification, that
which is applied to the above-mentioned antisense DNA may be exemplified.
The "antibody" of the present invention is a polyclonal antibody
(antiserum) or a monoclonal antibody and, preferably, a monoclonal antibody.
To be more specific, it is an antibody having a reactivity with the protein of
54
CA 02341777 2003-09-12
the present invention or a part thereof.
The "antibody" of the present invention covers an antibody of a natural type
which is prepared by immunizing non-human mammal such as mouse, rat, hamster,
guinea pig, rabbit, goat, sheep, etc. by a conventional method using the
protein of the
present invention or a part thereof (including natural substance, recombinant
and
chemically synthesized substance) or the cells in which the protein is
expressed
(regardless of natural cell, transformant cell, normal cell, tumor cell, etc.)
as
immunogen (antigen); a recombinant chimera monoclonal antibody and recombinant
human-type monoclonal antibody (CDR grafted antibody) which can be
manufactured
by means of genetic recombination technique; and a human antibody which can be
manufactured using human antibody-producible transgenic animal, etc.
In the case of a monoclonal antibody, there is covered a monoclonal antibody
having any isotype such as IgG, I gM, IgA, IgD and IgE. Preferably, it is IgG
or IgM.
The polyclonal antibody (antiserum) and the monoclonal antibody of the
present invention can be manufactured by the already-known general
manufacturing
methods.
Thus, for example, the above-mentioned immunogen (antigen) is immunized
to a chicken or a mammal, preferably to mouse, rat, hamster, guinea pig,
rabbit, cat,
dog, pig, goat, horse or cattle or, more preferably, to mouse, rat, hamster,
guinea pig
or rabbit together, if necessary, with a Freund's adjuvant.
The polyclonal antibody (antiserum) can be prepared from the serum obtained
from the immunologically sensitized animal.
The monoclonal antibody can be manufactured in such a manner that a
CA 02341777 2001-03-02
hybridoma is prepared from the antibody-producing cell (spleen, lymph node,
bone
marrow or tonsil; preferably, B cell of spleen) obtained from the
immunologically
sensitized animal with a cell of a bone marrow type (myeloma cell) having no
ability of autoantibody production, the hybridoma is cloned and a clone which
produces a monoclonal antibody showing a specific affinity to the antigen used
for
immunization of mammal is selected by an immunological measuring method
(such as ELISA).
To be more specific, the monoclonal antibody can be manufactured as
follows. Thus, the protein of the present invention or a part thereof
(including
natural substance, recombinant and chemically synthesized substance) or cell
wherein the protein is expressed (regardless of natural cell, transformant
cell,
normal cell or tumor cell) is used as an immunogen and the immunogen is
injected,
once or several times, or transplanted to mouse, rat, hamster, guinea pig,
chicken
or rabbit or, preferably, to mouse, rat or hamster (including a transgenic
animal
which is prepared so as to produce an antibody derived from other animal such
as
human antibody-producing transgenic mouse) subcutaneously, intramuscularly,
intravenously, into hood pad or intraperitoneally whereupon an immunological
sensitization is carried out together, if necessary, with a Freund's adjuvant.
Usually, one to four immunization(s) is/are carried out every 1 to 14 day(s)
from
the initial immunization and antibody-producing cells can be obtained from the
mammal which is immunologically sensitized for about 1 to 5 day(s) from the
final
immunization.
Preparation of a hybridoma secreting a monoclonal antibody can be
carried out by a modifying method of Kohler and Milstein (Nature, Vol. 256, p.
495-497, 1975) or by a method similar thereto.
56
CA 02341777 2001-03-02
Thus, it can be prepared by a cell fusion of antibody-producing cells
contained in spleen, lymph node, bone marrow or tonsil or, preferably, in
spleen
obtained from immunologically sensitized mammal as above with myeloma cells
having no ability of autoantibody production derived from mammal such as,
preferably, mouse, rat, guinea pig, hamster, rabbit or human being or, more
preferably, mouse, rat or human being.
With regard to the myeloma cells used for the cell fusion, it is possible to
use, for example, mouse-derived myeloma P3/X63-AG8.653 (653; ATCC No. CRL
1580), P3/NSI/1-Ag4-1 (NS-I), P3/X63-Ag8.U1 (P3U1), SP2/0-Ag14 (Sp2/0, Sp2),
PAI, FO or BW5147; rat-derived myeloma 21ORCY3-Ag.2.3.; and human-derived
myeloma U-266AR1, GM1500-6TG-Al-2, UC729-6, CEM-AGR, D1R11 or CEM-
T 15.
Screening of hybridoma clone producing the monoclonal antibody is
carried out by incubating the hybridoma in, for example, a microtiter plate
and by
measuring the reactivity of the incubated supernatant liquid of the well where
the
growth is noted to immunized antigen used in the above immunological
sensitization of mouse by means of an enzyme immunoassay such as RIA or
ELISA.
Manufacture of a monoclonal antibody from a hybridoma can be carried
out either in vitro or in vivo in the peritoneal effusion of mouse, rat,
guinea pig,
hamster or rabbit, preferably in mouse or rat or, more preferably, in mouse
followed by isolating from the resulting incubated supernatant liquid or
peritoneal
effusion of the mammal.
When an incubation in vitro is carried out, it is possible to carry out in
such a manner that the hybridoma is proliferated, maintained and stored
57
CA 02341777 2001-03-02
depending upon the various conditions such as characteristic of the cell
species to
be incubated, object of the test study, method of incubation, etc. and the
known
nutrient medium to be used for the production of a monoclonal antibody in the
supernatant fluid of the culture liquid or every nutrient medium induced and
prepared from a known basal medium is used.
With regard to a basal medium, a low-calcium medium such as Ham F12
medium, MCDB153 medium or low-calcium MEM medium; a high-calcium
medium such as MCDB104 medium, MEM medium, D-MEM medium, RPMI 1640
medium, ASF104 medium or RD medium; etc. may be exemplified. Depending
upon the object, the basal medium may contain serum, hormone, cytokine and/or
various inorganic or organic substances.
Isolation and purification of the monoclonal antibody can be carried out,
for example, by subjecting the above-mentioned incubated supernatant liquid or
peritoneal effusion to saturated ammonium sulfate euglobulin precipitating
method, caproic acid method, caprylic acid method, ion-exchange chromatography
(DEAE, DE52, etc.), affinity column chromatography using anti-immunoglobulin
column, protein A column, etc. and the like.
It is also possible that the gene coding for the monoclonal antibody is
cloned from the hybridoma, transgenic cow, goat, sheep or pig where the
antibody
coding gene is integrated in an intrinsic gene is prepared by means of a
transgenic
animal preparing technique and, from the milk of the transgenic animal, the
monoclonal antibody derived from the antibody gene is obtained in a large
amount
(Nikkei Science, issue of April 1997, p. 78-84).
The "recombinant chimera monoclonal antibody" of the present invention
is a monoclonal antibody which is prepared by a genetic engineering means and,
to
58
CA 02341777 2001-03-02
be more specific, it means a chimera monoclonal antibody such as mouse/human
chimera monoclonal antibody, characterized in that for example, its variable
region
is that which is derived from mouse immunoglobulin while its constant region
is
that which is derived from human immunoglobulin.
The constant region derived from human immunoglobulin has its own
amino acid sequence depending upon the isotypes of IgG, IgM, IgA, IgD and IgE
and the constant region of the recombinant chimera monoclonal antibody in the
present invention may be a constant region of human immunoglobulin belonging
to
any isotype. Preferably, it is a constant region of human IgG.
The chimera monoclonal antibody of the present invention may, for
example, be manufactured as follows. It goes without saying however that the
manufacture is not limited to such a method only.
For example, a mouse/human chimera monoclonal antibody can be
prepared by referring to Jikken Igaku (Special Issue), Vol. 16, No. 10, 1988
and
Japanese Patent Publication No. 73280/1991.
Thus, CH gene (C gene coding for H chain constant region) obtained from
DNA coding for human immunoglobulin is arranged in an expressible manner to
the downstream of active VH gene (rearranged VDJ gene coding for H chain
variable region) obtained from DNA coding for a mouse monoclonal antibody
isolated from a hybridoma which produces the mouse monoclonal antibody or CL
gene (C gene coding for L chain constant region) obtained from DNA coding for
human immunoglobulin is arranged in an expressible .manner to downstream of
active VL gene (rearranged VJ gene coding for L chain variable region)
obtained
from DNA coding for a mouse monoclonal antibody isolated from the hybridoma
whereby it is inserted into one or separate expression vector(s), host cell is
59
CA 02341777 2001-03-02
transformed by the expression vector and the transformed cell is incubated to
prepare an aimed one.
To be more specific, DNA is extracted from a mouse monoclonal antibody-
producing hybridoma by a common method and the DNA is digested by an
appropriate restriction enzyme (such as EcoRI, Hind III, etc.), subjected to
an
electrophoresis (using a 0.7% agarose gel for example) and subjected to a
southern
blotting. The migrated gel is stained by ethidium bromide for example and
photographed, position of the marker is marked and the gel is washed with
water
twice and dipped in a 0.25M HCl solution for 15 minutes. Then, it is dipped in
a
0.4N NaOH solution for 10 minutes and, during that period, it is gently
shaken.
It is transferred to a filter by a common method and, after 4 hours, the
filter is
recovered and washed with 2 x SSC twice. After the filter is well dried, it is
subjected to a baking (75 C for 3 hours). After completion of the baking, the
filter
is placed in a 0.1 x SSC10.1% SDS solution and treated at 65 C for 30 minutes.
Then it is dipped in a 3 x SSC/0.1% SDS solution. The resulting filter is
placed in
a vinyl bag together with a pre hybridization solution and treated at 65 C for
3-4
hours.
Then a probe DNA labeled with 32P and a hybridization solution are placed
therein and made to react at 65 C for around 12 hours. After completion of the
hybridization, the filter is washed under appropriate salt concentration,
reaction
temperature and time (e.g., 2 x SSC-0.1% SDS solution at room temperature for
10
minutes). The filter is placed in a vinyl bag and a small amount of 2 x SSC is
added, tightly sealed and subjected to an autoradiography.
Rearranged VDJ gene and VJ gene coding for H chain and L chain of the
mouse monoclonal antibody, respectively, are identified by the above-mentioned
CA 02341777 2001-03-02
southern blotting. The region containing the identified DNA fragments is
fractionated by a sucrose density gradient centrifugation, integrated into a
phage
vector (such as Charon 4A, Charon 28, A.EMBL3, a.EMBL4, etc.) and Escherichia
coli (such as LE392, NM539, etc.) is transformed by the phage vector to
prepare a
genome library. The genome library is subjected to a plaque hybridization
using
an appropriate probe (H chain J gene, L chain (x) J gene, etc.) according to,
for
example, a Benton-Davis method (Science, Vol. 196, p. 180-182, 1977) to
prepare a
positive clone containing each rearranged VDJ gene and VJ gene. A restriction
enzyme map of the resulting clone is prepared and a base sequence is
determined
whereupon it is confirmed that a gene containing the aimed rearranged VH (VDI)
gene or VL (VI) gene is obtained.
In the meanwhile, human CH gene and human CL gene each for the
preparation of chimera is isolated separately. For example, in. the
manufacture of
a chimeric antibody with human IgG1, Cy, gene which is a CH gene and Cx gene
which is a CL gene are isolated. Utilizing the high homology in base sequence
of
mouse immunoglobulin gene with human immunoglobulin gene, those genes can
be obtained by isolating from human genome library using mouse Cy, gene and
mouse Cx gene corresponding to human Cy, gene and human Cx gene as probes.
To be more specific for example, DNA fragment containing human Cx gene
and holding an enhancer region is isolated from human lambda Charon 4A
HaeI1I-AluI genome library (Cell, Vol. 15, p. 1157-1174, 1978) using Hind III-
BamHI fragment of 3 kb from clone Ig 146 (Proc. Nat]. Acad Sci. USA, Vol. 75,
p.
4709-4713, 1978) and EcoRI fragment of 6.8 kb from clone MEP 10 (Proc. Nat].
Acad. Sci. USA, Vol. 78, p. 474-478, 1981) as probes. In addition, for
example,
human fetal hepatic cell DNA is cleaved by Hind III and fractionated by an
agarose
61
CA 02341777 2001-03-02
gel electrophoresis, a band of 5.9 kb is inserted into k788 and the above-
mentioned
probe is used whereupon human Cy gene is isolated.
Using the mouse VH gene and the mouse VL gene and also the human CH
gene and the human CL gene isolated as such, the human CH gene to the
downstream of the mouse VH gene or the human CL gene to the downstream of the
mouse VL gene is integrated to an expression vector such as pSV2gpt or pSV2neo
using an appropriate restriction enzyme and DNA ligase according to a
conventional method taking the promoter region and the enhancer region, etc.
into
consideration. At that time, chimera genes of mouse VH gene/human CH gene and
mouse VL gene/human CL gene may be arranged in one expression vector at the
same time or may be arranged in each separate expression vector.
The expression vector into which chimera gene is inserted prepared as
such is introduced into a bone marrow cell which does not produce antibody by
itself such as P3X63.Ag8.653 cell or SP210 cell by means of a protoplast
fusion
method, a DEAE-dextran method, a calcium phosphate method or an
electroporation method. The transformed cell is selected by incubation in a
medium containing a pharmaceutical agent corresponding to the pharmaceutical-
resistant gene introduced into the expression vector whereupon the aimed
chimera
monoclonal antibody-producing cell is obtained.
A desired chimera monoclonal antibody is prepared from the supernatant
fluid of the incubated antibody-producing cell selected as such.
The "human type antibody (CDR-grafted antibody) of the present
invention is a monoclonal antibody which is prepared by a genetic engineering
means and, to be more specific, it means a human type monoclonal antibody
which
is characterized in that a part of or all of the complementarity-determining
region
62
CA 02341777 2001-03-02
of its hypervariable region is a complementarity-determining region of the
hypervariable region derived from the mouse monoclonal antibody, that a frame
region of its variable region is a frame region of the variable region derived
from
human immunoglobulin and that its constant region is a constant region derived
from human immunoglobulin.
Here, the complementarity-determining region of the hypervariable region
means three regions (complementarity-determining residues: CDR1, CDR2 and
CDR3) which are present in the hypervariable region of the variable region in
the
antibody and are the sites directly bonding to the antigen complementarily
while a
frame region of the variable region means the relatively conserved four
regions
(frameworks: FR1, FR2, FR3 and FR4) intervening before and after the three
complementarity-determining regions.
In other words, all regions which are other than a part of or all of the
complementarity-determining region of hypervariable region of mouse monoclonal
antibody for example mean a monoclonal antibody which is substituted for the
corresponding region of human immunoglobulin.
A constant region derived from human immunoglobulin has each specific
amino acid sequence by an isotype of IgG, IgM, IgA, IgD and IgE and the
constant
region of a human-type monoclonal antibody in the present invention may be a
constant region of human immunoglobulin belonging to any of the isotypes.
Preferably, it is a constant region of human IgG. There is no limitation for
the
frame region of the variable region derived from human immunoglobulin as well.
The human-type monoclonal antibody of the present invention can be
manufactured, for example, as follows although it goes without saying that the
manufacture is not limited to such a manufacturing method only.
63
CA 02341777 2001-03-02
For example, a recombinant human-type monoclonal antibody derived
from mouse monoclonal antibody can be prepared by a genetic engineering means
by referring to JP-W-4-506458 and Japanese Patent Laid-Open No. 296890/1987.
Thus, at least one mouse H chain CDR gene and at least one mouse L
chain CDR gene corresponding to the mouse H chain CDR gene are isolated from a
hybridoma which produces a mouse monoclonal antibody while, from human
immunoglobulin gene, a human H chain gene coding for whole regions except the
human H chain CDR corresponding to the above mouse H chain CDR and a human
L chain gene coding for all regions except the human L chain CDR corresponding
to the above mouse L chain CDR are isolated.
The mouse H chain CDR gene and the human H chain gene isolated as
such are introduced into an appropriate expression vector in an expressible
manner while, in a similar way, the mouse L chain CDR gene and the human L
chain gene are introduced into another appropriate expression vector in an
expressible manner. Alternatively, it is also possible that the mouse H chain
CDR
gene/human H chain gene and mouse L chain CDR gene/human L chain gene are
introduced into the same expression vector in an expressible manner. When a
host cell is transformed by the expression vector prepared as such, a
transformed
cell which is able to produce a human-type monoclonal antibody is obtained
and,
when the transformed cell is incubated, an aimed human-type monoclonal
antibody is obtained from the incubated supernatant liquid.
The "human antibody" of the present invention is an immunoglobulin
derived from the gene in which all regions including variable region of H
chain and
constant region of H chain and variable region of L chain and constant region
of L
chain constituting immunoglobulin code for human immunoglobulin.
64
CA 02341777 2001-03-02
The human antibody can be manufactured in the same manner as in the
above-mentioned method for the manufacture of polyclonal antibody or
monoclonal
antibody by a conventional method such as that a transgenic animal prepared by
incorporation of at least human immunoglobulin gene into locus of mammal
except
human being such as mouse is subjected to an immunological sensitization with
antigen.
For example, a transgenic mouse which produces human antibody can be
prepared by a method mentioned in Nature Genetics, Vol. 15, p. 146-156, 1997;
Nature Genetics, Vol. 7, p. 13-21, 1994; JP-W-4-504365; International Patent
Laid-Open No. WO 94/25585; Nikkei Science, issue of June, p. 40-50, 1995;
Nature,
Vol. 368, p. 856-859, 1994; and JP-W-6-500233.
"A part of the antibody" in the present invention means a part of the
region of the above-mentioned antibody or, preferably, the monoclonal antibody
of
the present invention and, to be more specific, it is F(ab')2, Fab', Fab, Fv
(variable
fragment of antibody), sFv, dsFv (disulphide stabilised Fv) or dAb (single
domain
antibody) (Exp. Opin. Ther. Patents, Vol. 6, No. 5, p. 441-456, 1996).
Here, "F(ab')2" and "Fab"' are the antibody fragments which are
manufactured by the treatment of immunoglobulin (monoclonal antibody) with a
protease such as pepsin or papain and is produced by digestion before and
after the
disulfide bond existing between the two H chains in a hinge region. For
example,
when IgG is treated with papain, it is cleaved at the upstream of the
disulfide bond
existing between the two H chains in the hinge region to manufacture two
homologous antibody fragments where L chain consisting of VL (L chain variable
region) and CL (L chain constant region) and H chain fragment consisting of VH
(H
chain variable region) and CHyl (yl region in H chain constant region) are
bonded
CA 02341777 2001-03-02
by a disulfide bond at the C terminal region. Each of those two homologous
antibody fragments is called Fab'.
When IgG is treated with pepsin, it is cleaved at the downstream of a
disulfide bond existing between two H chains in a hinge region to manufacture
an
antibody fragment where the above two Fab' are bonded in a hinge region and
the
size is a bit larger than the above. This antibody fragment is called F(ab')2.
The "monoclonal antibody-producing cell" of the present invention means
any cell which produces the above-mentioned monoclonal antibody of the present
invention. To be more specific, it is a cell mentioned in any of the following
(1) to
(3).
(1) The monoclonal antibody-producing B cell derived from non-human
mammal which produces the protein of the present invention as mentioned above,
the protein of the present invention obtained by immunization of non-human
mammal by a part thereof or by cells, etc. which express the protein or
monoclonal
antibody having a reactivity with a part thereof.
(2) The above-mentioned hybridoma (fused cell) obtained by subjecting the
antibody-producing B cell obtained as such to a cell fusion with a myeloma
cell
derived from mammal.
(3) The monoclonal antibody-producing transformed cell (genetically
recombined cell) obtained by transformation of cell except the monoclonal
antibody-producing B cell or monoclonal antibody-producing hybridoma with a
gene (anyone of gene coding for heavy chain and gene coding for light chain or
both
of them) coding for the monoclonal antibody isolated from the monoclonal
antibody-producing B cell or monoclonal antibody-producing hybridoma.
Here, the monoclonal antibody-producing transformed cell (genetically
66
CA 02341777 2001-03-02
recombined cell) mentioned in the above (3) means the genetically recombined
cell
which produces a genetic recombinant of the monoclonal antibody produced by
the
above B cell (1) or the above hybridoma (2). This recombined monoclonal
antibody-producing cell can be manufactured by the same method as used for the
manufacture of the above-mentioned chimera monoclonal antibody and human-
type antibody.
The "pharmaceutical composition" of the present invention is a
pharmaceutical composition consisting of, for example, any of the following
(a) to
(c) with a pharmaceutically acceptable carrier.
(a) the above-defined antibody (preferably, monoclonal antibody; that is
not limited to an antibody derived from nature or a recombined antibody) or a
part
of the antibody.
(b) DNA fragment useful as an antisense pharmaceutical agent such as
the following DNA:
"DNA containing a partial base sequence in the base sequence mentioned
in SEQ ID NO:1 or NO:3 or, preferably, the partial base sequence having 14 or
more bases or DNA where a part of the DNA is chemically modified; or DNA
containing a base sequence complementary to the partial base sequence or DNA
where a part of the DNA is chemically modified"
(c) RNA fragment which is useful as an antisense pharmaceutical agent
such as the following RNA:
"in an RNA containing a partial base sequence of the base sequence of
RNA having a base sequence complementary to the base sequence mentioned in
SEQ ID NO:26 or NO:27 or RNA where a part of the RNA is chemically modified,
the RNA which is characterized in that the RNA or the chemically modified RNA
is
67
CA 02341777 2001-03-02
hybridized to an RNA coding for the protein having an amino acid sequence
mentioned in SEQ ID NO:2".
Here, "pharmaceutically acceptable carrier" is, for example, excipient,
diluent, filler, disintegrating agent, stabilizer, preservative, buffer,
emulsifier,
aromatizer, coloring agent, sweetener, thickener, corrigent, solubilizing aid
and
other additives. One or more of such carrier(s) is/are used whereby a
pharmaceutical composition in a form of tablets, pills, diluted powder,
granules,
injections, liquids, capsules, troches, elixirs, suspensions, emulsions,
syrups, etc.
can be prepared.
Such a pharmaceutical composition can be administered either orally or
parenterally. Other forms for a parenteral administration include liquid agent
for
external use, suppositories for enteric administration and pessaries
containing one
or more active substance(s) and being formulated according to a conventional
method.
The dose may vary depending upon age, sex, body weight and symptom of
the patient, therapeutic effect, administering method, treating time, type of
the
active ingredient (the above-mentioned protein or antibody) contained in the
pharmaceutical composition, etc. but, usually, it is within a range of from 10
g to
1,000 mg (or from 10 ~tg to 500 mg) for one administration to an adult.
However,
the dose varies according to various conditions and, therefore, less amount
than
the above may be sometimes sufficient or more than the above range may be
sometimes necessary.
Especially in the case of an injection preparation, it is prepared, for
example, by dissolving or suspending the ingredient in a non-toxic
pharmaceutically acceptable carrier such as a physiological saline or
commercially
68
CA 02341777 2001-03-02
available distilled water for injection so as to make the concentration of
from 0.1 g
antibody/ml carrier to 10 mg antibody/ml carrier.
The injection preparation prepared as such may be administered to a
human patient to be treated from one to several times a day in a dose of from
1 g
to 100 mg or, preferably, from 50 jug to 50 mg per kg body weight for each
administration. Examples of the dosage form are medically appropriate dosage
forms such as intravenous injection, subcutaneous injection, intracutaneous
injection, intramuscular injection and intraperitoneal injection. Intravenous
injection is preferred.
In some cases, an injection preparation may be prepared as a suspension
or an emulsion using a non-aqueous diluent (for example, propylene glycol,
polyethylene glycol, vegetable oil such as olive oil, alcohol such as ethanol,
etc.).
Aseptization of such an injection preparation can be carried out by means
of a filtration sterilization passing through a bacteria-retaining filter,
compounding of bactericide or irradiation. Injection preparation can be
manufactured in a form of to-be-prepared-before-use. Thus, an aseptic solid
composition is prepared by means of freeze-drying or the like and may be used
by
dissolving in aseptic distilled water for injection or other solvent before
use.
The pharmaceutical composition of the present invention is able to inhibit
the biological activity of the amino acid transporter molecule of the present
invention or expression of the molecule and to inhibit the incorporation of
the
amino acid which is an essential nutrient for the existence or the
proliferation of
tumor cell into cells and can be used for the therapy of cancer.
The "transgenic mouse" of the present invention is a transgenic mouse
where DNA (cDNA or genomic DNA) coding for the protein derived from human
69
CA 02341777 2001-03-02
being included in the protein of the present invention is integrated onto the
intrinsic locus of the mouse and the protein of the present invention is
expressed in
the body.
To be more specific, it is a transgenic mouse mentioned in the above <52>
or <53> and is shown in the following (1) or (2).
(1) in a transgenic mouse having an extrinsic gene, a transgenic mouse
which is characterized in that, in the mouse, DNA coding for the protein
having an
amino acid sequence mentioned in SEQ ID NO:2 is incorporated onto its
intrinsic
gene whereby cells expressing the protein are present in the body.
(2) the transgenic mouse according to the above (1), wherein the DNA is a
DNA containing a base sequence consisting of the base sequence of from 66th to
1586th bases of the base sequence mentioned in SEQ ID NO:1 and any one of the
nonsense base sequences represented by TAG, TGA and TAA adjacent to the
1586th base.
The transgenic mouse can be prepared by a usual method which is
commonly used in the manufacture of transgenic animals (e.g., refer to Newest
Manual forAnirnal Cell Tests, published by LIC, Chapter 7, p. 361-408, 1990).
To be more specific, embryonic stem cell (ES cell) obtained from blastocyst
of normal mouse is transformed by an expression vector into which marker gene
(such as neomycin resistant gene) and gene coding for the protein having an
amino
acid sequence mentioned in SEQ ID NO:2 of the present invention are inserted
in'
an expressible manner. The ES cell where the gene coding for the protein is
integrated onto the intrinsic gene is selected by a conventional method
depending
upon the fact whether the marker gene is expressed. Then, the ES cell selected
as
such is microinjected into a fertilized ovum (blastocyst) obtained from
another
CA 02341777 2001-03-02
normal mouse (Prom. Nat]. Acad. Sci. USA, Vol. 77, No. 12, pp. 7380-7384,
1980;
U.S. Patent No. 4,873,191). The blastocyst is used as a preliminary parent and
is
transplanted to uterus of another normal mouse. As such, a founder mouse
(child
mouse) is born from the preliminary parent mouse. The founder mouse is crossed
with a normal mouse to give a heterogeneic transgenic mouse. The heterogeneic
transgenic mice are crossed to give a homogeneic transgenic mouse according to
Mendel's laws.
It is also possible to prepare the so-called "knockout mouse" based upon a
base sequence of DNA (particularly, genomic DNA) coding for protein derived
from
mouse involved in the present invention, that is, DNA (particularly, genomic
DNA)
coding for a mouse homologue of human-derived amino acid transporter having an
amino acid sequence mentioned in SEQ ID NO:2.
The knockout mouse is a mouse where the intrinsic gene coding for the
mouse homologue protein is knocked out (inactivated) and can be prepared, for
example, by a positive negative selection method applying a homologous
recombination (U.S. Patents Nos. 5,464,764, 5,487,992 and 5,627,059; Proc.
Nat].
Acad. Sci. USA, Vol. 86, p. 8932-8935, 1989; Nature, Vol. 342, p. 435-438,
1989;
etc.). Such a knockout mouse is an embodiment of the present invention as
well.
"Labeled DNA" of the present invention is a DNA labeled with enzyme,
fluorescent substance, chemiluminescent substance, biotin, avidin or
radioisotope
(such as 3H 14C, 1251, 1311, etc.) used for the labeling of "labeled
monoclonal
antibody" which will be mentioned later.
For example, a radiolabeled DNA which is labeled with a radioisotope can
be used as a reagent in various test methods, such as southern blotting, for
identification of gene coding for the protein of the present invention (Jikken
Igaku,
71
CA 02341777 2001-03-02
Supplementary Issue, "Handbook of Genetic Engineering", published by Yodosha,
p. 133-140, 1992).
In addition, a labeled DNA which is labeled with a radioactive substance
or with a non-radioactive substance such as biotin can be used as a reagent in
an
in situ hybridization for the analysis of the position of genomic DNA coding
for the
protein of the present invention on chromosomes (e.g., FISH (fluorescence in
situ
hybridization), Jikken Igaku, Supplementary Issue, "Handbook of Genetic
Engineering", published by Yodosha, 1992, p. 271-277).
"Radiolabeled RNA" of the present invention is an RNA where the RNA of
the present invention is labeled with a radioisotope such as 3H 14C+ 1251,
1311, etc.
The radiolabeled RNA is useful as a reagent for the analysis of expressed
state of mRNA coding for the protein of the present invention in cells,
tissues or
organs such as a northern blotting (Jikken Igaku, Supplementary Issue,
"Handbook of Genetic Engineering", published by Yodosha, p. 133-140, 1992).
The "labeled substance which can achieve a detectable signal by itself or
by the reaction with another substance" for labeling "labeled monoclonal
antibody"
of the present invention means a substance which is used for a step where it
is
bonded to the above-defined monoclonal antibody by a physicochemical bond,
etc.
so that the presence of the monoclonal antibody can be detected.
To be more specific, it is enzyme, fluorescent substance, chemiluminescent
substance, biotin, avidin, radioisotope, or the like.
To be still more specific, enzyme such as peroxidase (e.g., horseradish
peroxidase), alkaline phosphatase, (3-D-galactosidase, glucose oxidase,
glucose-6-
phosphate dehydrogenase, alcohol dehydrogenase, malic acid dehydrogenase,
penicillinase, catalase, apoglucose oxidase, urease, luciferase and
acetylcholine
72
CA 02341777 2001-03-02
esterase; fluorescent substance such as fluorescein isothiocyanate,
phycobiliprotein, rare earth metal chelate, dansyl chloride and tetramethyl
rhodamine isothiocyanate; radioisotope such as 3H 14C 1231 and 131I; biotin;
avidin;
and chemiluminescent substance may be exemplified.
Here, each of a radioisotope and a fluorescent substance is solely able to
give a detectable signal. On the contrary, each of enzyme, chemiluminescent
substance, biotin and avidin is solely unable to give a detectable signal and,
therefore, a detectable signal is resulted upon the reaction with one or more
other
substance(s). For example, in the case of enzyme, at least a substrate is
necessary and, depending upon a method for the measurement of the enzymatic
activity (e.g., colorimetric method, fluorescent method, bioluminescent
method,
chemiluminescent method, etc.), various substrates are used. For example, in
the
case of peroxidase, hydrogen peroxide is used as a substrate. In the case of
biotin,
it is common to conduct a reaction using at least avidin or an enzyme-modified
avidin (such as streptoavidin-(3-galactosidase) as a substrate although that
is not a
limitation. If necessary, various coloring substances depending upon the
substrate may be used. For example, when streptoavidin-(3-galactosidase is
used
as a substrate for biotin, it is possible to use 4-methyl-umbelliferyl-(3-D-
galactosidase as a coloring substance.
The "labeled monoclonal antibody" of the present invention and the
above-mentioned "labeled DNA" mean a monoclonal antibody and DNA,
respectively, which are labeled with various labeling substances as mentioned
above.
The labeled monoclonal antibody can be used for the detection or the
quantitative determination of the above-mentioned protein of the present
73
CA 02341777 2001-03-02
invention. To be more specific, it can be used for the detection of the
expression or
for the measurement of the expressed amount of the protein of the present
invention in various living body samples such as cells (regardless of normal
cells,
abnormal cells such as tumor cell derived from a living body suffering from
disease,
natural cells and genetically recombined cells), tissues (regardless of the
source
whether they are from healthy organism or from organism suffering from
disease)
or organs (regardless of the source whether they are from healthy organism or
from organism suffering from disease). Such a measurement can be carried out
according to a conventional method using a commonly used immunohistological
technique (Jikken Igaku, Supplementary Issue, "Handbook of Cell Engineering",
Yodosha, p. 207-213, 1992).
Further, the labeled monoclonal antibody of the present invention can be
used not only for the above-mentioned immunohistological test but also for a
western blotting method where a soluble membrane protein is prepared from the
cell, tissue, organ or a part thereof as a sample to be tested by a
conventional
method and the soluble membrane protein is made to react with the labeled
monoclonal antibody whereby the presence or absence of the protein of the
present
invention in the soluble membrane protein can be confirmed (Jikken Igaku,
Supplementary Issue, "Handbook of Cell Engineering", Yodosha, p. 201-206,
1992).
In the immunohistological measurement mentioned as above, any labeled
monoclonal antibody which is labeled with any of the above-mentioned labeling
substances may be used but, when high detection sensitivity or quantitative
sensitivity and convenience in the operation are taken into consideration, it
is
preferred to use a monoclonal antibody which is labeled with an enzyme such as
peroxidase or with biotin.
74
CA 02341777 2001-03-02
The present invention also relates to a method for the detection or for the
quantitative determination of the protein of the present invention by an
immmunohistological technique using the above-mentioned labeled monoclonal
antibody. To be more specific, it is a method as mentioned above containing,
for
example, the following steps (1) and (2).
(1) a step where the sample is contacted to the labeled monoclonal
antibody of the present invention; and
(2) a step where the amount of the labeled monoclonal antibody bonded to
the sample is measured by the detection of fluorescence, chemiluminescence or
radioactivity depending upon the type of the labeling substance bonded to the
labeled monoclonal antibody.
Here, "cell" covers a primary culture cell obtained from human organism,
cell line made into subculturable and genetically recombined cell (transformed
cell) where a genetic operation is carried out and, preferably, it is a
primary culture
cell. The cell further covers normal cell and abnormal cell obtained from
organism of a patient suffering from disease. Examples of the abnormal cell
are
various tumor cells. The term "tissue" means any tissue derived from organism
of
a healthy animal or of a patient suffering from disease and examples of the
tissue
derived from organism of the patient are tumor tissues. The term "organ or a
part thereof' means any organ derived from organism of a healthy animal or of
a
patient suffering from disease or a part thereof. Examples of the organ
derived
from the patient are organs having tumor.
To be more specific, the method of the present invention may, for example,
include the following steps although this is not a limitation.
(step 1) a step where normal cell, normal tissue or normal organ which is
CA 02341777 2001-03-02
derived, for example, from a healthy person which is excised upon surgical
operation and discarded or a part thereof or tumor cell, tumor tissue or tumor-
having organ derived from a patient suffering from cancer or a part thereof
(the
organ or a part thereof may, if necessary, be sliced to give a slice) is fixed
with
para-formaldehyde or the like to prepare a fixed sample;
(step 2) a step where the labeled monoclonal antibody of the present
invention which is labeled with biotin or enzyme such as peroxidase is added
to the
fixed sample to carry out an antigen-antibody reaction;
(step 3) a step where the fixed sample is washed if necessary and then
substrate depending upon the type of the enzyme used or avidin or enzyme-
modified avidin such as streptoavidin-3-galactosidase is added whereupon the
labeled substance on the labeled antibody is made to react with the substrate,
avidin or enzyme-modified avidin (with regard to the substrate, it is possible
to
add hydrogen peroxide together with diaminobenzidine, 4-chloro-1-naphthol or
aminoethylcarbazole in case a labeled antibody which is labeled with enzyme
such
as peroxidase is used in step 2; avidin or enzyme-modified avidin is used when
a
labeled antibody which is labeled with biotin is used in step 2);
(step 4) a step where, in case an enzyme-modified avidin is used in step 3,
a substrate depending upon the type of the enzyme used for the modification
(such
as 4-methyl -umbelliferyl-(3-D-galactoside) is added whereupon the substrate
is
made to react with the enzyme bonded to avidin;
(step 5) a step where the fixed sample is washed if necessary so that an
enzymatic reaction and a coloring reaction are stopped; and
(step 6) a step where the fixed sample is observed under a microscope to
measure the color intensity, fluorescence intensity or luminescence intensity.
76
CA 02341777 2001-03-02
Since the amino acid transporter protein of the present invention shows a
specific expression in a broad range of tumor cells as compared with the
expression
in normal cells, there is a possibility to judge whether the cell or tissue to
be tested
is normal or abnormal such as tumor cell when the expression of the protein is
detected in various cells or tissues of organism using the above-mentioned
immunohistological method.
Another feature of the present invention is to identify a substance which
has an ability of inhibiting the biological activity of the protein of the
present
invention. To be specific, it is a method which was mentioned already for
example.
"A method for identifying a substance having an action of suppressing the
ability for mediating the incorporation of any one amino acid selected from a
group
consisting of leucine (Leu), isoleucine (Ile), phenylalanine (Phe), methionine
(Met),
tyrosine (Tyr), histidine (His), tryptophan (Trp) and valine (Val) into cells
where
the ability is a biological function of the protein having an amino acid
sequence
mentioned in SEQ ID NO:2 or NO:4, characterized in that, the method comprises
the steps of the following (1) and (2).
(1) a step in which any of the cells mentioned in the following (a) to (d) is
incubated in the coexistence of the substance and a radiolabeled amino acid
where
any one amino acid selected from a group consisting of leucine (Leu),
isoleucine
(Ile), phenylalanine (Phe), methionine (Met), tyrosine (Tyr), histidine (His),
tryptophan (Trp) and valine (Val) is labeled with a radioisotope or in the
presence
of the radiolabeled amino acid only:
(a) a naturally-occurring cell in which a protein having an amino acid
sequence mentioned in SEQ ID NO:2 or NO:4 and a protein having an amino acid
77
CA 02341777 2001-03-02
sequence mentioned in SEQ ID NO:6 are co-expressed;
(b) a recombinant cell in which a protein having an amino acid sequence
mentioned in SEQ ID NO:2 and a protein having an amino acid sequence
mentioned in SEQ ID NO:6 or NO:8 are co-expressed by a co-transformation using
a DNA containing a base sequence of a translation region in the base sequence
mentioned in SEQ ID NO:1 or NO:3;
(c) a non-human-derived recombinant cell in which a protein having an
amino acid sequence mentioned in SEQ ID NO:2 and a protein having an amino
acid sequence mentioned in SEQ ID NO:6 are co-expressed by a co-introduction
of
an RNA containing a base sequence of 1st to 1521st bases in the base sequence
mentioned in SEQ ID NO:26 and a base sequence comprising any one nonsense
base sequence represented by UAG, UGA or UAA adjacent to the 1521st base and
an RNA containing a base sequence of 1st to 1587th bases in the base sequence
mentioned in SEQ ID NO:27 and a base sequence comprising any one nonsense
base sequence represented by UAG, UGA or UAA adjacent to the 1587th base; or
(d) a tumor cell derived from human being; and
(2) a step in which the radioactivity of the cell incubated in the coexistence
of the substance and the radiolabeled amino acid and the radioactivity of the
cell
incubated in the presence of the radiolabeled amino acid only are measured and
the difference between them is compared.
Thus, the method of the present invention is a method which is
characterized in that a property of a cell in which the amino acid transporter
protein of the present invention (having an amino acid sequence mentioned in
SEQ
ID NO:2) and the human-derived cell membrane surface molecule 4F2hc (having
an amino acid sequence mentioned in SEQ ID NO:6) are co-expressed has an
78
CA 02341777 2001-03-02
ability of incorporating at least any amino acid from leucine (Leu),
isoleucine (Ile),
phenylalanine (Phe), methionine (Met), tyrosine (Tyr), histidine (His),
tryptophan
(Trp) and valine (Val).
Thus, the inhibiting activity of the test substance can be measured by a
comparison of the amount of the labeled amino acid incorporated by the cell in
an
incubation of the cell in the presence of any of the above-mentioned amino
acids
labeled with a radioisotope (3H 14C 125, or 1311, etc.) and the test substance
with the
amount of the labeled amino acid incorporated by the cell in an incubation of
the
cell in the presence of the labeled amino acid only containing no the test
substance.
With regard to the cell, any cell may be utilized so far as it is a cell which
co-expresses the two protein molecules. For example, any of the natural cell
mentioned in the above (a), the transformed cell (genetically recombined cell)
which is transformed by two DNA's coding for each of the both protein
molecules as
mentioned in (b), the cell into which RNA coding for each of the both protein
molecules as mentioned in (c) is introduced and the tumor cell derived from
human
being as mentioned in (d) may be used.
With regard to the host cell used for the preparation of the transformed
cell, various cells which are mentioned in the passage where a method for the
expression of the protein of the present invention using the DNA of the
present
invention is mentioned in detail may be used.
For example, various cells such as natural cell or artificially established
recombinant cell which are commonly used in the technical field of the present
invention (e.g., bacteria (such as those belonging to genus Escherichia and to
genus Bacillus), yeast (genus Saccharomyces, Pichia, etc.), animal cells or
insect
cells) may be exemplified.
79
CA 02341777 2001-03-02
Preferred ones are Escherichia coli and animal cells and, to be more
specific, E. coli (DH5a, TB1, HB101, etc.), cells derived from mouse (COP, L,
C127,
Sp2/0, NS-1, NIH3T3, etc.), cells derived from rat (PC 12, PC12h, etc.), cells
derived
from hamster (BHK, CHO, etc.), cells derived from monkey (COS1, COS3, COST,
CV1, Velo, etc.) and cells derived from human being (HeLa, cells derived from
diploid fibroblast, HEK293 cell, myeloma cell, Namalwa, etc.) may be
exemplified.
With regard to the cell into which the RNA is infused, oocytes of Xenopus
laevis may be exemplified (Special Issue of Jikken Igaku, "Experimental
Methods
for Biosignals", Vol. 11, No. 3, p. 30-38, 1993).
With regard to the tumor cell derived from human being, any tumor cell
may be used although it is preferred to use a tumor cell where the protein
having
an amino acid sequence mentioned in SEQ ID NO:2 and the protein having an
amino acid sequence mentioned in SEQ ID NO:6 are confirmed to be co-expressed.
Here, "substance" means a natural substance existing in nature and any
substance which is artificially prepared. The substance may be roughly
classified
into "peptide substance" and "non-peptide substance".
With regard to the "peptide substance", the above fully mentioned
antibody of the present invention (preferably monoclonal antibody and,
particularly preferably, recombined human-type monoclonal antibody or human
monoclonal antibody), oligopeptide and chemically modified substance of any of
them. With regard to the oligopeptide, a peptide comprising 5 to 30 amino
acids
or, preferably, 5 to 20 amino acids may be exemplified. The chemical
modification
may be designed depending upon various objects such as an increase in half
life in
blood when administered to organism, an increase in resistance to
decomposition
or absorption in a digestive organ when administered orally, etc.
CA 02341777 2001-03-02
With regard to the "non-peptide substance", there may be exemplified
"DNA containing a partial base sequence or chemically modified DNA prepared by
a chemical modification thereof' useful as an antisense pharmaceutical agent
fully
mentioned in the definition of the invention in the above-mentioned <4>, "RNA
containing a partial base sequence or chemically modified RNA prepared by a
chemical modification thereof' useful as an antisense pharmaceutical agent
fully
mentioned in the definition of the invention in the above-mentioned <6> and
chemically synthesized any "compound". Here, with regard to the "compound",
there may be exemplified a compound having a molecular weight of about 100 to
about 1,000, preferably from about 100 to about 800 or, more preferably, from
about 100 to about 600 except DNA, RNA and the above-mentioned peptide
substance.
With regard to the substance which can identified by the method for the
identification of the present invention, a substance having an ability of
inhibiting
the proliferation of any tumor cell generated in any tissue of human body is
desired. Examples of the tissue are brain, neck, liver, spleen, kidney, large
intestine, small intestine, duodenum, prostate gland, lung, stomach, heart,
skin,
bone marrow, uterus, ovary, testicle, mouth, tongue, bone and chest.
Still another feature of the present invention is a method for the
identification of a substance having an ability of inhibiting the
transcription of the
gene coding for the protein of the present invention to mRNA or the expression
of
protein of the present invention. To be more specific, it is the following
method
which was mentioned already.
"a method for the identification of a substance having an ability of
inhibiting the transcription of the gene coding for the protein having an
amino acid
81
CA 02341777 2001-03-02
sequence mentioned in SEQ ID NO:2 or NO:4 to mRNA or the expression of the
protein having an amino acid sequence mentioned in SEQ ID NO:2 or 4 which is
characterized in containing the following steps:
(1) a step where a cell which is a cell co-transformed by the DNA of the
following (a), (b) and (c) and the cell is transformed in such a manner that,
depending upon the expression of the protein having an amino acid sequence of
SEQ ID NO:2 coded by the DNA of the (a), a reporter protein coded by the DNA
of
the (c) is expressed at the same time is incubated in the presence or absence
of the
substance:
(a) DNA containing a base sequence of the translation region of the base
sequence mentioned in SEQ ID NO:1 or NO:3;
(b) DNA containing a base sequence of the translation region of the base
sequence mentioned in SEQ ID NO:5 or NO:7;
(c) DNA coding for a reporter protein; and
(2) a step where expressed amounts of the reporter protein in each of the
cells incubated in the presence of the substance and those incubated in the
absence
of the substance are measured and compared".
The method is the so-called "reporter gene assay" and, to be more specific,
it is a method where DNA coding for the amino acid transporter molecule of the
present invention, DNA coding for the expression adjustment controlling region
of
the DNA and DNA coding for reporter protein generating fluorescence
(luciferase
derived from firefly, umishiitake [a kind of marine plants], etc.; GFP (green
fluorescence protein) derived from jellyfish; etc,) are inserted in such a
manner
that the reporter protein molecular can be expressed depending upon the
expression of the transporter molecule, cell which is commonly used for the
82
CA 02341777 2001-03-02
manufacture of genetically recombined protein is transformed by the above-
prepared expression vector, the resulting one is contacted to the test
compound
and the amount of transporter molecule expressed depending upon the action of
the compound is indirectly measured by measuring the amount of fluorescence
generated by the reporter protein which is expressed together with the
expression
of the molecule whereupon it is analyzed whether the compound affects the
expression of the transporter molecule (U.S. Patent Nos. 5,436,128 and
5,401,629
may be referred to for example).
Incidentally, although the identification of the compound using the
present assay is possible by means of a manual operation, that can be carried
out
quickly and easily using the so-called high through-put screening where the
assay
is carried out automatically using a machine (robot) (Soshiki Baiyo Kogaku,
Vol. 23,
No. 13, p. 521-524; U.S. Patent No. 5,670,113).
The terms "cell" and "substance" used in the above-mentioned method are
the same as those defined already.
Examples
The present invention will now be illustrated in more detail by way of
Examples although it goes without saying that the present invention is not
limited
to the embodiments mentioned in those Examples only.
Incidentally, in the following Examples, each operation was carried out
according to the method mentioned in Molecular Cloning (by Sambrook, J.,
Fritsh,
E. F. and Maniatis, T.; published by Cold Spring Harbor Press in 1989) unless
otherwise mentioned or, when a commercially available reagent or kit was used,
it
was used according to the directions for use thereof.
83
CA 02341777 2001-03-02
Example 1. Isolation of cDNA of human cell membrane surface molecule 4F2hc
and preparation of cRNA.
(1) Preparation of cDNA fragment coding for rat 4F2hc by means of an
RT-PCR.
According to the conventional method, pure poly(A)+RNA was prepared
from liver of rat. 5'-Primer (SEQ ID NO:9) and 3'-primer (SEQ ID NO:10) were
also synthesized based upon a cDNA sequence (Biochem. I, Vol. 312, p. 863,
1995)
coding for rat 4F2hc.
An RT-PCR (reverse transcription-polymerase chain reaction; Jikken
Igaku, Supplementary Issue, "PCR and Its Applications", Vol. 8, No. 9, 1990;
and
"Gene Amplification PCR - Its Basis and New Developments", published by
Kyoritsu Shuppan, 1992) was carried out using the two primers and Taq
polymerase (manufactured by Takara) where the poly(A)+RNA was used as a
template. The reaction was carried out according to the protocol attached the
polymerase using a DNA Thermal Cycler (manufactured by Perkin Elmer Cetus).
The amplified cDNA was subjected to an agarose electrophoresis and
purified using a DNA extraction kit (manufactured by Qiagen) to prepare a
fragment of rat 4F2hc gene (from 34th to 479th bases of the base sequence
mentioned in SEQ ID NO:7).
Incidentally, the cDNA sequence coding for the rat 4F2hc and the
corresponding amino acid sequence were mentioned in SEQ ID NO:7 and NO:8,
respectively.
(2) Manufacture of cDNA coding for human 4F2hc and preparation of
cRNA.
84
CA 02341777 2003-09-12
A kit for the synthesis of cDNA (trade name: Superscript Choice System;
manufacture by Gibco) is used and, according to the experimental operation
method
attached to the kit, human cDNA was prepared from poly(A)RNA (manufactured by
Clontech) derived from human placenta and the cDNA was integrated into a
cleaved
site of a phage vector ? ZipLox TM (manufactured by Gibco) with a restriction
enzyme
EcoRI using a DNA ligase (manufactured by Gibco) to prepare a human cDNA
library.
The gene fragment of rat 4F2hc prepared in the above (1) was labeled with 32
to manufacture a probe and that was used as a probe for a plaque
hybridization.
The above-prepared human cDNA library was screened as follows using the
probe.
The cDNA library was sown on an agar plate and a replica was prepared using
a commercially available filter membrane. A hybridization was carried out at
37 C for
one night in a hybridization solution using the replica and the radioactive
probe. With
regard to the solution for the hybridization, a buffer of pH 6.5 containing 5
x SSC, 3 x
Denhard's solution, 0.2% of SDS, 10% of dextran sulfate, 50% of formamide,
0.01 %
of Antifoam B (an antifoaming agent manufactured by Sigma), 0.2 mg/ml of
salmon
sperm-modified DNA, 2.5 mM of sodium pyrophosphate and 25 mM of MES was
used. The filter membrane was washed with 0.1 x SSC/0.1 % SDS at 37 C.
The positive clone selected by the hybridization was isolated by a single
plaque, subjected to an in vivo excision, recombined to a plasmid pZLI
(manufactured by Gibco) and recovered as a plasmid DNA. The plasmid DNA was
further subcloned to a pBlueScriptII TM SR (-) (manufactured by Stratagene).
CA 02341777 2001-03-02
In order to determine the base sequence of cDNA of human 4F2hc
contained in the resulting clone, seven kinds of primers were synthesized (SEQ
ID
NO:11 to SEQ ID NO:17). The base sequence of cDNA was determined by a
dyeterminator cycle sequencing method (by Applied Biosystems) using the seven
kinds of synthetic primers and T7 primers and SP6 primers which were the
commercially available universal primers (manufactured by Stratagene). As a
result, it was confirmed that the cloned cDNA was that of the gene of human
4F2hc.
Incidentally, the cDNA sequence coding for the human 4F2hc and the
corresponding amino acid sequence were mentioned in SEQ ID NO:5 and SEQ ID
NO:6, respectively.
From the plasmid containing the cDNA of human 4F2hc prepared as above,
cRNA (an RNA complementary to cDNA; SEQ ID NO:27) was prepared according
to a conventional method using a T7 RNA polymerase (manufactured by
Stratagene) (Special Issue of Jikken Igaku, "Method of Experiments of
Biosignals",
Vol. 11, No. 3, p. 33-34, 1993).
Example 2. Isolation of cDNA of human amino acid transporter LAT1 and
preparation of cRNA.
Human cDNA was prepared from poly(A)+RNA (purchased from Clontech)
derived from human teratocarcinoma cell line PA-1 using a kit for the
synthesis of
cDNA (trade name: Superscript Choice System; manufactured by Gibco) according
to an experimental operation method attached to the kit and then the cDNA was
integrated into a site of a phage vector XZipLox (manufactured by Gibco)
cleaved
by a restriction enzyme EcoRI using a DNA ligase (manufactured by Gibco) to
86
CA 02341777 2003-09-12
prepare a human cDNA library.
cDNA (DDBJ/EMBL/Gen Bank TM registration No: AB015432; a segment
corresponding to 1135th to 1529th bases of SEQ ID NO:3) coding for a rat amino
acid transporter LAT1 was excised by a restriction enzyme BamHI. Incidentally,
an
amino acid sequence of the rat amino acid transporter LAT1 was mentioned in
SEQ
ID N0t4.
This DNA segment was labeled with 32 to prepare a probe and it was used as
a probe for a plaque hybridization.
The above-prepared human cDNA library was screened as followes using the
probe.
The cDNA library was sown on an agar plate and a replica was prepared using
a commercially available filter membrane. A hybridization was carried out for
one
night at 37 C in a hybridization solution using the replica and the
radioactive probe.
With regard to the solution for the hybridization, a buffer of pH 6.5
containing 5 x
SSC, 3 x Denhard's solution, 0.2% of SDS, 10% of dextran sulfate, 50% of
formamide, 0.0 1% of Antifoam B (an antifoaming agent manufactured by Sigma),
0.2 mg/ml of salmon sperm-modified I)NA, 2.5 mM of sodium pyrophosphate and 25
mM of MES was used. The filter membrane was washed with 0.1 x SSC/0.1% SDS at
37 C.
The positive clone selected by the hybridization was isolated by a single
plaque, subjected to an in vivo excision, recombined to a plasmid pZL I
(manufactured
by Stratagene) and recovered as a plasmid DNA. The plasmid DNA was excised by
a
restriction enzyme PstI to give three cDNA fragments having the sizes of 1.8
kb, 2.5
kb and 4.3 kb. Each of the fragments of 1.8 kb and 2.5 kb was subcloned to a
pBlueScriptllTM SR (-) (manufactured by Stratagene).
87
CA 02341777 2001-03-02
The cDNA fragment of 4.3 kb was subjected to a self-ligation.
In order to determine the base sequence of cDNA of human amino acid
transporter LAT1 contained in each of the plasmids having the three cDNA
fragments, eight kinds of primers were synthesized (SEQ ID NO:18 to SEQ ID
NO:25). The base sequence of cDNA was determined by a diterminator cycle
sequencing method (by Applied Biosystems) using the eight kinds of synthetic
primers and M13 forward primer and M13R reverse primer which were the
commercially available universal primers (manufactured by Stratagene).
The resulting sequence of full-length cDNA coding for the human amino
acid transporter LAT1 and the corresponding amino acid sequence were mentioned
in SEQ ID NO:1 and SEQ ID NO:2, respectively.
Further, from the resulting plasmid containing the cDNA of human 4F2hc
coding for the human amino acid transporter LAT1, cRNA (SEQ ID NO:26; an RNA
complementary to cDNA) was prepared using a T3 RNA polymerase
(manufactured by Stratagene).
When a homology in the amino acid sequences for a rat amino acid
transporter LAT1 and for a human amino acid transporter LAT1 was analyzed, the
human LAT1 had an amino acid homology of about 91% to the rat LAT1. The
result is shown in Fig. 1.
When an amino acid sequence of the human amino acid transporter LAT1
was analyzed by a hydrophobic plot analysis (Kyte-Doolittle hydropathy
analysis),
it was estimated that the human LAT1 was a cell membrane surface molecule
having 12 transmembrane domains (membrane-spanning domains). The result is
shown in Fig. 2.
88
CA 02341777 2001-03-02
Example 3. Analysis of expression of mRNA of human amino acid transporter
LAT1 in various tissues of human being.
The cDNA coding for the human amino acid transporter LAT1 (cDNA
fragment corresponding to 649th to 1128th bases of SEQ ID NO: 1) was excised
by a
restriction enzyme Smal and labeled with 32P-dCTP to prepare a hybridization
probe. A northern blotting to various tissues of human being was carried out
using the probe as follows.
A Nylon membrane where human poly(A)+RNA was blotted (trade name:
MTN Blot; manufactured by Clontech) was subjected to hybridization and washing
using the 32P-dCTP-labeled human LAT1 probe according to the protocol attached
to the kit. The result is shown in Fig. 3.
As a result, expression of mRNA of human LAT1 having a size of about 4.8
kb was noted in placenta, brain, testis, bone marrow and fetal liver. A weak
expression of mRNA was noted in peripheral leukocytes as well.
Example 4. Analysis of biological activity of human amino acid transporter
LAT1.
(1) Analysis of ability of mediating the transport of amino acid into the
cell.
From the studies up to now concerning the proliferation of tumor cells, it
has been predicted that the known heavy chain (4F2hc) of a cell membrane
surface
antigen which is a heterodimer of heavy chain classified under a glycoprotein
of
type II and light chain and named 4F2 (CD98) may play an important role in
activation of an amino acid transporter which has not been identified yet (J
Immunol., Vol. 126, p. 1409-1414, 1981; J. Immunol., Vol. 129, p. 623-628,
1982;
Proc. Nat]. Acad. Sci. USA, Vol. 84, p. 6526-6530, 1987; Cancer Res., Vol. 46,
p.
89
CA 02341777 2001-03-02
1478-1484, 1986; J. Biol. Chem., Vol. 267, p. 15285-18288, 1992; Proc. Natl.
Acad.
Sci. USA, Vol. 89, p. 5606-5610, 1992; Biochem. J., Vol. 324, p. 535-541,
1997; and J.
Expt. Biol., Vol. 196, p. 123-137, 1994).
In view of the above, the fact whether the amino acid transporter LAT1 of
the present invention carries the transport of the amino acid into the cells
was
analyzed by such a method that the cells in which only human LAT1 was
expressed and other cells in which both human LAT1 and human 4F2hc were
expressed together were used and the incorporated amounts of leucine (neutral
amino acid) into each cells were measured.
Incidentally, such a test method is based upon a method where oocytes of
Xenopus laevis which are commonly used in the incorporation test of various
substances into cells are used (Special Issue of Jikken Igaku, "Method of
Experiments of Biosignals", Vol. 11, No. 3, p. 30-38, 1993).
A sole cRNA (25 ng) coding for the human LAT1 prepared in the above
Example, a sole cRNA (25 ng) coding for the human 4F2hc prepared in the above
Example, or the cRNA (17.5 ng) coding for the human LATI together with the
cRNA (7.5 ng) coding for the human 4F2hc was injected into oocytes of Xenopus
laevis and incubated for 2 or 5 days whereupon oocytes expressing the human
LAT1 only, oocytes expressing the human 4F2hc only and oocytes co-expressing
the
human LAT1 and the human 4F2hc were prepared, respectively.
A radiolabeled leucine which was radiolabeled with 14C was used as a
substrate and incorporation of the labeled leucine for each oocytes was
carried out
as follows according to a method by Kanai, et al. (Kanai and Hediger, Nature,
Vol.
360, p. 467-471, 1992).
Thus, to be specific, each oocytes were incubated for 30 minutes in a
CA 02341777 2001-03-02
choline chloride uptake solution (consisting of 100 mM of choline chloride, 2
mM of
potassium chloride, 1.8 mM of calcium chloride, 1 mM of magnesium chloride and
5mM of HEPES; pH 7.4) containing 14C-labeled leucine (50 P.M) whereby the
amount of the 14C-labeled leucine incorporated into the oocytes was determined
by
measuring the radioactivity of the oocytes by means of a scintillation
counter.
Incidentally, as a control, the same experiment was carried out using the
oocytes
where any of the above RNA was not injected but only water was infused. The
result is shown in Fig. 4.
The result was that, in the oocytes where only human LAT1 was expressed,
incorporation of leucine was rarely noted like in the case of oocytes into
which only
water was injected as a control while, in the case of oocytes where both human
LAT1 and human 4F2hc were expressed, a large incorporation of leucine was
confirmed. The result was believed to be due to the fact that human 4F2hc is
necessary in order that the human amino acid transporter LAT1 achieves the
function of mediating the incorporation of amino acid.
(2) Analysis of salt-dependency of the transport of amino acid into the
cells.
The fact whether there is a salt-dependency of the human amino acid
transporter LAT1 in the ability of mediating the transport of amino acid into
the
cells was analyzed as follows. To be specific, the analysis was carried out by
observing the changes in the incorporated amount of leucine into the cells by
changing the type of the uptake solution which incubated the oocytes in the
above-mentioned Example 4(1).
The oocytes of Xenopus laevis co-expressing the human LAT1 and the
human 4F2hc prepared in Example 4(1) were incubated for 30 minutes in the
91
CA 02341777 2001-03-02
above-mentioned choline chloride uptake solution containing 14C-labeled
leucine
(50 NM), a sodium uptake solution containing 14C-labeled leucine (50 CM) (100
mM
of choline chloride in the above choline uptake solution were changed to 100
mM of
sodium chloride) or a gluconic acid uptake solution containing 14C-labeled
leucine
(50 ~M) (100 mM of sodium chloride in the above sodium uptake solution were
changed to 100 mM of sodium gluconate).
Amount of the 14C-labeled leucine incorporated into the oocytes was
determined by measuring the radioactivity of the oocytes by means of a
scintillation counter. The result is shown in Fig. 5.
The result shows that, even when choline outside the oocytes was changed
to sodium or even when chlorine ion outside the oocytes was changed to
gluconic
acid ion, that did not affect the incorporation of leucine into the oocytes at
all.
Therefore, it was noted that the human amino acid transporter LAT1 was a
transporter molecule which acted independently upon sodium ion and chlorine
ion.
(3) Affinity of the human amino acid transporter LAT1 to the substrate.
In order to analyze the affinity of the human amino acid transporter LAT1
to the substrate, a Michaelis-Menten kinetic test (Dictionary of Biochemistry,
second edition, p. 1307-1308, 4th printing, 1992) was carried out.
This kinetic test was carried out by checking the changes in the
incorporated rate of leucine depending upon the difference in the
concentration of
leucine as a substrate.
The incorporation experiment of leucine was carried out according to the
method mentioned in the above Example 4(1) using oocytes of Xenopus laevis
where the human LAT1 and the human 4F2hc were co-expressed. The result is
shown in Fig. 6.
92
CA 02341777 2001-03-02
As a result, the Michaelis constant (Km) was about 21 pM.
(4) Analysis of substrate specificity of the human amino acid transporter
LAT 1 (No.1)
The substrate specificity of the human amino acid transporter LAT1 (type
of the substrate incorporated into the cells mediated by LAT1) was analyzed by
a
competitive antagonism test.
To be specific, oocytes of Xenopus laevis which co-expressed the human
LAT1 and the human 4F2hc were analyzed by measuring the changes in the
incorporated amount of "C-labeled leucine as a substrate into the oocytes when
incubated in the presence of a test substance (various amino acid,
pharmaceuticals,
physiologically active substances or other low-molecular synthetic compounds).
When the incorporated amount of the 14C-labeled leucine decreased as compared
with the control where no test substance was added, it was noted that the test
substance was incorporated into the oocytes mediated by the human amino acid
transporter LAT1.
Oocytes of Xenopus laevis co-expressing the human LAT1 and the human
4F2hc prepared in Example 4(1) were incubated for 30 minutes in a choline
chloride uptake solution containing 14C-labeled leucine (20 PM) and any of the
following test substances (2 mM).
Incidentally, as a control, incubation was similarly carried out in a choline
uptake solution containing 14C-labeled leucine but containing none of the test
substance.
[Test Substances]
Glycine, alanine, serine, threonine, cysteine, leucine, isoleucine,
phenylalanine, methionine, tyrosine, histidine, tryptophan, valine,
asparagine,
93
CA 02341777 2001-03-02
glutamine, aspartic acid, glutamic acid, lysine, arginine, proline and BCH (2-
amino-2-norbornane-carboxylic acid).
Amount of the 14C-labeled leucine incorporated into the oocytes was
determined by measuring the radioactivity of the oocytes by means of a
scintillation counter. The result is shown in Fig. 7.
Further, incorporation of the following test substances into oocytes was
also tested according to the above-mentioned method using 14C-labeled
phenylalanine instead of 14C-labeled leucine. As a control, incubation in a
choline
uptake solution containing 14C-labeled phenylalanine but containing none of
the
test substance was carried out similarly.
[Test Substances]
L-DOPA (a therapeutic agent for Parkinson's disease) and
triiodothyronine (a thyroid hormone).
The result is shown in Fig. 8 and Fig. 9.
As a result, in various amino acids, pharmaceuticals and physiologically
active substances, a cis-inhibiting action for incorporation of 14C-labeled
leucine or
14C-labeled phenylalanine into the cells (oocytes) was observed. Particularly,
leucine, isoleucine, phenylalanine, methionine, tyrosine, histidine,
tryptophan and
valine strongly inhibited the incorporation of 14C-labeled leucine mediated by
the
human LATl and, therefore, it was strongly suggested that any of the amino
acids
was transported into the oocytes mediated by the human LAT1. 2-Amino-2-
norbornane-carboxylic acid (BCH) which was known as an inhibitor for
incorporation of neutral amino acids also inhibited the incorporation of 14C-
labaled
leucine. Further, incorporation of 14C-labeled phenylalanine into oocytes was
strongly inhibited by the pharmaceutical agents such as L-DOPA (a therapeutic
94
CA 02341777 2001-03-02
agent for Parkinson's disease) and the physiologically active substances such
as
triiodothyronine (thyroid hormone). On the contrary, when acidic amino acids
(such as glutamic acid and aspartic acid) or basic amino acids (such as lysine
and
arginine) were used as the test substances, incorporation of 14C-labeled
leucine
mediated by the human LAT1 was not affected at all.
The result strongly suggests that the human amino acid transporter LAT1
mediates the transport of various amino acids (particularly neutral or nearly
neutral amino acids), various pharmaceuticals, various physiologically active
substances and other low-molecular synthetic compounds into cells.
(5) Analysis of the substrate specificity of the human amino acid
transporter LAT1 (No. 2).
Based upon the result of Example 4(4), an analysis was carried out
whether leucine, isoleucine, phenylalanine, methionine, tyrosine, histidine,
tryptophan and valine were incorporated into oocytes mediated by the human
LAT 1.
The test was carried out in the same manner as in Example 2(1) using
each of the following 14C-labeled amino acids prepared by labeling each of the
above-mentioned amino acids with 14C instead of 14C-labeled leucine as a
substrate.
[14C-Labeled Amino Acids]
14C-Labeled leucine, 14C-labeled isoleucine, 14C-labeled phenylalanine, "C-
labeled methionine, 14C_ labeled tyrosine, 14C-labeled histidine, 14C-labeled
tryptophan and 14C-labeled valine.
For the sake of comparison, the same test was carried out using "C-
labeled glycine, 14C-labeled serine, 14C-labeled D-leucine and 14C-labeled D-
phenylalanine. The result is shown in Fig. 10.
CA 02341777 2001-03-02
As a result, it was confirmed that leucine, isoleucine, phenylalanine,
methionine, tyrosine, histidine, tryptophan and valine were significantly
incorporated into oocytes. In addition, D-leucine and D- phenylalanine were
also
shown to be incorporated into the oocytes.
Example 5. Analysis of expression of mRNA of the human amino acid transporter
LAT1 in various tumor cells derived from human being.
Total RNA was collected from various tumor cells derived from human
being by a conventional method using Isogen (trade name; manufactured by
Nippon Gene) and the RNA was subjected to an agarose electrophoresis by a
conventional method and blotted to a nitrocellulose membrane.
The cDNA fragment coding for the human amino acid transporter LAT1
prepared in Example 3 was subjected to a northern blotting using a
hybridization
probe prepared by labeling with 32P-dCTP. The northern blotting was carried
out
according to a protocol attached to a commercially available Nylon membrane
for
northern blotting (such as MTN Blot [trade name] manufactured by Clontech)
where various poly(A)+RNA was blotted.
As a result of the northern blotting, expression of mRNA coding for the
human LAT1 in various tumor cells derived from human being was able to be
confirmed.
Example 6. Cloning of a rat neutral amino acid transporter.
(1) Isolation of cDNA of rat 4F2hc and preparation of cRNA.
A cDNA library was prepared from poly(A)+RNA purified from rat liver
using a kit for the synthesis of cDNA (trade name: Superscript Choice System;
96
CA 02341777 2001-03-02
manufactured by Gibco) and integrated into the excised site of the restriction
enzyme EcoRI of a phage vector ?.ZipLox (manufactured by Gibco). A segment
corresponding to from 135th to 580th bases of a rat 4F2hc gene (Broer, et al.,
Biochem. J., Vol. 312, p. 863, 1995) was amplified by a PCR and labeled with
32P-
dCTP and the resulting probe was used for the screening of a rat liver cDNA
library. Hybridization was carried out for one night in a solution for
hybridization
of 37 C and the filter membrane was washed with 0.1 x SSC/0.1% SDS at 37 C.
With regard to the solution for the hybridization, a buffer of pH 6.5
containing 5 x
SSC, 3 x Denhard's solution, 0.2% of SDS, 10% of dextran sulfate, 50% of
formamide, 0.01% of Antifoam B (an antifoaming agent manufactured by Sigma),
0.2 mg/ml of salmon sperm-modified DNA, 2.5 mM of sodium pyrophosphate and
25 mM of MES was used. The cDNA moiety of the ?.ZipLox phage into which
cDNA was incorporated was incorporated into a plasmid pZL1 and then further
subcloned to a plasmid pBluescript II SK- (manufactured by Stratagene).
With regard to the resulting clone, i.e. a clone containing cDNA of rat
4F2hc, a base sequence of cDNA was determined by a dideoxy method using a
synthetic primer for the determination of base sequence and a kit for the
determination of base sequence (trade name: Sequenase ver. 2.0; manufactured
by
Amersham). As such, it was confirmed that the cloned cDNA was that of a rat
4F2hc gene. The base sequence of the resulting 4F2hc was shown in SEQ ID
NO:2 in the Sequence Listing which will be given later.
From the above-prepared plasmid containing the cDNA of the rat 4F2hc,
cRNA (an RNA complementary to cDNA) was prepared using a T7 RNA
polymerase.
(2) Cloning of a rat neutral amino acid transporter LAT1.
97
CA 02341777 2001-03-02
This was carried out as follows by means of an expression cloning method
according to a method by Kanai, et al. (Kanai and Hediger, Nature, Vol. 360,
p.
467-471, 1992).
A rat C6 glioma cell poly(A)+RNA (400 tug) was fractionated by a gel
electrophoresis.
Each of the fractions obtained by the fractionation was injected into
oocytes together with the cRNA of rat 4F2hc obtained in the above (1) followed
by
incubating for two days.
For the oocytes into which RNA was injected, an experiment of
incorporation of a substrate was carried out using leucine as a substrate as
follows
according to a method by Kanai, et al. (Kanai and Hediger, Nature, Vol. 360,
p.
467-471, 1992). Thus, the oocytes were incubated for 30 minutes in a choline
chloride uptake solution containing 50 M of 14C-leucine as a substrate (100
mM of
choline chloride, 2 mM of potassium chloride, 1.8 mM of calcium chloride, 1 mM
of
magnesium chloride and 5 mM of HEPES; pH 7.4) and the incorporated rate of the
substrate was measured by counting the radioactivity which was incorporated
into
the oocytes. Incidentally, in this system, it was confirmed that a synergistic
enhancement in the incorporation was noted in the oocytes into which both rat
C6
glioma cell poly(A) 'RNA (mRNA) and cRNA of rat 4F2hc were injected as
compared with the oocytes into which each of them was solely infused (Fig.
11).
Among the RNA fractions prepared by the fractionation, the oocytes into
which RNA was infused selected a fraction showing the highest incorporation
rate
of leucine. A cDNA library was prepared for the poly(A)+RNA (2.8-4.0 kb) of
this
fraction using a kit for the synthesis of cDNA and a plasmid cloning (trade
name:
Superscript Plasmid System; manufactured by Gibco). Those DNA's were
98
CA 02341777 2001-03-02
integrated into the sites recognizing the restriction enzymes Sall and Notl of
the
plasmid pSPORT1 (manufactured by Gibco) and the resulting recombined plasmid
DNA was introduced into a competent cell of Escherichia coli DH10B strain
(trade
name: Electro Max DH lOB Competent Cell; manufactured by Gibco). The
resulting transformant was incubated on a nitrocellulose membrane to give
about
500 colonies per plate. A plasmid DNA was prepared from those colonies
followed
by excising with a restriction enzyme NotI. The resulting DNA was subjected to
an in vitro transcription to synthesize a capped cRNA.
The resulting cRNA (about 45 ng) was infused into oocytes together with
the rat 4F2hc cRNA (5 ng) obtained hereinabove (1). With regard to those
oocytes,
a screening for positive clone was carried out by conducting a leucine
incorporation
experiment according to the same way as mentioned above. In conducting the
screening, the group where DNA extracted from plural clones was pooled was
checked and, when incorporation of leucine was confirmed in some groups, they
were further subdivided into plural groups and a screening was further carried
out.
With regard to the resulting clone, i.e. the clone containing cDNA of the
rat neutral amino acid transporter LAT1, the base sequence thereof was
determined by a dideoxy method using a synthetic primer for the determination
of
group sequence and a kit for the determination of base sequence, (trade name:
Sequenase ver. 2.0; manufactured by Amersham).
As a result, a base sequence of the rat neutral amino acid transporter
LAT1 gene was obtained. In addition, the base sequence of cDNA was analyzed
by a conventional method and the translation region of cDNA and the amino acid
sequence of LAT1 encoded there were determined. The translation region was
99
CA 02341777 2001-03-02
64th to 1599th bases.
Those sequences were shown in SEQ ID NO:4 (amino acid sequence) and
NO:3 (base sequence) in the Sequence Listing which will be given later.
As a result of analysis of the amino acid sequence of LAT1 by means of a
Kyte-Doolittle hydropathy analysis (hydrophobic plot), 12 transmembrane
regions
(membrane-spanning domains) were predicted as shown in Fig. 12. Further, in
the second hydrophilic loop, there was a tyrosine phosphorylated site and, in
the
fourth and eighth hydrophilic loops, there were two sites supposed to be
proteinkinase-C-dependent phosphorylated sites.
(3) Expression of LAT1 gene in various tissues of rat and in an cultured rat
cell line (analysis by northern blotting).
A cDNA fragment corresponding to 202nd to 1534th bases of the rat LATI
gene was labeled with 32P-dCTP and, using it as a probe, a northern blotting
was
carried out as follows for the RNA extracted from various tissues of rat and
from
cultured tumor cell line derived from rat. Thus, 3 ~tg of poly(A)+RNA were
subjected to an electrophoresis using 1% agarose/formaldehyde gell and
transferred to a nitrocellulose filter. The filter was subjected to a
hybridization
for one night in a hybridization solution containing the LAT1 cDNA fragment
labeled with 32P-dCTP at 42 C. The filter was washed with 0.1 x SSC containing
0.1% of SDS at 65 C.
As a result of the northern blotting (Fig. 13), bands were detected at about
3.8 kb in C6 glioma cell, placenta, brain, spleen, large intestine and testis
and, in
placenta, another band was detected at about 2.6 kb in addition to the above
whereupon expression was noted. Although the expression was very weak in
normal liver, a strong band was detected at about 3.8 kb in rat hepatoma cell
line
100
CA 02341777 2001-03-02
and rat hepatocarcinoma cell line whereupon an expression was noted (Fig. 14).
Further, upon long exposure, a faint band was noted at about 3.8 kb even
in other tissues.
(4) Expression of LAT1 gene in a human tumor cell line (analysis by a
northern blotting).
A cDNA fragment corresponding to 202nd to 1534th bases of the rat LAT1
gene was labeled with 32P-dCTP and, using this as a probe, RNA extracted from
an
cultured tumor cell line derived from human being was subjected to a northern
blotting as follows. Poly(A)+RNA (3 rig) was subjected to an electrophoresis
by 1%
agarose/formaldehyde gel and transferred to a nitrocellulose filter. The
filter was
subjected to a hybridization for one night in a hybridization solution
containing the
rat LAT1 cDNA fragment labeled with 32P-dCTP at 37 C. The filter was washed
with 0.1 x SSC containing 0.1% of SDS at 37 C.
As a result of the northern blotting (Fig. 15), strong bands were detected
at about 4.0 kb in stomach signet ring cell carcinoma cell line, lung small-
cell
carcinoma cell line and melanoma cell line while a weak band was detected at
4.0
kb in neuroblastoma cell line whereupon an expression was noted.
Example 7 (Characterization of the neutral amino acid transporter LAT1)
(1) Role of 4F2hc in the transporting activity of LAT1.
Activities in the incorporation of leucine in case the rat LAT1 gene cRNA
was solely expressed in oocytes and in case the rat LAT1 gene cRNA and the
4F2hc
gene cRNA were simultaneously expressed in oocytes were compared.
Rat LAT1 gene cRNA (25 ng), rat 4F2hc gene cRNA (25 ng) or rat LAT1
gene cRNA (12.5 g)/rat 4F2hc gene cRNA (12.5 ng) was expressed by injecting
into
101
CA 02341777 2001-03-02
the oocytes and incubated for 2 days or 5 days.
An experiment of the incorporation of leucine was carried out as follows in
accordance with a method mentioned in the above Example 6(2). Thus, the
oocytes into which rat LAT1 gene cRNA, rat 4F2hc gene cRNA or rat LAT1 gene
cRNA/rat 4F2hc gene cRNA was injected were incubated for 30 minutes in an
uptake solution containing 14C-leucine (50 pM) and incorporation of
radioactivity
into the oocytes was measured.
The result (Fig. 16) was that, in the oocytes into which only LAT1 was
expressed, incorporation of leucine was in the same level as in the oocytes
into
which water was injected as a control but, in the oocytes into which both LAT
1 and
4F2hc were expressed, a big incorporation of leucine was noted whereupon 4F2hc
was believed to be necessary for LAT1 for achieving its function.
(2) Salt-dependency of the transport activity of LAT1.
Influence of a salt added to the medium was tested in a test of
incorporation of leucine into the oocytes when both rat LAT 1 gene cRNA and
4F2hc
gene cRNA were used.
An experiment of the incorporation of leucine was carried out according to
a method mentioned in the above Example 6(2) using the oocytes into which both
rat LAT1 gene cRNA and rat 4F2hc gene cRNA were injected. With regard to an
uptake solution however, a sodium uptake solution (100 mM choline chloride was
changed to 100 mM sodium chloride) was used instead of a choline chloride
uptake
solution when an influence of sodium ion was checked. When an influence of
chlorine ion was checked, a gluconic acid uptake solution (100 mM sodium
chloride
was changed to 100 mM sodium gluconate) was used instead of a sodium uptake
solution.
102
CA 02341777 2001-03-02
The result (Fig. 17) was that, even when choline outside the oocytes was
changed to sodium and even when chlorine ion outside the oocytes was changed
to
gluconic acid ion, there was no affection in the incorporation of leucine at
all.
From the result, it was shown that LAT1 was a transporter which acted
independently of sodium ion and chlorine ion.
(3) Michaelis-Menten kinetic test of LAT1.
A Michaelis-Menten kinetic test was carried out for a neutral amino acid
transporter. By checking the changes in the incorporating rate of leucine with
the
difference in the concentrations of the substrate leucine, a Michaelis-Menten
kinetic test of the neutral amino acid transporter was carried out.
An experiment of the incorporation of leucine was carried out according to
a method mentioned in the above Example 6(2) using the oocytes into which both
rat LAT1 gene cRNA and rat 4F2hc gene cRNA were injected. Asa result (Fig.
18),
the Km value was about 24 tM.
(4) Substrate-specificity of LAT1 (an inhibiting experiment by addition of
amino acid and a similar substance thereto).
In an experiment of the incorporation of leucine by the oocytes into which
both rat LAT1 gene cRNA and rat 4F2hc gene cRNA were injected, an influence of
addition of various amino acids and similar substances thereto to the system
was
tested.
An experiment of the incorporation of leucine was carried out according to
a method mentioned in the above Example 6(2) using the oocytes into which both
rat LAT1 gene cRNA and rat 4F2hc gene cRNA were injected. In this case
however, a choline uptake solution was used and the incorporation of 14C-
leucine
(20 M) was measured in the presence or absence of 2 mM of various compound
103
CA 02341777 2001-03-02
(unlabeled).
The result (Fig. 19) was that a cis-inhibiting effect was observed in various
kinds of neutral amino acids. Especially, leucine, isoleucine, phenylalanine,
methionine, tyrosine, histidine, tryptophan and valine strongly inhibited the
incorporation of 14C-leucine mediated by LAT1. In addition, in the substances
other than the standard amino acids, the incorporation of 14C-leucine mediated
by
LAT1 was also inhibited by pharmaceutical agents and physiologically active
substances such as L-DOPA (a therapeutic agent for Parkinson's disease),
melphalan (antitumor agent), triiodothyronine (thyroid hormone), thyroxin
(thyroid hormone). Further, 2-amino-2-norbornane-carboxylic acid which was
known as an inhibitor for the incorporation of neutral amino acids inhibited
the
incorporation of 14C-leucine as well. Acidic amino acids and basic amino acids
did
not affect the incorporation of 14C-leucine mediated by LAT1.
(5) Substrate-selectivity of LAT1 (a test on the incorporation using various
kinds of amino acids and similar substances thereto as substrates).
Incorporation by LAT1 was tested using various kinds of amino acids and
similar substances thereto as substrate.
A test on the incorporation using various kinds of amino acids and similar
substances thereto was carried out according to the method mentioned in the
above Example 6(2) using the oocytes into which both rat LAT1 gene cRNA and
rat
5F2hc gene cRNA were injected. As a substrate however, various radiolabeled
compounds were used in place of 14C-leucine.
The result was that incorporation into the oocytes was noted when leucine
(a 14C compound), isoleucine (a "C compound), phenylalanine (a 14C compound),
methionine (a 14C compound), tyrosine (a 14C compound), histidine (a '4C
104
CA 02341777 2003-09-12
compound), tryptophan (a 14C compound) and valine (a 14C compound) were used
as
substrates.
Example S. Control of cell proliferation by suppression of the neutral amino
acid
transporter LAT 1.
(1) Inhibition of suppressing the cell proliferation by an LATI suppression.
A suppressing effect to the cell proliferation of a LATI suppression by an
LATI suppressive agent was tested.
A rat liver cell line where LAT I was highly expressed was incubated on a
William's medium, 20mM of D-leucine or BCH which suppressed the incorporation
mediated by LATI were added to the medium and, by means of an incubation for
48
hours, cell numbers were investigated using a Cell Counting Kit-8 TM
(manufactured
by Dojindo Laboratories). The cell numbers were measured as an absorption at
450
nm (O.D. 450).
The result (Fig. 20) was that, in a group where D-leucine or BCH was added, a
reduction in the cell numbers was noted as compared with a control group where
neither D-leucine nor BCH was added whereupon it was believed that cell
proliferation was suppressed by a neutral amino acid incorporation suppression
by
LATI suppression.
Example 9. Expression of LATI gene and 4F2hc gene in various tumor cell lines
of human being (an analysis by a northern blotting).
A cDNA fragment corresponding to 649th to 1128th bases of the hLATI gene
was excised by a restriction enzyme Smal, a probe was prepared by labeling
with 32P-
dCTP and a northern blotting to human tumor cell line was carried out as
105
CA 02341777 2001-03-02
follows. From various human tumor cell lines was extracted poly(A)+RNA and
then hybridization and washing using 32P-dCTP labeled LATI probe were carried
out.
The cDNA fragment corresponding to 106th to 645th bases of the h4F2hc
gene was excised by a restriction enzyme Pstl, a probe was prepared by
labeling
with 32P-dCTP and a northern blotting to human tumor cell line was carried out
in
the same manner.
As a result of the northern blotting, in all tumor cell lines investigated in
Fig. 21 and Fig. 22, expression of LAT1 was noted near 4.8 kb. With regard to
the
4F2hc, expression was noted in most of the tumor cell lines near 2.2 kb.
However,
strength of the expression varied depending upon the cells and, particularly
in the
case of leukemia cell lines Daudi, CCRF-SB and P30/OHK, no signal by a
northern
blotting was detected (Fig. 22).
Example 10. Significance of T24 cells derived from human bladder cancer as an
evaluating system for LAT1 inhibitors.
T24 cells derived from human bladder cancer were incubated and
maintained in an Eagle's minimal essential medium containing 10% of fetal
bovine
serum. A test for the incorporation of amino acids into T24 cells was carried
out
by incubating the T24 cells on a 24-well plate and finished when the state
became
confluent. The amino acid incorporation test was started by removing the
incubating solution and adding a Dulbecco's PBS (manufactured by Gibco)
containing 14C-amino acid and finished by removing it, cooling with ice and
washing with a Dulbecco's PBS. After washing, the above was dissolved in 0.1N
NaOH and the radioactivity was measured by a liquid scintillation counter.
106
CA 02341777 2001-03-02
(1) Na+-dependency of T24 cells for the incorporation of leucine.
Influence of sodium ion in the medium on the leucine incorporation
experiment by T24 cells was investigated.
With regard to the solution for the incorporation, a choline uptake solution
(where sodium chloride was substituted with choline chloride) was used in
place of
a Dulbecco's PBS when influence of sodium ion in the medium on the
incorporation
of leucine was checked.
As a result (Fig. 23), there was no affection at all for the incorporation of
leucine even when choline outside the cells was changed to sodium. Therefore,
it
was noted that the incorporation of leucine by T24 cells was carried on a
transport
system which was not dependent upon sodium ion.
(2) Michaelis-Menten kinetic test for the incorporation of leucine by T24
cells.
A Michaelis-Menten kinetic test was carried out for the incorporation of
leucine by T24 cells. The Michaelis-Menten kinetic test was conducted by
investigating the changes in the incorporated rate of leucine by the
difference in
the concentration of the substrate leucine.
As a result (Fig. 24), Km value was 100.3 aM and Vmax value was 23,870
pmol/mg protein/minute.
(3) Experiment on the inhibition of incorporation of leucine by T24 cells by
addition of amino acid and similar substance thereto.
In an experiment of the incorporation of leucine by T24 cells, influence of
addition of various amino acids and similar substances thereto was
investigated.
In an experiment of the incorporation of leucine, the incorporation of 14C-
leucine (20 ,aM) in the presence and absence of 2 mM of various compounds
107
CA 02341777 2001-03-02
(unlabeled) was measured.
As a result (Fig. 25), a strong cis-inhibiting effect was observed by
methionine, leucine, isoleucine, valine, phenylalanine, tyrosine, tryptophan,
histidine and cysteine. BCH which was an amino acid transport system L-
specific
inhibitor strongly inhibited the incorporation of leucine. The result of this
inhibiting experiment was identical with the result when LAT1 was expressed in
the oocytes of Xenopus.
(4) Inhibiting mode of the leucine incorporation by T24 cells by BCH, an
incorporation inhibitor.
Dependency of the 14C-leucine incorporation by T24 cells on the
concentration was measured in the absence of BCH, in the presence of 50 ,uM of
BCH and in the presence of 100 ,a M of BCH and the inhibiting mode was
investigated by means of double reciprocal plots.
As a result (Fig. 26), it was clarified that the inhibition by BCH was a
competitive inhibition and its Ki value was 156 ,aM.
Example 11. Effect of BCH, an amino acid incorporation inhibitor, on the
proliferation of human tumor cell line.
T24 cells derived from human bladder cancer were incubated and
maintained in an Eagle's minimal essential medium containing 10% of fetal
bovine
serum. Human Daudi cells were incubated and maintained in an RPMI medium
containing 20% of fetal bovine serum. T24 cells or Daudil cells were incubated
in
a 24-well plate (800 cells/well) for 5 days in a medium with or without 20 mM
of
BCH and the cell numbers were counted.
As a result (Fig. 27), it was clarified that the cell proliferation was rapid
in
108
CA 02341777 2001-03-02
the case of T24 cells as compared with in the case of Daudi cells and that,
although
BCH highly suppressed the proliferation of T24, it rarely showed a suppressing
effect for the proliferation of Daudi cells.
T24 cells were strongly expressed together with LAT1 and 4F2hc (Fig. 21)
and, as shown in Example 10, LAT1 showed a strong function activity in T24
cells.
On the contrary, in Daudi cells, although LAT1 was strongly expressed, no
expression of 4F2hc necessary for achieving the function of LAT1 was detected
(Fig.
22) and, therefore, it is believed that, in Daudi cells, LAT1 does not
function. The
fact that the proliferation of T24 cells having a strong function activity of
LAT1
was rapid, that BCH showed a high suppression for cell proliferation, that the
proliferation of Daudi cells where LAT1 was believed not to function was slow
and
that BCH showed no effect of suppression of the proliferation supports the
hypothesis that the incorporation of essential amino acids mediated by LAT1
forms
one of the rate-determining steps for the cell proliferation and that such a
inhibition shows the suppression of cell proliferation.
In CCRF-SB cells and P30/OHK cells (Fig. 22) where expression of 4F2hc
was not detected like Daudi cells, it was confirmed that, like Daudi cells,
the
proliferation was slow and the effect of BCH was weak and that, like T24
cells, the
proliferation was quick in the cells where both LAT1 and 4F2hc were strongly
expressed and BCH showed a strong suppressing effect.
Example 13. Survival effect of BCH, an amino acid transporter suppressor, in
tumor-inoculated mouse.
Mouse sarcoma 180 cells were intraperitoneally transplanted (1 x 106) to
male ICR mouse and, from the next day of the transplantation, BCH which was a
109
CA 02341777 2001-03-02
inhibitor for the amino acid transporter, D-Leu having a inhibiting effect on
amino
acid transporter and D-Ala having no inhibiting action thereon were
administered
at the dose of 300 mg/kg for ten days. After the transplantation, it was
confirmed
every day whether the mouse was dead or alive.
As a result of the observation for 19 days, all cases were alive in the
untreated control while, in the group inoculated with sarcoma 180 cells, the
group
inoculated with sarcoma 180 cells and the group administered with a vehicle
after
inoculation of sarcoma 180 cells, the living periods were significantly
shortened as
compared with the control (Fig. 28). On the contrary, in the group where BCH
was administered or D-Leu was administered after the inoculation of sarcoma
180
cells, a significant survival effect by treatment with such an agent was noted
(Fig.
28). No survival effect was noted in D-Ala (Fig. 28).
Industrial Applicability
The amino acid transporter molecule of the present invention has an
important biological function of mediating the incorporation of various amino
acids
which are essential nutrients for the manufacture and the proliferation of
cells and,
in addition, it shows an expression in a broad range of tumor cells as
compared
with the expression in normal cells whereby the molecule is quite hopeful as a
target in the development of, for example, antitumor agents (anticancer
agents).
Thus, when a pharmaceutical agent having the biological activity on the
molecule or the activity for suppressing the expression of the molecule (such
as
antisense DNA pharmaceutical agent, antisense RNA pharmaceutical agent,
antibody pharmaceutical agent, antibody fragment pharmaceutical agent, peptide
antagonist pharmaceutical agent and non-peptide antagonist pharmaceutical
110
CA 02341777 2001-03-02
agent such as low-molecular compounds) is used and suppresses the
incorporation
of the nutrients (various amino acids and physiologically active substances)
mediated by the molecule into the tumor cells, it is now possible to make the
tumor
cells in a state of amino acid starvation and to inhibit the existence and the
proliferation of tumor cells.
Accordingly, the protein of the present invention or a part thereof, DNA
coding for the protein or a part thereof, RNA coding for the protein or a part
thereof, DNA which hybridizes to the DNA, expression vector containing the
DNA,
transformed cell which is transformed by the DNA or by the vector, cell into
which
the RNA is introduced, antibody or a part thereof having a reactivity with the
protein or a part thereof, cell which produces the antibody, labeled DNA where
the
a part of the DNA is radiolabeled, labeled RNA where a part of the RNA is
radiolabeled, labeled antibody where the antibody or a part of the antibody is
labeled, a kit comprising the labeled DNA, a kit comprising the labeled RNA
and a
kit comprising the labeled antibody are able to be provided as pharmaceutical
agents having such an antitumor effect and/or reagents in the development of
such
pharmaceutical agents.
In addition, when various substances such as DNA, RNA or transformed
cells of the present invention are used, it is now possible to conduct a drug
design,
a screening (such as a reporter gene assay) and an identification of
pharmaceutical
agents which control (activate, suppress or inhibit) the biological activity
of the
protein of the present invention, pharmaceutical agents which inhibit the
transcription of the protein of the present invention to mRNA, pharmaceutical
agents which inhibit the translation of the protein of the present invention
from
the mRNA, pharmaceutical agents which inhibit the interaction of the protein
with
111
CA 02341777 2001-03-02
other molecules, etc.
Further, a part of DNA and RNA of the present invention is able to be
provided as a probe in the identification of DNA or RNA which hybridizes
therewith using a colony hybridization method or a plaque hybridization
method.
Furthermore, a part of DNA of the present invention is able to be provided as
a
primer for the amplification of the gene coding for DNA of the present
invention or
transporter molecule of the present invention by a PCR.
Still further, a part of DNA of the present invention, DNA complementary
to the DNA or a part of RNA of the present invention is able to be provided
not only
as the above-mentioned reagent but also as the so-called antisense DNA
pharmaceutical agent or antisense RNA pharmaceutical agent.
As mentioned above, the protein of the present invention is able to identify
the pharmaceutical agent which controls the biological activity of the protein
of the
present invention or the expression of the protein when the state where the
protein
molecule is expressed on the cell surface is utilized. It is also possible
that, based
upon the amino acid sequence of the protein, a peptide antagonist having an
ability of inhibiting the biological activity of the protein is designed. The
peptide
antagonist which is designed as such competitively inhibits the bond of the
amino
acid transporter which is the protein of the present invention with various
substrates or the bond of the protein of the present invention with other
molecule
whereby it is able to be provided as a pharmaceutical agent which does not
make
the biological function of the protein of the present invention achieved.
The protein of the present invention or a part thereof and cells such as a
transformed cell expressing the protein are able to be provided as immune
sensitizing antigens in the preparation of antibody (antiserum, monoclonal
112
CA 02341777 2001-03-02
antibody) to the protein of the present invention.
Antiserum (polyclonal antibody) and monoclonal antibody having a
reactivity with the amino acid transporter molecule which is the protein of
the
present invention are able to be provided as an antibody pharmaceutical agent
where achievement of the biological activity of the molecule is inhibited
(neutralized) when bonded to the molecule.
Further, when the antibody is labeled with various substances which are
able to give a detectable signal, it is able to be provided as a reagent in
the analysis
(immunohistological staining, western blotting, ELISA, etc.) of expressed
state of
the protein of the present invention in various biological materials (such as
cells,
tissues, organs and body fluid).
As same as such a labeled antibody, the labeled DNA labeled with various
substances being able to give a signal by which DNA of the present invention
or a
part thereof is detectable can be provided as a reagent in the test (such as a
southern blotting and an FISH) in the identification of the gene coding for
the
protein of the present invention.
Further and similarly, a radiolabeled RNA where the RNA of the present
invention or a part thereof is labeled with a radioisotope is able to be
provided as a
reagent in the analysis (such as a northern blotting) of the expressed state
of
mRNA coding for the protein of the present invention in cells, tissue or
organs.
113
CA 02341777 2001-08-27
SEQUENCE LISTING
<110> Japan Science and Technology Corporation
<120> Amino Acid Transporter and Gene Thereof
<130> 34831-0017
<140> 2,341,777
<141> 1999-09-03
<150> PCT/JP99/04789
<151> 1999-09-03
<150> JP10-249993/1998
<151> 1998-09-03
<150> JP11-248546/1999
<151> 1999-09-02
<160> 29
<170> Patentln Ver. 2.1
<210> 1
<211> 4539
<212> DNA
<213> Homo sapiens
<220>
<221> 5'UTR
<222> (1) .. (65)
<220>
<221> CDS
<222> (66)..(1589)
<220>
<221> 3'UTR
<222> (1590)..(4474)
<400> 1
cggcgcgcac actgctcgct gggccgcggc tcccgggtgt cccaggcccg gccggtgcgc 60
agagc atg gcg ggt gcg ggc ccg aag cgg cgc gcg cta gcg gcg ccg gcg 110
Met Ala Gly Ala Gly Pro Lys Arg Arg Ala Leu Ala Ala Pro Ala
1 5 10 15
gcc gag gag aag gaa gag gcg cgg gag aag atg ctg gcc gcc aag agc 158
Ala Glu Glu Lys Glu Glu Ala Arg Glu Lys Met Leu Ala Ala Lys Ser
20 25 30
gcg gac ggc tcg gcg ccg gca ggc gag ggc gag ggc gtg acc ctg cag 206
Ala Asp Gly Ser Ala Pro Ala Gly Glu Gly Glu Gly Val Thr Leu Gln
35 40 45
cgg aac atc acg ctg ctc aac ggc gtg gcc atc atc gtg ggg acc att 254
Arg Asn Ile Thr Leu Leu Asn Gly Val Ala Ile Ile Val Gly Thr Ile
50 55 60
1/32
CA 02341777 2001-08-27
atc ggc tcg ggc atc ttc gtg acg ccc acg ggc gtg ctc aag gag gca 302
Ile Gly Ser Gly Ile Phe Val Thr Pro Thr Gly Val Leu Lys Glu Ala
65 70 75
ggc tcg ccg ggg ctg gcg ctg gtg gtg tgg gcc gcg tgc ggc gtc ttc 350
Gly Ser Pro Gly Leu Ala Leu Val Val Trp Ala Ala Cys Gly Val Phe
80 85 90 95
tcc atc gtg ggc gcg ctc tgc tac gcg gag ctc ggc acc acc atc tcc 398
Ser Ile Val Gly Ala Leu Cys Tyr Ala Glu Leu Gly Thr Thr Ile Ser
100 105 110
aaa tcg ggc ggc gac tac gcc tac atg ctg gag gtc tac ggc tcg ctg 446
Lys Ser Gly Gly Asp Tyr Ala Tyr Met Leu Glu Val Tyr Gly Ser Leu
115 120 125
ccc gcc ttc ctc aag ctc tgg atc gag ctg ctc atc atc cgg cct tca 494
Pro Ala Phe Leu Lys Leu Trp Ile Glu Leu Leu Ile Ile Arg Pro Ser
130 135 140
tcg cag tac atc gtg gcc ctg gtc ttc gcc acc tac ctg ctc aag ccg 542
Ser Gln Tyr Ile Val Ala Leu Val Phe Ala Thr Tyr Leu Leu Lys Pro
145 150 155
ctc ttc ccc acc tgc ccg gtg ccc gag gag gca gcc aag ctc gtg gcc 590
Leu Phe Pro Thr Cys Pro Val Pro Glu Glu Ala Ala Lys Leu Val Ala
160 165 170 175
tgc ctc tgc gtg ctg ctg ctc acg gcc gtg aac tgc tac agc gtg aag 638
Cys Leu Cys Val Leu Leu Leu Thr Ala Val Asn Cys Tyr Ser Val Lys
180 185 190
gcc gcc acc cgg gtc cag gat gcc ttt gcc gcc gcc aag ctc ctg gcc 686
Ala Ala Thr Arg Val Gln Asp Ala Phe Ala Ala Ala Lys Leu Leu Ala
195 200 205
ctg gcc ctg atc atc ctg ctg ggc ttc gtc cag atc ggg aag ggt gat 734
Leu Ala Leu Ile Ile Leu Leu Gly Phe Val Gln Ile Gly Lys Gly Asp
210 215 220
gtg tcc aat cta gat ccc aac ttc tca ttt gaa ggc acc aaa ctg gat 782
Val Ser Asn Leu Asp Pro Asn Phe Ser Phe Glu Gly Thr Lys Leu Asp
225 230 235
gtg ggg aac att gtg ctg gca tta tac agc ggc ctc ttt gcc tat gga 830
Val Gly Asn Ile Val Leu Ala Leu Tyr Ser Gly Leu Phe Ala Tyr Gly
240 245 250 255
gga tgg aat tac ttg aat ttc gtc aca gag gaa atg atc aac ccc tac 878
Gly Trp Asn Tyr Leu Asn Phe Val Thr Glu Glu Met Ile Asn Pro Tyr
260 265 270
aga aac ctg ccc ctg gcc atc atc atc tcc ctg ccc atc gtg acg ctg 926
Arg Asn Leu Pro Leu Ala Ile Ile Ile Ser Leu Pro Ile Val Thr Leu
275 280 285
gtg tac gtg ctg acc aac ctg gcc tac ttc acc acc ctg tcc acc gag 974
Val Tyr Val Leu Thr Asn Leu Ala Tyr Phe Thr Thr Leu Ser Thr Glu
290 295 300
2/32
CA 02341777 2001-08-27
cag atg ctg tcg tcc gag gcc gtg gcc gtg gac ttc ggg aac tat cac 1022
Gln Met Leu Ser Ser Glu Ala Val Ala Val Asp Phe Gly Asn Tyr His
305 310 315
ctg ggc gtc atg tcc tgg atc atc ccc gtc ttc gtg ggc ctg tcc tgc 1070
Leu Gly Val Met Ser Trp Ile Ile Pro Val Phe Val Gly Leu Ser Cys
320 325 330 335
ttc ggc tcc gtc aat ggg tcc ctg ttc aca tcc tcc agg ctc ttc ttc 1118
Phe Gly Ser Val Asn Gly Ser Leu Phe Thr Ser Ser Arg Leu Phe Phe
340 345 350
gtg ggg tcc cgg gaa ggc cac ctg ccc tcc atc ctc tcc atg atc cac 1166
Val Gly Ser Arg Glu Gly His Leu Pro Ser Ile Leu Ser Met Ile His
355 360 365
cca cag ctc ctc acc ccc gtg ccg tcc ctc gtg ttc acg tgt gtg atg 1214
Pro Gln Leu Leu Thr Pro Val Pro Ser Leu Val Phe Thr Cys Val Met
370 375 380
acg ctg ctc tac gcc ttc tcc aag gac atc ttc tcc gtc atc aac ttc 1262
Thr Leu Leu Tyr Ala Phe Ser Lys Asp Ile Phe Ser Val Ile Asn Phe
385 390 395
ttc agc ttc ttc aac tgg ctc tgc gtg gcc ctg gcc atc atc ggc atg 1310
Phe Ser Phe Phe Asn Trp Leu Cys Val Ala Leu Ala Ile Ile Gly Met
400 405 410 415
atc tgg ctg cgc cac aga aag cct gag ctt gag cgg ccc atc aag gtg 1358
Ile Trp Leu Arg His Arg Lys Pro Glu Leu Glu Arg Pro Ile Lys Val
420 425 430
aac ctg gcc ctg cct gtg ttc ttc atc ctg gcc tgc ctc ttc ctg atc 1406
Asn Leu Ala Leu Pro Val Phe Phe Ile Leu Ala Cys Leu Phe Leu Ile
435 440 445
gcc gtc tcc ttc tgg aag aca ccc gtg gag tgt ggc atc ggc ttc acc 1454
Ala Val Ser Phe Trp Lys Thr Pro Val Glu Cys Gly Ile Gly Phe Thr
450 455 460
atc atc ctc agc ggg ctg ccc gtc tac ttc ttc ggg gtc tgg tgg aaa 1502
Ile Ile Leu Ser Gly Leu Pro Val Tyr Phe Phe Gly Val Trp Trp Lys
465 470 475
aac aag ccc aag tgg ctc ctc cag ggc atc ttc tcc acg acc gtc ctg 1550
Asn Lys Pro Lys Trp Leu Leu Gln Gly Ile Phe Ser Thr Thr Val Leu
480 485 490 495
tgt cag aag ctc atg cag gtg gtc ccc cag gag aca tag ccaggaggcc 1599
Cys Gln Lys Leu Met Gln Val Val Pro Gln Glu Thr
500 505
gagtggctgc cggaggagca tgcgcagagg ccagttaaag tagatcacct cctcgaaccc 1659
actccggttc cccgcaaccc acagctcagc tgcccatccc agtccctcgc cgtccctccc 1719
aggtcgggca gtggaggctg ctgtgaaaac tctggtacga atctcatccc tcaactgagg 1779
gccagggacc caggtgtgcc tgtgctcctg cccaggagca gcttttggtc tccttgggcc 1839
3/32
CA 02341777 2001-08-27
ctttttccct tccctccttt gtttacttat atatatattt tttttaaact taaattttgg 1899
gtcaacttga caccactaag atgatttttt aaggagctgg gggaaggcag gagccttcct 1959
ttctcctgcc ccaagggccc agaccctggg caaacagagc tactgagact tggaacctca 2019
ttgctacgac agacttgcac tgaagccgga cagctgccca gacacatggg cttgtgacat 2079
tcgtgaaaac caaccctgtg ggcttatgtc tctgccttag ggtttgcaga gtggaaactc 2139
agccgtaggg tggcactggg agggggtggg ggatctgggc aaggtgggtg attcctccca 2199
ggaggtgctt gaggccccga tggactcctg accataatcc tagccccgag acaccatcct 2259
gagccaggga acagccccag ggttgggggg tgccggcatc tcccctagCt caccaggcct 2319
ggcctctggg cagtgtggcc tcttggctat ttctgttcca gttttggagg ctgagttctg 2379
gttcatgcag acaaagccct gtccttcagt cttctagaaa cagagacaag aaaggcagac 2439
acaccgcggc caggcaccca tgtgggcgcc caccctgggc tccacacagc agtgtcccct 2499
gccccagagg tcgcagctac cctcagcctc caatgcattg gcctctgtac cgcccggcag 2559
ccccttctgg ccggtgctgg gttcccactc ccggcctagg cacctccccg ctctccctgt 2619
cacgctcatg tcctgtcctg gtcctgatgc ccgttgtcta ggagacagag ccaagcactg 2679
ctcacgtctc tgccgcctgc gtttggaggc ccctgggctc tcacccagtc cccacccgcc 2739
tgcagagagg gaactagggc accccttgtt tctgttgttc ccgtgaattt ttttcgctat 2799
gggaggcagc ccagtcctgg ccaatgcggc ccactttcct gagctttcgc tgcctccatg 2859
gcagcagcca aggaccccca gaacaagaag acccccccgc agtatccctc ctgagctcgg 2919
ggggctctgc cttctcaggc cccgggcttc ccttctcccc agccagaggt ggagccaagt 2979
ggtccagcgt cactccagtg ctcagctgtg gctggaggag ctggcctgtg gcaaagccct 3039
gagtgtccca agccgggagc caacgaagcc ggacacggct tcactgacca gcggctgctc 3099
aagccgcaag ctctcagcaa gtgcccagtg gagcctgccg cccccacctg ggcaccggga 3159
ccccctcacc atccattggg cccggagaaa cctgatgaac agtttgggga ctcaggacca 3219
gatgtccgtc tctcttgctt gaggaatgaa gacctttatt cacccctgcc ccgttgcttc 3279
ccgctgcaca tggacagact tcacagcgtc tggtcatagg acctgcatcc ttcctgggga 3339
cgaattccac tcgtccaagg gacagcccac ggtctggagg ccgaggacca ccagcaggca 3399
ggtggactga ctgtgttggg caagacctct tccctctggg cctgttctct tggctgcaaa 3459
taaggacagc agctggtgcc ccacctgcct ggtgcattgc tgtgtgaatc caggaggcag 3519
tggacatcgt aggcagccac ggccccgggt ccaggagaag tgctccctgg aggcacgcac 3579
cactgcttcc cactggggcc ggcggggccc acgcacgacg tcagcctctt accttcccgc 3639
4/32
CA 02341777 2001-08-27
ctcggctagg ggtcctcggg atgccgttct gttccaacct cctgctctgg gaggtggaca 3699
tgcctcaagg atacagggag ccggcggcct ctcgacggca cgcacttgcc tgttggctgc 3759
tgcggctgtg ggcgagcatg ggggctgcca gcgtctgttg tggaaagtag ctgctagtga 3819
aatggctggg gccgctgggg tccgtcttca cactgcgcag gtctcttctg ggcgtctgag 3879
ctggggtggg agctcctccg cagaaggttg gtggggggtc cagtctgtga tccttggtgc 3939
tgtgtgcccc actccagcct ggggacccca cttcagaagg taggggccgt gtcccgcggt 3999
gctgactgag gcctgcttcc ccctccccct cctgctgtgc tggaattcca cagggaccag 4059
ggccaccgca ggggactgtc tcagaagact tgatttttcc gtcccttttt ctccacactc 4119
cactgacaaa cgtccccagc ggtttccact tgtgggcttc aggtgttttc aagcacaacc 4179
caccacaaca agcaagtgca ttttcagtcg ttgtgctttt ttgttttgtg ctaacgtctt 4239
actaatttaa agatgctgtc ggcaccatgt ttatttattt ccagtggtca tcctcagcct 4299
tgctgctctg cgtggcgcag gtgccatgcc tgctccctgt ctgtgtccca gccacgcagg 4359
gccatccact gtgacgtcgg ccgaccaggc tggacaccct ctgccgagta atgacgtgtg 4419
tggctgggac cttctttatt ctgtgttaat ggctaacctg ttacactggg ctgggttggg 4479
tagggtgttc tggctttttt gtggggtttt tatttttaaa gaaacactca atcatcctag 4539
<210> 2
<211> 507
<212> PRT
<213> Homo sapiens
<400> 2
Met Ala Gly Ala Gly Pro Lys Arg Arg Ala Leu Ala Ala Pro Ala Ala
1 5 10 15
Glu Glu Lys Glu Glu Ala Arg Glu Lys Met Leu Ala Ala Lys Ser Ala
20 25 30
Asp Gly Ser Ala Pro Ala Gly Glu Gly Glu Gly Val Thr Leu Gln Arg
35 40 45
Asn Ile Thr Leu Leu Asn Gly Val Ala Ile Ile Val Gly Thr Ile Ile
50 55 60
Gly Ser Gly Ile Phe Val Thr Pro Thr Gly Val Leu Lys Glu Ala Gly
65 70 75 80
Ser Pro Gly Leu Ala Leu Val Val Trp Ala Ala Cys Gly Val Phe Ser
85 90 95
Ile Val Gly Ala Leu Cys Tyr Ala Glu Leu Gly Thr Thr Ile Ser Lys
100 105 110
Ser Gly Gly Asp Tyr Ala Tyr Met Leu Glu Val Tyr Gly Ser Leu Pro
115 120 125
Ala Phe Leu Lys Leu Trp Ile Glu Leu Leu Ile Ile Arg Pro Ser Ser
130 135 140
Gin Tyr Ile Val Ala Leu Val Phe Ala Thr Tyr Leu Leu Lys Pro Leu
145 150 155 160
Phe Pro Thr Cys Pro Val Pro Glu Glu Ala Ala Lys Leu Val Ala Cys
165 170 175
Leu Cys Val Leu Leu Leu Thr Ala Val Asn Cys Tyr Ser Val Lys Ala
5/32
CA 02341777 2001-08-27
180 185 190
Ala Thr Arg Val Gln Asp Ala Phe Ala Ala Ala Lys Leu Leu Ala Leu
195 200 205
Ala Leu Ile Ile Leu Leu Gly Phe Val Gln Ile Gly Lys Gly Asp Val
210 215 220
Ser Asn Leu Asp Pro Asn Phe Ser Phe Glu Gly Thr Lys Leu Asp Val
225 230 235 240
Gly Asn Ile Val Leu Ala Leu Tyr Ser Gly Leu Phe Ala Tyr Gly Gly
245 250 255
Trp Asn Tyr Leu Asn Phe Val Thr Glu Glu Met Ile Asn Pro Tyr Arg
260 265 270
Asn Leu Pro Leu Ala Ile Ile Ile Ser Leu Pro Ile Val Thr Leu Val
275 280 285
Tyr Val Leu Thr Asn Leu Ala Tyr Phe Thr Thr Leu Ser Thr Glu Gln
290 295 300
Met Leu Ser Ser Glu Ala Val Ala Val Asp Phe Gly Asn Tyr His Leu
305 310 315 320
Gly Val Met Ser Trp Ile Ile Pro Val Phe Val Gly Leu Ser Cys Phe
325 330 335
Gly Ser Val Asn Gly Ser Leu Phe Thr Ser Ser Arg Leu Phe Phe Val
340 345 350
Gly Ser Arg Glu Gly His Leu Pro Ser Ile Leu Ser Met Ile His Pro
355 360 365
Gln Leu Leu Thr Pro Val Pro Ser Leu Val Phe Thr Cys Val Met Thr
370 375 380
Leu Leu Tyr Ala Phe Ser Lys Asp Ile Phe Ser Val Ile Asn Phe Phe
385 390 395 400
Ser Phe Phe Asn Trp Leu Cys Val Ala Leu Ala Ile Ile Gly Met Ile
405 410 415
Trp Leu Arg His Arg Lys Pro Glu Leu Glu Arg Pro Ile Lys Val Asn
420 425 430
Leu Ala Leu Pro Val Phe Phe Ile Leu Ala Cys Leu Phe Leu Ile Ala
435 440 445
Val Ser Phe Trp Lys Thr Pro Val Glu Cys Gly Ile Gly Phe Thr Ile
450 455 460
Ile Leu Ser Gly Leu Pro Val Tyr Phe Phe Gly Val Trp Trp Lys Asn
465 470 475 480
Lys Pro Lys Trp Leu Leu Gln Gly Ile Phe Ser Thr Thr Val Leu Cys
485 490 495
Gln Lys Leu Met Gln Val Val Pro Gln Glu Thr
500 505
<210> 3
<211> 3455
<212> DNA
<213> Rat
<220>
<221> 5'UTR
<222> (1)..(63)
<220>
<221> CDS
<222> (64)..(1602)
<220>
<221> 3'UTR
<222> (1603)..(3455)
6/32
CA 02341777 2001-08-27
<400> 3
cgcggagagc ggctcggccg cgcgcacgcc gggtatccag gccgagccgg gaacgtcgag 60
agc atg gcg gtc gcg ggc gca aag cgg cgc gcg gtt gcg gcc ccc gcg 108
Met Ala Val Ala Gly Ala Lys Arg Arg Ala Val Ala Ala Pro Ala
1 5 10 15
acg acg gcg gcg gag gag gag cgg cag gcg cgg gag aag atg ctg gag 156
Thr Thr Ala Ala Glu Glu Glu Arg Gln Ala Arg Glu Lys Met Leu Glu
20 25 30
gcg cgg cgc ggg gac ggc gcg gac ccc gag ggc gaa ggc gtg acc ctg 204
Ala Arg Arg Gly Asp Gly Ala Asp Pro Glu Gly Glu Gly Val Thr Leu
35 40 45
cag cgc aat atc aca ctg atc aat ggt gtg gcc atc ata gtg ggc acc 252
Gln Arg Asn Ile Thr Leu Ile Asn Gly Val Ala Ile Ile Val Gly Thr
50 55 60
atc atc ggt tcg ggc atc ttc gtg acg ccc acc ggc gtg ctc aag gaa 300
Ile Ile Gly Ser Gly Ile Phe Val Thr Pro Thr Gly Val Leu Lys Glu
65 70 75
gcc ggc tcg ccc gga ctg tcg ctt gtg gtg tgg get gtg tgc ggc gtc 348
Ala Gly Ser Pro Gly Leu Ser Leu Val Val Trp Ala Val Cys Gly Val
80 85 90 95
ttc tcc atc gtg ggc gca ctg tgc tac gcg gag ctg ggc act acc atc 396
Phe Ser Ile Val Gly Ala Leu Cys Tyr Ala Glu Leu Gly Thr Thr Ile
100 105 110
tca aag tca ggc ggc gac tat gcc tac atg cta gag gtc tac ggc tcg 444
Ser Lys Ser Gly Gly Asp Tyr Ala Tyr Met Leu Glu Val Tyr Gly Ser
115 120 125
ctg ccc gcc ttc ctc aag ctc tgg atc gag ctg ctc atc att cgg ccc 492
Leu Pro Ala Phe Leu Lys Leu Trp Ile Glu Leu Leu Ile Ile Arg Pro
130 135 140
tcc tca cag tac atc gtg gcg ctg gtc ttc gcc aca tac ctg ctc aag 540
Ser Ser Gln Tyr Ile Val Ala Leu Val Phe Ala Thr Tyr Leu Leu Lys
145 150 155
ccg gtc ttc ccc act tgt ccc gtg ccc gag gag get gcc aag ctc gtg 588
Pro Val Phe Pro Thr Cys Pro Val Pro Glu Glu Ala Ala Lys Leu Val
160 165 170 175
gcc tgc ctc tgc gtg cta cta ctc acg get gtg aac tgc tac agt gtg 636
Ala Cys Leu Cys Val Leu Leu Leu Thr Ala Val Asn Cys Tyr Ser Val
180 185 190
aag get get acc cgt gtg cag gat gcc ttt gcg get gcc aaa ctg ctg 684
Lys Ala Ala Thr Arg Val Gln Asp Ala Phe Ala Ala Ala Lys Leu Leu
195 200 205
gcc ctg gcc ctc atc atc ctg ctc ggc ttc atc cag atg gga aag gac 732
Ala Leu Ala Leu Ile Ile Leu Leu Gly Phe Ile Gln Met Gly Lys Asp
210 215 220
7/32
CA 02341777 2001-08-27
ata gga caa ggg gat gca tcc aac ctg cac cag aag ttg tcc ttt gaa 780
Ile Gly Gln Gly Asp Ala Ser Asn Leu His Gln Lys Leu Ser Phe Glu
225 230 235
ggc acc aat ctg gac gtg ggg aac att gtg ttg gca ttg tac agt ggc 828
Gly Thr Asn Leu Asp Val Gly Asn Ile Val Leu Ala Leu Tyr Ser Gly
240 245 250 255
ctc ttc gcc tac gga gga tgg aac tat ctg aat ttt gtc acg gag gag 876
Leu Phe Ala Tyr Gly Gly Trp Asn Tyr Leu Asn Phe Val Thr Glu Glu
260 265 270
atg atc aac ccc tac agg aac ctc ccc ctg gcc atc atc atc tcc ttg 924
Met Ile Asn Pro Tyr Arg Asn Leu Pro Leu Ala Ile Ile Ile Ser Leu
275 280 285
ccc att gtc acc ctg gtc tat gtg ctg acg aac ctg gcc tac ttc act 972
Pro Ile Val Thr Leu Val Tyr Val Leu Thr Asn Leu Ala Tyr Phe Thr
290 295 300
acc ctg tct acc aac cag atg ctg aca tct gaa gcc gtg get gtg gat 1020
Thr Leu Ser Thr Asn Gln Met Leu Thr Ser Glu Ala Val Ala Val Asp
305 310 315
ttt ggg aac tac cac ctg gga gtc atg tcc tgg atc att cct gtc ttc 1068
Phe Gly Asn Tyr His Leu Gly Val Met Ser Trp Ile Ile Pro Val Phe
320 325 330 335
gtg ggc ttg tcc tgc ttc ggc tct gtc aat ggg tct ctg ttc acg tcc 1116
Val Gly Leu Ser Cys Phe Gly Ser Val Asn Gly Ser Leu Phe Thr Ser
340 345 350
tca aga ctg ttc ttc gtg gga tcc agg gag ggc cac ctg cct tcc atc 1164
Ser Arg Leu Phe Phe Val Gly Ser Arg Glu Gly His Leu Pro Ser Ile
355 360 365
ctc tcc atg atc cac cca cag ctt ctg aca ccg gtg cca tca ctg gtg 1212
Leu Ser Met Ile His Pro Gln Leu Leu Thr Pro Val Pro Ser Leu Val
370 375 380
ttc acg tgt gtc atg acc ctg atg tac gcc ttc tcc aga gac atc ttc 1260
Phe Thr Cys Val Met Thr Leu Met Tyr Ala Phe Ser Arg Asp Ile Phe
385 390 395
tcc atc atc aac ttc ttc agc ttc ttc aac tgg ctg tgt gtg gcc ctg 1308
Ser Ile Ile Asn Phe Phe Ser Phe Phe Asn Trp Leu Cys Val Ala Leu
400 405 410 415
gcc atc atc ggc atg atg tgg ctc cgc ttt aag aag cct gag ctg gag 1356
Ala Ile Ile Gly Met Met Trp Leu Arg Phe Lys Lys Pro Glu Leu Glu
420 425 430
cgt ccc atc aag gtg aat ctg gcc ctc cca gtg ttc ttt atc ctg gcc 1404
Arg Pro Ile Lys Val Asn Leu Ala Leu Pro Val Phe Phe Ile Leu Ala
435 440 445
tgc ctc ttc ctc atc gcc gtg tcc ttc tgg aag aca ccc ctg gag tgc 1452
Cys Leu Phe Leu Ile Ala Val Ser Phe Trp Lys Thr Pro Leu Glu Cys
450 455 460
8/32
CA 02341777 2001-08-27
ggc att ggc ttc gcc atc atc ctc agc ggg ctg cct gtc tac ttc ttt 1500
Gly Ile Gly Phe Ala Ile Ile Leu Ser Gly Leu Pro Val Tyr Phe Phe
465 470 475
ggt gtg tgg tgg aaa aac aag ccc aaa tgg atc ctg cag gtc atc ttc 1548
Gly Val Trp Trp Lys Asn Lys Pro Lys Trp Ile Leu Gln Val Ile Phe
480 485 490 495
tcc gtg acc gtg ctc tgc cag aag ctg atg cag gtg gtt cct cag gag 1596
Ser Val Thr Val Leu Cys Gln Lys Leu Met Gln Val Val Pro Gln Glu
500 505 510
act tag ccacgtgtcc tgggtcccgc gggagagtgc actgtgactg cttccagaca 1652
Thr
actcaccttt ggaaaagcag cgtccaggcc cgtcatcccc acagctccag tgagcaccac 1712
taactatctt aacaccatcc gctgtccctc aaaggtcagg tgtccacagt ggccgtgaaa 1772
gaaacctggt acgaatttgg tcccagatgg tgaccatcca tgcatacata gcagccactg 1832
tgaggtgtgc tgtggcctga ggcctggtct ttctgacttt ggggactgcc acatctgggc 1892
tttctcctct atgatttttt gttttgtttt tgtagcgttc atttgggtca agtttacact 1952
accgagatga ttattttttg acaaaacagg gtagcaaaga gcaggagatg gtgtggccgg 2012
acattccggc tctgagtggg aactgcaggc cacagctctt ctccgactgt tgttcgttca 2072
gtagcacatt gtggctggag gggaccacat cactgtcacc aagtcagaac tactgagact 2132
caaacatcac cttttccact gtggacttgc actgacaaac ggacgatgaa tgtgctagct 2192
tgggtttgag ttttctgggt ctgtcctaga gatgaaaccc caacctgacc cacgaggcag 2252
agctctactg tgggtcattt gttccattgt aaatgcagag ctccggtctg accactctga 2312
agtcctggtg attccccttc ccctggctcc aaatgaaaga cctctgcagc cataacccta 2372
gtggcacctg gccaccaact gtcaactgcg gggccatgtg ctcctgtgca cacaagctgg 2432
ctctacacat tcaaggggca ctgctctggg tcttactccc tgtcccaccc cagctctcct 2492
agaaccagac cggcaccatg gggctccacc acacacctct gtccacctcc ataattcctg 2552
agactgctag cagctctctg tcaagtcacc accgtccccc ctcagccccc cgggccactg 2612
ttcaaaagaa taggcaccaa ctacccttct gctctctgcc acctgtgtga cgtgaccact 2672
ccagctccct gagcgtgaaa actgctggct acgtgctgct gtccctcctg tgtgggacca 2732
gtctgttccg gggagacggt tgagtccagc agcacatcca ctgaagcagc tgatctgact 2792
gaaggacttg agggcatgag aatcccccgc tggcccttcc attgcctcag agctggcctc 2852
cctgaggggg tgtcaactgg agtgtctact gtgaagctct tacatagtgg caccctgata 2912
tctcctgggg ttcccttgtg ttggggtgag gaggcagagg tcaaggtcag agtgccccta 2972
gaaggctctc cagagatgtg aactcaggtc cccagacaca agcctgggtt caaagggcag 3032
9/32
CA 02341777 2001-08-27
ggcaagtctt ggtccacgtt catggtgctg acccaggccc tctgagaagg ccctgtcatt 3092
cctattctga tgtcctgagg acgcccatct gtaggttttt ggttttaaat caagccacag 3152
ccacagtcat ttggcccaat gctttgcatt gtgttgtcct aacacatcac tgccctgtgg 3212
aacccccctg cctggccctt ttcagtggtc agtgtccagt gctgggtacg gtgtgttccc 3272
accacactgg gtccacctgc tgtgccactg gacttagtgc tgtggttgta atgtctttta 3332
ctattgtatt aatgactagt ctgttacatt agactggggg tggggtgcaa gggtctgctg 3392
gtttgtgagg ctttttgatt gggggggtgg tttgtttttt ttttttaaag ctattggagt 3452
tct 3455
<210> 4
<211> 512
<212> PRT
<213> Rat
<400> 4
Met Ala Val Ala Gly Ala Lys Arg Arg Ala Val Ala Ala Pro Ala Thr
1 5 10 15
Thr Ala Ala Glu Glu Glu Arg Gln Ala Arg Glu Lys Met Leu Glu Ala
20 25 30
Arg Arg Gly Asp Gly Ala Asp Pro Glu Gly Glu Gly Val Thr Leu Gln
35 40 45
Arg Asn Ile Thr Leu Ile Asn Gly Val Ala Ile Ile Val Gly Thr Ile
50 55 60
Ile Gly Ser Gly Ile Phe Val Thr Pro Thr Gly Val Leu Lys Glu Ala
65 70 75 80
Gly Ser Pro Gly Leu Ser Leu Val Val Trp Ala Val Cys Gly Val Phe
85 90 95
Ser Ile Val Gly Ala Leu Cys Tyr Ala Glu Leu Gly Thr Thr Ile Ser
100 105 110
Lys Ser Gly Gly Asp Tyr Ala Tyr Met Leu Glu Val Tyr Gly Ser Leu
115 120 125
Pro Ala Phe Leu Lys Leu Trp Ile Glu Leu Leu Ile Ile Arg Pro Ser
130 135 140
Ser Gln Tyr Ile Val Ala Leu Val Phe Ala Thr Tyr Leu Leu Lys Pro
145 150 155 160
Val Phe Pro Thr Cys Pro Val Pro Glu Glu Ala Ala Lys Leu Val Ala
165 170 175
Cys Leu Cys Val Leu Leu Leu Thr Ala Val Asn Cys Tyr Ser Val Lys
180 185 190
Ala Ala Thr Arg Val Gln Asp Ala Phe Ala Ala Ala Lys Leu Leu Ala
195 200 205
Leu Ala Leu Ile Ile Leu Leu Gly Phe Ile Gln Met Gly Lys Asp Ile
210 215 220
Gly Gln Gly Asp Ala Ser Asn Leu His Gln Lys Leu Ser Phe Glu Gly
225 230 235 240
Thr Asn Leu Asp Val Gly Asn Ile Val Leu Ala Leu Tyr Ser Gly Leu
245 250 255
Phe Ala Tyr Gly Gly Trp Asn Tyr Leu Asn Phe Val Thr Glu Glu Met
260 265 270
Ile Asn Pro Tyr Arg Asn Leu Pro Leu Ala Ile Ile Ile Ser Leu Pro
275 280 285
10/32
CA 02341777 2001-08-27
Ile Val Thr Leu Val Tyr Val Leu Thr Asn Leu Ala Tyr Phe Thr Thr
290 295 300
Leu Ser Thr Asn Gln Met Leu Thr Ser Glu Ala Val Ala Val Asp Phe
305 310 315 320
Gly Asn Tyr His Leu Gly Val Met Ser Trp Ile Ile Pro Val Phe Val
325 330 335
Gly Leu Ser Cys Phe Gly Ser Val Asn Gly Ser Leu Phe Thr Ser Ser
340 345 350
Arg Leu Phe Phe Val Gly Ser Arg Glu Gly His Leu Pro Ser Ile Leu
355 360 365
Ser Met Ile His Pro Gln Leu Leu Thr Pro Val Pro Ser Leu Val Phe
370 375 380
Thr Cys Val Met Thr Leu Met Tyr Ala Phe Ser Arg Asp Ile Phe Ser
385 390 395 400
Ile Ile Asn Phe Phe Ser Phe Phe Asn Trp Leu Cys Val Ala Leu Ala
405 410 415
Ile Ile Gly Met Met Trp Leu Arg Phe Lys Lys Pro Glu Leu Glu Arg
420 425 430
Pro Ile Lys Val Asn Leu Ala Leu Pro Val Phe Phe Ile Leu Ala Cys
435 440 445
Leu Phe Leu Ile Ala Val Ser Phe Trp Lys Thr Pro Leu Glu Cys Gly
450 455 460
Ile Gly Phe Ala Ile Ile Leu Ser Gly Leu Pro Val Tyr Phe Phe Gly
465 470 475 480
Val Trp Trp Lys Asn Lys Pro Lys Trp Ile Leu Gln Val Ile Phe Ser
485 490 495
Val Thr Val Leu Cys Gln Lys Leu Met Gln Val Val Pro Gln Glu Thr
500 505 510
<210> 5
<211> 1863
<212> DNA
<213> Homo sapiens
<220>
<221> 5'UTR
<222> (1)..(109)
<220>
<221> CDS
<222> (110)..(1699)
<220>
<221> 3'UTR
<222> (1700)..(1863)
<400> 5
gcgcggagcc acagaggccg gggagagcgt tctgggtccg agggtccagg taggggttga 60
gccaccatct gaccgcaagc tgcgtcgtgt cgccggttct gcaggcacc atg agc cag 118
Met Ser Gln
1
gac acc gag gtg gat atg aag gag gtg gag ctg aat gag tta gag ccc 166
Asp Thr Glu Val Asp Met Lys Glu Val Glu Leu Asn Glu Leu Glu Pro
10 15
gag aag cag ccg atg aac gcg gcg tct ggg gcg gcc atg tcc ctg gcg 214
11/32
CA 02341777 2001-08-27
Glu Lys Gln Pro Met Asn Ala Ala Ser Gly Ala Ala Met Ser Leu Ala
20 25 30 35
gga gcc gag aag aat ggt ctg gtg aag atc aag gtg gcg gaa gac gag 262
Gly Ala Glu Lys Asn Gly Leu Val Lys Ile Lys Val Ala Glu Asp Glu
40 45 50
gcg gag gcg gca gcc gcg get aag ttc acg ggc ctg tcc aag gag gag 310
Ala Glu Ala Ala Ala Ala Ala Lys Phe Thr Gly Leu Ser Lys Glu Glu
55 60 65
ctg ctg aag gtg gca ggc agc ccc ggc tgg gta cgc acc cgc tgg gca 358
Leu Leu Lys Val Ala Gly Ser Pro Gly Trp Val Arg Thr Arg Trp Ala
70 75 80
ctg ctg ctg ctc ttc tgg ctc ggc tgg ctc ggc atg ctt get ggt gcc 406
Leu Leu Leu Leu Phe Trp Leu Gly Trp Leu Gly Met Leu Ala Gly Ala
85 90 95
gtg gtc ata atc gtg cga gcg ccg cgt tgt cgc gag cta ccg gcg cag 454
Val Val Ile Ile Val Arg Ala Pro Arg Cys Arg Glu Leu Pro Ala Gln
100 105 110 115
aag tgg tgg cac acg ggc gcc ctc tac cgc atc ggc gac ctt cag gcc 502
Lys Trp Trp His Thr Gly Ala Leu Tyr Arg Ile Gly Asp Leu Gln Ala
120 125 130
ttc cag ggc cac ggc gcg ggc aac ctg gcg ggt ctg aag ggg cgt ctc 550
Phe Gln Gly His Gly Ala Gly Asn Leu Ala Gly Leu Lys Gly Arg Leu
135 140 145
gat tac ctg agc tct ctg aag gtg aag ggc ctt gtg ctg ggt cca att 598
Asp Tyr Leu Ser Ser Leu Lys Val Lys Gly Leu Val Leu Gly Pro Ile
150 155 160
cac aag aac cag aag gat gat gtc get cag act gac ttg ctg cag atc 646
His Lys Asn Gln Lys Asp Asp Val Ala Gln Thr Asp Leu Leu Gln Ile
165 170 175
gac ccc aat ttt ggc tcc aag gaa gat ttt gac agt ctc ttg caa tcg 694
Asp Pro Asn Phe Gly Ser Lys Glu Asp Phe Asp Ser Leu Leu Gln Ser
180 185 190 195
get aaa aaa aag agc atc cgt gtc att ctg gac ctt act ccc aac tac 742
Ala Lys Lys Lys Ser Ile Arg Val Ile Leu Asp Leu Thr Pro Asn Tyr
200 205 210
cgg ggt gag aac tcg tgg ttc tcc act cag gtt gac act gtg gcc acc 790
Arg Gly Glu Asn Ser Trp Phe Ser Thr Gln Val Asp Thr Val Ala Thr
215 220 225
aag gtg aag gat get ctg gag ttt tgg ctg caa get ggc gtg gat ggg 838
Lys Val Lys Asp Ala Leu Glu Phe Trp Leu Gln Ala Gly Val Asp Gly
230 235 240
ttc cag gtt cgg gac ata gag aat ctg aag gat gca tcc tca ttc ttg 886
Phe Gln Val Arg Asp Ile Glu Asn Leu Lys Asp Ala Ser Ser Phe Leu
245 250 255
get gag tgg caa aat atc acc aag ggc ttc agt gaa gac agg ctc ttg 934
12/32
CA 02341777 2001-08-27
Ala Glu Trp Gln Asn Ile Thr Lys Gly Phe Ser Glu Asp Arg Leu Leu
260 265 270 275
att gcg ggg act aac tcc tcc gac ctt cag cag atc ctg agc cta ctc 982
Ile Ala Gly Thr Asn Ser Ser Asp Leu Gln Gin Ile Leu Ser Leu Leu
280 285 290
gaa tcc aac aaa gac ttg ctg ttg act agc tca tac ctg tct gat tct 1030
Glu Ser Asn Lys Asp Leu Leu Leu Thr Ser Ser Tyr Leu Ser Asp Ser
295 300 305
ggt tct act ggg gag cat aca aaa tcc cta gtc aca cag tat ttg aat 1078
Gly Ser Thr Gly Glu His Thr Lys Ser Leu Val Thr Gln Tyr Leu Asn
310 315 320
gcc act ggc aat cgc tgg tgc agc tgg agt ttg tct cag gca agg ctc 1126
Ala Thr Gly Asn Arg Trp Cys Ser Trp Ser Leu Ser Gln Ala Arg Leu
325 330 335
ctg act tcc ttc ttg ccg get caa ctt ctc cga ctc tac cag ctg atg 1174
Leu Thr Ser Phe Leu Pro Ala Gln Leu Leu Arg Leu Tyr Gln Leu Met
340 345 350 355
ctc ttc acc ctg cca ggg acc cct gtt ttc agc tac ggg gat gag att 1222
Leu Phe Thr Leu Pro Gly Thr Pro Val Phe Ser Tyr Gly Asp Glu Ile
360 365 370
ggc ctg gat gca get gcc ctt cct gga cag cct atg gag get cca gtc 1270
Gly Leu Asp Ala Ala Ala Leu Pro Gly Gln Pro Met Glu Ala Pro Val
375 380 385
atg ctg tgg gat gag tcc agc ttc cct gac atc cca ggg get gta agt 1318
Met Leu Trp Asp Glu Ser Ser Phe Pro Asp Ile Pro Gly Ala Val Ser
390 395 400
gcc aac atg act gtg aag ggc cag agt gaa gac cct ggc tcc ctc ctt 1366
Ala Asn Met Thr Val Lys Gly Gln Ser Glu Asp Pro Gly Ser Leu Leu
405 410 415
tcc ttg ttc cgg cgg ctg agt gac cag cgg agt aag gag cgc tcc cta 1414
Ser Leu Phe Arg Arg Leu Ser Asp Gln Arg Ser Lys Glu Arg Ser Leu
420 425 430 435
ctg cat ggg gac ttc cac gcg ttc tcc get ggg cct gga ctc ttc tcc 1462
Leu His Gly Asp Phe His Ala Phe Ser Ala Gly Pro Gly Leu Phe Ser
440 445 450
tat atc cgc cac tgg gac cag aat gag cgt ttt ctg gta gtg ctt aac 1510
Tyr Ile Arg His Trp Asp Gln Asn Glu Arg Phe Leu Val Val Leu Asn
455 460 465
ttt ggg gat gtg ggc ctc tcg get gga ctg cag gcc tcc gac ctg cct 1558
Phe Gly Asp Val Gly Leu Ser Ala Gly Leu Gln Ala Ser Asp Leu Pro
470 475 480
gcc agc gcc agc ctc cca gcc aag get gac ctc ctg ctc agc acc cag 1606
Ala Ser Ala Ser Leu Pro Ala Lys Ala Asp Leu Leu Leu Ser Thr Gln
485 490 495
cca ggc cgt gag gag ggc tcc cct ctt gag ctg gaa cgc ctg aaa ctg 1654
13/32
CA 02341777 2001-08-27
Pro Gly Arg Glu Glu Gly Ser Pro Leu Glu Leu Glu Arg Leu Lys Leu
500 505 510 515
gag cct cac gaa ggg ctg ctg ctc cgc ttc ccc tac gcg gcc tga 1699
Glu Pro His Glu Gly Leu Leu Leu Arg Phe Pro Tyr Ala Ala
520 525 530
cttcagcctg acatggaccc actacccttc tcctttcctt cccaggccct ttggttctga 1759
tttttctctt ttttaaaaac aaacaaacaa actgttgcag attatgagtg aacccccaaa 1819
tagggtgttt tctgccttca aataaaagtc acccctgcat ggtg 1863
<210> 6
<211> 529
<212> PRT
<213> Homo sapiens
<400> 6
Met Ser Gln Asp Thr Glu Val Asp Met Lys Glu Val Glu Leu Asn Glu
1 5 10 15
Leu Glu Pro Glu Lys Gin Pro Met Asn Ala Ala Ser Gly Ala Ala Met
20 25 30
Ser Leu Ala Gly Ala Glu Lys Asn Gly Leu Val Lys Ile Lys Val Ala
35 40 45
Glu Asp Glu Ala Glu Ala Ala Ala Ala Ala Lys Phe Thr Gly Leu Ser
50 55 60
Lys Glu Glu Leu Leu Lys Val Ala Gly Ser Pro Gly Trp Val Arg Thr
65 70 75 80
Arg Trp Ala Leu Leu Leu Leu Phe Trp Leu Gly Trp Leu Gly Met Leu
85 90 95
Ala Gly Ala Val Val Ile Ile Val Arg Ala Pro Arg Cys Arg Glu Leu
100 105 110
Pro Ala Gln Lys Trp Trp His Thr Gly Ala Leu Tyr Arg Ile Gly Asp
115 120 125
Leu Gln Ala Phe Gln Gly His Gly Ala Gly Asn Leu Ala Gly Leu Lys
130 135 140
Gly Arg Leu Asp Tyr Leu Ser Ser Leu Lys Val Lys Gly Leu Val Leu
145 150 155 160
Gly Pro Ile His Lys Asn Gln Lys Asp Asp Val Ala Gin Thr Asp Leu
165 170 175
Leu Gln Ile Asp Pro Asn Phe Gly Ser Lys Glu Asp Phe Asp Ser Leu
180 185 190
Leu Gin Ser Ala Lys Lys Lys Ser Ile Arg Val Ile Leu Asp Leu Thr
195 200 205
Pro Asn Tyr Arg Gly Glu Asn Ser Trp Phe Ser Thr Gln Val Asp Thr
210 215 220
Val Ala Thr Lys Val Lys Asp Ala Leu Glu Phe Trp Leu Gln Ala Gly
225 230 235 240
Val Asp Gly Phe Gln Val Arg Asp Ile Glu Asn Leu Lys Asp Ala Ser
245 250 255
Ser Phe Leu Ala Glu Trp Gln Asn Ile Thr Lys Gly Phe Ser Glu Asp
260 265 270
Arg Leu Leu Ile Ala Gly Thr Asn Ser Ser Asp Leu Gln Gln Ile Leu
275 280 285
Ser Leu Leu Glu Ser Asn Lys Asp Leu Leu Leu Thr Ser Ser Tyr Leu
290 295 300
Ser Asp Ser Gly Ser Thr Gly Glu His Thr Lys Ser Leu Val Thr Gin
305 310 315 320
14/32
CA 02341777 2001-08-27
Tyr Leu Asn Ala Thr Gly Asn Arg Trp Cys Ser Trp Ser Leu Ser Gln
325 330 335
Ala Arg Leu Leu Thr Ser Phe Leu Pro Ala Gln Leu Leu Arg Leu Tyr
340 345 350
Gln Leu Met Leu Phe Thr Leu Pro Gly Thr Pro Val Phe Ser Tyr Gly
355 360 365
Asp Glu Ile Gly Leu Asp Ala Ala Ala Leu Pro Gly Gln Pro Met Glu
370 375 380
Ala Pro Val Met Leu Trp Asp Glu Ser Ser Phe Pro Asp Ile Pro Gly
385 390 395 400
Ala Val Ser Ala Asn Met Thr Val Lys Gly Gln Ser Glu Asp Pro Gly
405 410 415
Ser Leu Leu Ser Leu Phe Arg Arg Leu Ser Asp Gln Arg Ser Lys Glu
420 425 430
Arg Ser Leu Leu His Gly Asp Phe His Ala Phe Ser Ala Gly Pro Gly
435 440 445
Leu Phe Ser Tyr Ile Arg His Trp Asp Gln Asn Glu Arg Phe Leu Val
450 455 460
Val Leu Asn Phe Gly Asp Val Gly Leu Ser Ala Gly Leu Gin Ala Ser
465 470 475 480
Asp Leu Pro Ala Ser Ala Ser Leu Pro Ala Lys Ala Asp Leu Leu Leu
485 490 495
Ser Thr Gln Pro Gly Arg Glu Glu Gly Ser Pro Leu Glu Leu Glu Arg
500 505 510
Leu Lys Leu Glu Pro His Glu Gly Leu Leu Leu Arg Phe Pro Tyr Ala
515 520 525
Ala
<210> 7
<211> 1797
<212> DNA
<213> Rat
<220>
<221> 5'UTR
<222> (1)..(19)
<220>
<221> CDS
<222> (20)..(1603)
<220>
<221> 3'UTR
<222> (1604)..(1797)
<400> 7
cgttgctgtc gcaggtacc atg agc cag gac acc gaa gtg gac atg aaa gat 52
Met Ser Gln Asp Thr Glu Val Asp Met Lys Asp
1 5 10
gtg gag ctg aac gag ctg gaa ccg gag aag cag cct atg aat gca gcg 100
Val Glu Leu Asn Glu Leu Glu Pro Glu Lys Gln Pro Met Asn Ala Ala
15 20 25
gac ggg gcg gca gcc ggg gag aag aac ggt ctg gtg aag att aag gtg 148
Asp Gly Ala Ala Ala Gly Glu Lys Asn Gly Leu Val Lys Ile Lys Val
30 35 40
15/32
CA 02341777 2001-08-27
gcc gaa gac gag gcg gaa gcc ggg gtc aag ttc aca ggc tta tcc aag 196
Ala Glu Asp Glu Ala Glu Ala Gly Val Lys Phe Thr Gly Leu Ser Lys
45 50 55
gag gag cta ttg aag gta get ggc agc ccg ggc tgg gtg cgc acc cgc 244
Glu Glu Leu Leu Lys Val Ala Gly Ser Pro Gly Trp Val Arg Thr Arg
60 65 70 75
tgg gcg ctg ctg ctg ctc ttc tgg ctc ggt tgg ctg ggt atg ctg gcg 292
Trp Ala Leu Leu Leu Leu Phe Trp Leu Gly Trp Leu Gly Net Leu Ala
80 85 90
ggc gcc gtg gtt atc atc gtt cgg gcg cca cgc tgc cgt gag ctg ccg 340
Gly Ala Val Val Ile Ile Val Arg Ala Pro Arg Cys Arg Glu Leu Pro
95 100 105
gta cag aga tgg tgg cac aag ggc gcc ctc tac cgc atc ggc gac ctt 388
Val Gln Arg Trp Trp His Lys Gly Ala Leu Tyr Arg Ile Gly Asp Leu
110 115 120
cag gcc ttc gta ggc ccg gaa gcg aga ggc ata get ggt ctg aag aac 436
Gln Ala Phe Val Gly Pro Glu Ala Arg Gly Ile Ala Gly Leu Lys Asn
125 130 135
cat ctg gag tac ttg agc acc ctg aag gtg aag ggc cta gtt ttg ggc 484
His Leu Glu Tyr Leu Ser Thr Leu Lys Val Lys Gly Leu Val Leu Gly
140 145 150 155
cca att cac aag aac cag aag gat gaa gtc aat gaa acc gac ttg aaa 532
Pro Ile His Lys Asn Gin Lys Asp Glu Val Asn Glu Thr Asp Leu Lys
160 165 170
cag att gat ccc gat tta ggc tcc cag gaa gat ttt aaa gac ctt cta 580
Gln Ile Asp Pro Asp Leu Gly Ser Gln Glu Asp Phe Lys Asp Leu Leu
175 180 185
caa agt gcc aag aaa aag agc att cac atc att ttg gac ctc act ccc 628
Gln Ser Ala Lys Lys Lys Ser Ile His Ile Ile Leu Asp Leu Thr Pro
190 195 200
aac tat aag ggc cag aat gca tgg ttc ctc cct cct cag get gac att 676
Asn Tyr Lys Gly Gln Asn Ala Trp Phe Leu Pro Pro Gln Ala Asp Ile
205 210 215
gta gcc acc aaa atg aag gag get ctg agt tct tgg ttg cag gac ggt 724
Val Ala Thr Lys Met Lys Glu Ala Leu Ser Ser Trp Leu Gln Asp Gly
220 225 230 235
gtg gat ggg ttc caa gtt cgg gat gtg gga aag ctg gcg aat gca tcc 772
Val Asp Gly Phe Gln Val Arg Asp Val Gly Lys Leu Ala Asn Ala Ser
240 245 250
ttg tac ttg get gag tgg cag aat atc acc aag aac ttc agt gag gac 820
Leu Tyr Leu Ala Glu Trp Gin Asn Ile Thr Lys Asn Phe Ser Glu Asp
255 260 265
agg ctt ttg att gca ggg acc gcg tcc tct gac ctg caa caa att gtc 868
Arg Leu Leu Ile Ala Gly Thr Ala Ser Ser Asp Leu Gln Gln Ile Val
270 275 280
16/32
CA 02341777 2001-08-27
aac ata ctt gaa tcc acc agc gat ctg ctg ctg acc agc tca tac ctg 916
Asn Ile Leu Glu Ser Thr Ser Asp Leu Leu Leu Thr Ser Ser Tyr Leu
285 290 295
tca cag ccc gtt ttc act ggg gag cat gca gaa ctc cta gtg att aag 964
Ser Gln Pro Val Phe Thr Gly Glu His Ala Glu Leu Leu Val Ile Lys
300 305 310 315
tat ttg aat gcc act ggc agc cgc tgg tgc agc tgg agt gtg tcg cag 1012
Tyr Leu Asn Ala Thr Gly Ser Arg Trp Cys Ser Trp Ser Val Ser Gln
320 325 330
gca gga ctc ctg aca tcc ttt ata ccg get cag ttt ctc cga ctc tac 1060
Ala Gly Leu Leu Thr Ser Phe Ile Pro Ala Gln Phe Leu Arg Leu Tyr
335 340 345
cag ctg ctg ctc ttc act ctg cca gga act cct gtt ttc agc tat ggg 1108
Gln Leu Leu Leu Phe Thr Leu Pro Gly Thr Pro Val Phe Ser Tyr Gly
350 355 360
gat gag ctt ggc ctt cag gca gtt gcc ctt cct gga cag cct atg gag 1156
Asp Glu Leu Gly Leu Gln Ala Val Ala Leu Pro Gly Gln Pro Met Glu
365 370 375
get cca ttc atg ctg tgg aat gag tct agc aac tcc caa acc tca agt 1204
Ala Pro Phe Met Leu Trp Asn Glu Ser Ser Asn Ser Gln Thr Ser Ser
380 385 390 395
cct gta agc ctc aac atg aca gtg aag ggc caa aat gaa gac ccc ggc 1252
Pro Val Ser Leu Asn Met Thr Val Lys Gly Gln Asn Glu Asp Pro Gly
400 405 410
tcc ctc ctc acc cag ttc cgg cga ctg agt gac ctc cgt ggt aag gag 1300
Ser Leu Leu Thr Gln Phe Arg Arg Leu Ser Asp Leu Arg Gly Lys Glu
415 420 425
cgc tct ctg tta cac ggt gac ttt gat gca ctg tct tcc tca tct ggg 1348
Arg Ser Leu Leu His Gly Asp Phe Asp Ala Leu Ser Ser Ser Ser Gly
430 435 440
ctc ttc tcc tac gtc cgc cac tgg gac cag aat gag cgt tac ctg gtg 1396
Leu Phe Ser Tyr Val Arg His Trp Asp Gln Asn Glu Arg Tyr Leu Val
445 450 455
gtg ctc aac ttc cag gat gtg ggc ctg tca gcc agg gta gga gcc tcc 1444
Val Leu Asn Phe Gln Asp Val Gly Leu Ser Ala Arg Val Gly Ala Ser
460 465 470 475
aac ctc cct get ggc ata agc ctg cca gcc agt get aac ctt ttg ctt 1492
Asn Leu Pro Ala Gly Ile Ser Leu Pro Ala Ser Ala Asn Leu Leu Leu
480 485 490
agt act gac agc acc cgg cta agc cgt gag gag ggc acc tcc ctg agc 1540
Ser Thr Asp Ser Thr Arg Leu Ser Arg Glu Glu Gly Thr Ser Leu Ser
495 500 505
ctg gaa aac ctg agc ctg aat cct tat gag ggc ttg ttg tta cag ttc 1588
Leu Glu Asn Leu Ser Leu Asn Pro Tyr Glu Gly Leu Leu Leu Gln Phe
510 515 520
17/32
CA 02341777 2001-08-27
cct ttt gtg gcc tga tccctctaca cagaacctgc cacccttctt tcctctctca 1643
Pro Phe Val Ala
525
ggcctttgga attctggtct ttctctcctt attttgtttt tgtttttaaa cttttgcaga 1703
ttacatatga attcttacac tgggggtttt tgttttcaaa ataaaaaaaa tcacccctaa 1763
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaa 1797
<210> 8
<211> 527
<212> PRT
<213> Rat
<400> 8
Met Ser Gln Asp Thr Glu Val Asp Met Lys Asp Val Glu Leu Asn Glu
1 5 10 15
Leu Glu Pro Glu Lys Gln Pro Met Asn Ala Ala Asp Gly Ala Ala Ala
20 25 30
Gly Glu Lys Asn Gly Leu Val Lys Ile Lys Val Ala Glu Asp Glu Ala
35 40 45
Glu Ala Gly Val Lys Phe Thr Gly Leu Ser Lys Glu Glu Leu Leu Lys
50 55 60
Val Ala Gly Ser Pro Gly Trp Val Arg Thr Arg Trp Ala Leu Leu Leu
65 70 75 80
Leu Phe Trp Leu Gly Trp Leu Gly Met Leu Ala Gly Ala Val Val Ile
85 90 95
Ile Val Arg Ala Pro Arg Cys Arg Glu Leu Pro Val Gln Arg Trp Trp
100 105 110
His Lys Gly Ala Leu Tyr Arg Ile Gly Asp Leu Gln Ala Phe Val Gly
115 120 125
Pro Glu Ala Arg Gly Ile Ala Gly Leu Lys Asn His Leu Glu Tyr Leu
130 135 140
Ser Thr Leu Lys Val Lys Gly Leu Val Leu Gly Pro Ile His Lys Asn
145 150 155 160
Gln Lys Asp Glu Val Asn Glu Thr Asp Leu Lys Gln Ile Asp Pro Asp
165 170 175
Leu Gly Ser Gln Glu Asp Phe Lys Asp Leu Leu Gln Ser Ala Lys Lys
180 185 190
Lys Ser Ile His Ile Ile Leu Asp Leu Thr Pro Asn Tyr Lys Gly Gln
195 200 205
Asn Ala Trp Phe Leu Pro Pro Gln Ala Asp Ile Val Ala Thr Lys Met
210 215 220
Lys Glu Ala Leu Ser Ser Trp Leu Gln Asp Gly Val Asp Gly Phe Gln
225 230 235 240
Val Arg Asp Val Gly Lys Leu Ala Asn Ala Ser Leu Tyr Leu Ala Glu
245 250 255
Trp Gln Asn Ile Thr Lys Asn Phe Ser Glu Asp Arg Leu Leu Ile Ala
260 265 270
Gly Thr Ala Ser Ser Asp Leu Gln Gln Ile Val Asn Ile Leu Glu Ser
275 280 285
Thr Ser Asp Leu Leu Leu Thr Ser Ser Tyr Leu Ser Gln Pro Val Phe
290 295 300
Thr Gly Glu His Ala Glu Leu Leu Val Ile Lys Tyr Leu Asn Ala Thr
305 310 315 320
Gly Ser Arg Trp Cys Ser Trp Ser Val Ser Gln Ala Gly Leu Leu Thr
325 330 335
Ser Phe Ile Pro Ala Gln Phe Leu Arg Leu Tyr Gln Leu Leu Leu Phe
18/32
CA 02341777 2001-08-27
340 345 350
Thr Leu Pro Gly Thr Pro Val Phe Ser Tyr Gly Asp Glu Leu Gly Leu
355 360 365
Gin Ala Val Ala Leu Pro Gly Gln Pro Met Glu Ala Pro Phe Met Leu
370 375 380
Trp Asn Glu Ser Ser Asn Ser Gln Thr Ser Ser Pro Val Ser Leu Asn
385 390 395 400
Met Thr Val Lys Gly Gln Asn Glu Asp Pro Gly Ser Leu Leu Thr Gln
405 410 415
Phe Arg Arg Leu Ser Asp Leu Arg Gly Lys Glu Arg Ser Leu Leu His
420 425 430
Gly Asp Phe Asp Ala Leu Ser Ser Ser Ser Gly Leu Phe Ser Tyr Val
435 440 445
Arg His Trp Asp Gln Asn Glu Arg Tyr Leu Val Val Leu Asn Phe Gln
450 455 460
Asp Val Gly Leu Ser Ala Arg Val Gly Ala Ser Asn Leu Pro Ala Gly
465 470 475 480
Ile Ser Leu Pro Ala Ser Ala Asn Leu Leu Leu Ser Thr Asp Ser Thr
485 490 495
Arg Leu Ser Arg Glu Glu Gly Thr Ser Leu Ser Leu Glu Asn Leu Ser
500 505 510
Leu Asn Pro Tyr Glu Gly Leu Leu Leu Gln Phe Pro Phe Val Ala
515 520 525
<210> 9
<211> 22
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:Primer
<220>
<221> primer bind
<222> (1)..(22)
<400> 9
cgaagtggac atgaaagatg tg 22
<210> 10
<211> 22
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:Primer
<220>
<221> primer bind
<222> (1) .. (22)
<400> 10
aaactaggcc cttcaccttc ag 22
<210> 11
19/32
CA 02341777 2001-08-27
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:Primer
<220>
<221> primer - bind
<222> (1) .. (24)
<400> 11
actgctgctg ctcttctggc tcgg 24
<210> 12
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:Primer
<220>
<221> primer - bind
<222> (1)..(24)
<400> 12
gtggatgggt tccaggttcg ggac 24
<210> 13
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:Primer
<220>
<221> primer bind
<222> (1)..(24)
<400> 13
tgctgtggga tgagtccagc ttcc 24
<210> 14
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:Primer
<220>
<221> primer bind
<222> (1) .. (24)
<400> 14
20/32
CA 02341777 2001-08-27
gcaggaggtc agccttggct ggca 24
<210> 15
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:Primer
<220>
<221> primer bind
<222> (1) .. (24)
<400> 15
cttgcctgag acaaactcca gctg 24
<210> 16
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:Primer
<220>
<221> primer - bind
<222> (1)..(24)
<400> 16
actgtcaaaa tcttccttgg agcc 24
<210> 17
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:Primer
<220>
<221> primer - bind
<222> (1) (4)
<400> 17
ttctcgggct ctaactcatt cagc 24
<210> 18
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:Primer
<220>
21/32
CA 02341777 2001-08-27
<221> primer bind
<222> (1) (23)
<400> 18
tgctgctgct cacggccgtg aac 23
<210> 19
<211> 17
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:Primer
<220>
<221> primer bind
<222> (1)..(17)
<400> 19
tggcggcctt cacgctg 17
<210> 20
<211> 25
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:Primer
<220>
<221> primer bind
<222> (1) (25)
<400> 20
atctagattg gacacatcac ccttc 25
<210> 21
<211> 22
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:Primer
<220>
<221> primer - bind
<222> (1) .. (22)
<400> 21
gtggtgaagt aggccaggtt gg 22
<210> 22
<211> 21
<212> DNA
<213> Artificial Sequence
22/32
CA 02341777 2001-08-27
<220>
<223> Description of Artificial Sequence:Primer
<220>
<221> primer bind
<222> (1) .. (21)
<400> 22
gtggggtccc gggaaggcca c 21
<210> 23
<211> 22
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:Primer
<220>
<221> primer bind
<222> (1)..(22)
<400> 23
cttgtttttc caccagaccc cg 22
<210> 24
<211> 22
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:Primer
<220>
<221> primer bind
<222> (1)..(22)
<400> 24
tgagggatga gattcgtacc ag 22
<210> 25
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:Primer
<220>
<221> primer - bind
<222> (1)..(23)
<400> 25
cctgggagga atcacccacc ttg 23
<210> 26
23/32
CA 02341777 2001-08-27
<211> 1524
<212> RNA
<213> Homo sapiens
<220>
<221> CDS
<222> (1)..(1524)
<400> 26
aug gcg ggu gcg ggc ccg aag cgg cgc gcg cua gcg gcg ccg gcg gcc 48
Met Ala Gly Ala Gly Pro Lys Arg Arg Ala Leu Ala Ala Pro Ala Ala
1 5 10 15
gag gag aag gaa gag gcg cgg gag aag aug cug gcc gcc aag agc gcg 96
Glu Glu Lys Glu Glu Ala Arg Glu Lys Met Leu Ala Ala Lys Ser Ala
20 25 30
gac ggc ucg gcg ccg gca ggc gag ggc gag ggc gug acc cug cag cgg 144
Asp Gly Ser Ala Pro Ala Gly Glu Gly Glu Gly Val Thr Leu Gln Arg
35 40 45
aac auc acg cug cuc aac ggc gug gcc auc auc gug ggg acc auu auc 192
Asn Ile Thr Leu Leu Asn Gly Val Ala Ile Ile Val Gly Thr Ile Ile
50 55 60
ggc ucg ggc auc uuc gug acg ccc acg ggc gug cuc aag gag gca ggc 240
Gly Ser Gly Ile Phe Val Thr Pro Thr Gly Val Leu Lys Glu Ala Gly
65 70 75 80
ucg ccg ggg cug gcg cug gug gug ugg gcc gcg ugc ggc guc uuc ucc 288
Ser Pro Gly Leu Ala Leu Val Val Trp Ala Ala Cys Gly Val Phe Ser
85 90 95
auc gug ggc gcg cuc ugc uac gcg gag cuc ggc acc acc auc ucc aaa 336
Ile Val Gly Ala Leu Cys Tyr Ala Glu Leu Gly Thr Thr Ile Ser Lys
100 105 110
ucg ggc ggc gac uac gcc uac aug cug gag guc uac ggc ucg cug ccc 384
Ser Gly Gly Asp Tyr Ala Tyr Met Leu Glu Val Tyr Gly Ser Leu Pro
115 120 125
gcc uuc cuc aag cuc ugg auc gag cug cuc auc auc cgg Ccu uca ucg 432
Ala Phe Leu Lys Leu Trp Ile Glu Leu Leu Ile Ile Arg Pro Ser Ser
130 135 140
cag uac auc gug gcc cug guc uuc gcc acc uac cug cuc aag ccg cuc 480
Gln Tyr Ile Val Ala Leu Val Phe Ala Thr Tyr Leu Leu Lys Pro Leu
145 150 155 160
uuc ccc acc ugc ccg gug ccc gag gag gca gcc aag cuc gug gcc ugc 528
Phe Pro Thr Cys Pro Val Pro Glu Glu Ala Ala Lys Leu Val Ala Cys
165 170 175
cuc ugc gug cug cug cuc acg gcc gug aac ugc uac agc gug aag gcc 576
Leu Cys Val Leu Leu Leu Thr Ala Val Asn Cys Tyr Ser Val Lys Ala
180 185 190
gcc acc cgg guc cag gau gcc uuu gcc gcc gcc aag cuc cug gcc cug 624
Ala Thr Arg Val Gln Xaa Ala Phe Ala Ala Ala Lys Leu Leu Ala Leu
195 200 205
24/32
CA 02341777 2001-08-27
gcc cug auc auc cug cug ggc uuc guc cag auc ggg aag ggu gau gug 672
Ala Leu Ile Ile Leu Leu Gly Phe Val Gln Ile Gly Lys Gly Xaa Val
210 215 220
ucc aau cua gau ccc aac uuc uca uuu gaa ggc acc aaa cug gau gug 720
Ser Asn Leu Xaa Pro Asn Phe Ser Phe Glu Gly Thr Lys Leu Xaa Val
225 230 235 240
ggg aac auu gug cug gca uua uac agc ggc cuc uuu gcc uau gga gga 768
Gly Asn Ile Val Leu Ala Leu Tyr Ser Gly Leu Phe Ala Tyr Gly Gly
245 250 255
ugg aau uac uug aau uuc guc aca gag gaa aug auc aac ccc uac aga 816
Trp Asn Tyr Leu Asn Phe Val Thr Glu Glu Met Ile Asn Pro Tyr Arg
260 265 270
aac cug ccc cug gcc auc auc auc ucc cug ccc auc gug acg cug gug 864
Asn Leu Pro Leu Ala Ile Ile Ile Ser Leu Pro Ile Val Thr Leu Val
275 280 285
uac gug cug acc aac cug gcc uac uuc acc acc cug ucc acc gag cag 912
Tyr Val Leu Thr Asn Leu Ala Tyr Phe Thr Thr Leu Ser Thr Glu Gln
290 295 300
aug cug ucg ucc gag gcc gug gcc gug gac uuc ggg aac uau cac cug 960
Met Leu Ser Ser Glu Ala Val Ala Val Asp Phe Gly Asn Tyr His Leu
305 310 315 320
ggc guc aug ucc ugg auc auc ccc guc uuc gug ggc cug ucc ugc uuc 1008
Gly Val Met Ser Trp Ile Ile Pro Val Phe Val Gly Leu Ser Cys Phe
325 330 335
ggc ucc guc aau ggg ucc cug uuc aca ucc ucc agg cuc uuc uuc gug 1056
Gly Ser Val Asn Gly Ser Leu Phe Thr Ser Ser Arg Leu Phe Phe Val
340 345 350
ggg ucc cgg gaa ggc cac cug ccc ucc auc cuc ucc aug auc cac cca 1104
Gly Ser Arg Glu Gly His Leu Pro Ser Ile Leu Ser Met Ile His Pro
355 360 365
cag cuc cuc acc ccc gug ccg ucc cuc gug uuc acg ugu gug aug acg 1152
Gln Leu Leu Thr Pro Val Pro Ser Leu Val Phe Thr Cys Val Met Thr
370 375 380
cug cuc uac gcc uuc ucc aag gac auc uuc ucc guc auc aac uuc uuc 1200
Leu Leu Tyr Ala Phe Ser Lys Asp Ile Phe Ser Val Ile Asn Phe Phe
385 390 395 400
agc uuc uuc aac ugg cuc ugc gug gcc cug gcc auc auc ggc aug auc 1248
Ser Phe Phe Asn Trp Leu Cys Val Ala Leu Ala Ile Ile Gly Met Ile
405 410 415
ugg cug cgc cac aga aag ccu gag cuu gag cgg ccc auc aag gug aac 1296
Trp Leu Arg His Arg Lys Pro Glu Leu Glu Arg Pro Ile Lys Val Asn
420 425 430
cug gcc cug ccu gug uuc uuc auc cug gcc ugc cuc uuc cug auc gcc 1344
Leu Ala Leu Pro Val Phe Phe Ile Leu Ala Cys Leu Phe Leu Ile Ala
435 440 445
25/32
CA 02341777 2001-08-27
guc ucc uuc ugg aag aca ccc gug gag ugu ggc auc ggc uuc acc auc 1392
Val Ser Phe Trp Lys Thr Pro Val Glu Cys Gly Ile Gly Phe Thr Ile
450 455 460
auc cuc agc ggg cug ccc guc uac uuc uuc ggg guc ugg ugg aaa aac 1440
Ile Leu Ser Gly Leu Pro Val Tyr Phe Phe Gly Val Trp Trp Lys Asn
465 470 475 480
aag ccc aag ugg cuc cuc cag ggc auc uuc ucc acg acc guc cug ugu 1488
Lys Pro Lys Trp Leu Leu Gln Gly Ile Phe Ser Thr Thr Val Leu Cys
485 490 495
cag aag cuc aug cag gug guc ccc cag gag aca uag 1524
Gln Lys Leu Met Gln Val Val Pro Gln Glu Thr
500 505
<210> 27
<211> 507
<212> PRT
<213> Homo sapiens
<400> 27
Met Ala Gly Ala Gly Pro Lys Arg Arg Ala Leu Ala Ala Pro Ala Ala
1 5 10 15
Glu Glu Lys Glu Glu Ala Arg Glu Lys Met Leu Ala Ala Lys Ser Ala
20 25 30
Asp Gly Ser Ala Pro Ala Gly Glu Gly Glu Gly Val Thr Leu Gln Arg
35 40 45
Asn Ile Thr Leu Leu Asn Gly Val Ala Ile Ile Val Gly Thr Ile Ile
50 55 60
Gly Ser Gly Ile Phe Val Thr Pro Thr Gly Val Leu Lys Glu Ala Gly
65 70 75 80
Ser Pro Gly Leu Ala Leu Val Val Trp Ala Ala Cys Gly Val Phe Ser
85 90 95
Ile Val Gly Ala Leu Cys Tyr Ala Glu Leu Gly Thr Thr Ile Ser Lys
100 105 110
Ser Gly Gly Asp Tyr Ala Tyr Met Leu Glu Val Tyr Gly Ser Leu Pro
115 120 125
Ala Phe Leu Lys Leu Trp Ile Glu Leu Leu Ile Ile Arg Pro Ser Ser
130 135 140
Gln Tyr Ile Val Ala Leu Val Phe Ala Thr Tyr Leu Leu Lys Pro Leu
145 150 155 160
Phe Pro Thr Cys Pro Val Pro Glu Glu Ala Ala Lys Leu Val Ala Cys
165 170 175
Leu Cys Val Leu Leu Leu Thr Ala Val Asn Cys Tyr Ser Val Lys Ala
180 185 190
26/32
CA 02341777 2001-08-27
Ala Thr Arg Val Gln Xaa Ala Phe Ala Ala Ala Lys Leu Leu Ala Leu
195 200 205
Ala Leu Ile Ile Leu Leu Gly Phe Val Gln Ile Gly Lys Gly Xaa Val
210 215 220
Ser Asn Leu Xaa Pro Asn Phe Ser Phe Glu Gly Thr Lys Leu Xaa Val
225 230 235 240
Gly Asn Ile Val Leu Ala Leu Tyr Ser Gly Leu Phe Ala Tyr Gly Gly
245 250 255
Trp Asn Tyr Leu Asn Phe Val Thr Glu Glu Met Ile Asn Pro Tyr Arg
260 265 270
Asn Leu Pro Leu Ala Ile Ile Ile Ser Leu Pro Ile Val Thr Leu Val
275 280 285
Tyr Val Leu Thr Asn Leu Ala Tyr Phe Thr Thr Leu Ser Thr Glu Gln
290 295 300
Met Leu Ser Ser Glu Ala Val Ala Val Asp Phe Gly Asn Tyr His Leu
305 310 315 320
Gly Val Met Ser Trp Ile Ile Pro Val Phe Val Gly Leu Ser Cys Phe
325 330 335
Gly Ser Val Asn Gly Ser Leu Phe Thr Ser Ser Arg Leu Phe Phe Val
340 345 350
Gly Ser Arg Glu Gly His Leu Pro Ser Ile Leu Ser Met Ile His Pro
355 360 365
Gln Leu Leu Thr Pro Val Pro Ser Leu Val Phe Thr Cys Val Met Thr
370 375 380
Leu Leu Tyr Ala Phe Ser Lys Asp Ile Phe Ser Val Ile Asn Phe Phe
385 390 395 400
Ser Phe Phe Asn Trp Leu Cys Val Ala Leu Ala Ile Ile Gly Met Ile
405 410 415
Trp Leu Arg His Arg Lys Pro Glu Leu Glu Arg Pro Ile Lys Val Asn
420 425 430
Leu Ala Leu Pro Val Phe Phe Ile Leu Ala Cys Leu Phe Leu Ile Ala
435 440 445
Val Ser Phe Trp Lys Thr Pro Val Glu Cys Gly Ile Gly Phe Thr Ile
450 455 460
Ile Leu Ser Gly Leu Pro Val Tyr Phe Phe Gly Val Trp Trp Lys Asn
465 470 475 480
Lys Pro Lys Trp Leu Leu Gln Gly Ile Phe Ser Thr Thr Val Leu Cys
485 490 495
Gln Lys Leu Met Gln Val Val Pro Gln Glu Thr
500 505
27/32
CA 02341777 2001-08-27
<210> 28
<211> 1590
<212> RNA
<213> Homo sapiens
<220>
<221> CDS
<222> (1)..(1590)
<400> 28
aug agc cag gac acc gag gug gau aug aag gag gug gag cug aau gag 48
Met Ser Gln Asp Thr Glu Val Xaa Met Lys Glu Val Glu Leu Asn Glu
1 5 10 15
uua gag ccc gag aag cag ccg aug aac gcg gcg ucu ggg gcg gcc aug 96
Leu Glu Pro Glu Lys Gln Pro Met Asn Ala Ala Ser Gly Ala Ala Met
20 25 30
ucc cug gcg gga gcc gag aag aau ggu cug gug aag auc aag gug gcg 144
Ser Leu Ala Gly Ala Glu Lys Asn Gly Leu Val Lys Ile Lys Val Ala
35 40 45
gaa gac gag gcg gag gcg gca gcc gcg gcu aag uuc acg ggc cug ucc 192
Glu Asp Glu Ala Glu Ala Ala Ala Ala Ala Lys Phe Thr Gly Leu Ser
50 55 60
aag gag gag cug cug aag gug gca ggc agc ccc ggc ugg gua cgc acc 240
Lys Glu Glu Leu Leu Lys Val Ala Gly Ser Pro Gly Trp Val Arg Thr
65 70 75 80
cgc ugg gca cug cug cug cuc uuc ugg cuc ggc ugg cuc ggc aug cuu 288
Arg Trp Ala Leu Leu Leu Leu Phe Trp Leu Gly Trp Leu Gly Met Leu
85 90 95
gcu ggu gcc gug guc aua auc gug cga gcg ccg cgu ugu cgc gag cua 336
Ala Gly Ala Val Val Ile Ile Val Arg Ala Pro Arg Cys Arg Glu Leu
100 105 110
ccg gcg cag aag ugg ugg cac acg ggc gcc cuc uac cgc auc ggc gac 384
Pro Ala Gln Lys Trp Trp His Thr Gly Ala Leu Tyr Arg Ile Gly Asp
115 120 125
cuu cag gcc uuc cag ggc cac ggc gcg ggc aac cug gcg ggu cug aag 432
Leu Gln Ala Phe Gln Gly His Gly Ala Gly Asn Leu Ala Gly Leu Lys
130 135 140
ggg cgu cuc gau uac cug agc ucu cug aag gug aag ggc cuu gug cug 480
Gly Arg Leu Xaa Tyr Leu Ser Ser Leu Lys Val Lys Gly Leu Val Leu
145 150 155 160
ggu cca auu cac aag aac cag aag gau gau guc gcu cag acu gac uug 528
Gly Pro Ile His Lys Asn Gln Lys Xaa Xaa Val Ala Gln Xaa Asp Leu
165 170 175
cug cag auc gac ccc aau uuu ggc ucc aag gaa gau uuu gac agu cuc 576
Leu Gln Ile Asp Pro Asn Phe Gly Ser Lys Glu Xaa Phe Asp Ser Leu
180 185 190
28/32
CA 02341777 2001-08-27
uug caa ucg gcu aaa aaa aag agc auc cgu guc auu cug gac cuu acu 624
Leu Gln Ser Ala Lys Lys Lys Ser Ile Arg Val Ile Leu Asp Leu Xaa
195 200 205
ccc aac uac cgg ggu gag aac ucg ugg uuc ucc acu cag guu gac acu 672
Pro Asn Tyr Arg Gly Glu Asn Ser Trp Phe Ser Xaa Gln Val Asp Xaa
210 215 220
gug gcc acc aag gug aag gau gcu cug gag uuu ugg cug caa gcu ggc 720
Val Ala Thr Lys Val Lys Xaa Ala Leu Glu Phe Trp Leu Gln Ala Gly
225 230 235 240
gug gau ggg uuc cag guu cgg gac aua gag aau cug aag gau gca ucc 768
Val Xaa Gly Phe Gln Val Arg Asp Ile Glu Asn Leu Lys Xaa Ala Ser
245 250 255
uca uuc uug gcu gag ugg caa aau auc acc aag ggc uuc agu gaa gac 816
Ser Phe Leu Ala Glu Trp Gln Asn Ile Thr Lys Gly Phe Ser Glu Asp
260 265 270
agg cuc uug auu gcg ggg acu aac ucc ucc gac cuu cag cag auc cug 864
Arg Leu Leu Ile Ala Gly Xaa Asn Ser Ser Asp Leu Gln Gln Ile Leu
275 280 285
agc cua cuc gaa ucc aac aaa gac uug cug uug acu agc uca uac cug 912
Ser Leu Leu Glu Ser Asn Lys Asp Leu Leu Leu Xaa Ser Ser Tyr Leu
290 295 300
ucu gau ucu ggu ucu acu ggg gag cau aca aaa ucc cua guc aca cag 960
Ser Xaa Ser Gly Ser Xaa Gly Glu His Thr Lys Ser Leu Val Thr Gln
305 310 315 320
uau uug aau gcc acu ggc aau cgc ugg ugc agc ugg agu uug ucu cag 1008
Tyr Leu Asn Ala Xaa Gly Asn Arg Trp Cys Ser Trp Ser Leu Ser Gln
325 330 335
gca agg cuc cug acu ucc uuc uug ccg gcu caa cuu cuc cga cuc uac 1056
Ala Arg Leu Leu Xaa Ser Phe Leu Pro Ala Gln Leu Leu Arg Leu Tyr
340 345 350
cag cug aug cuc uuc acc cug cca ggg acc ccu guu uuc agc uac ggg 1104
Gln Leu Met Leu Phe Thr Leu Pro Gly Thr Pro Val Phe Ser Tyr Gly
355 360 365
gau gag auu ggc cug gau gca gcu gcc cuu ccu gga cag ccu aug gag 1152
Xaa Glu Ile Gly Leu Xaa Ala Ala Ala Leu Pro Gly Gln Pro Met Glu
370 375 380
gcu cca guc aug cug ugg gau gag ucc agc uuc ccu gac auc cca ggg 1200
Ala Pro Val Met Leu Trp Xaa Glu Ser Ser Phe Pro Asp Ile Pro Gly
385 390 395 400
gcu gua agu gcc aac aug acu gug aag ggc cag agu gaa gac ccu ggc 1248
Ala Val Ser Ala Asn Met Xaa Val Lys Gly Gln Ser Glu Asp Pro Gly
405 410 415
ucc cuc cuu ucc uug uuc cgg cgg cug agu gac cag cgg agu aag gag 1296
Ser Leu Leu Ser Leu Phe Arg Arg Leu Ser Asp Gln Arg Ser Lys Glu
420 425 430
29/32
CA 02341777 2001-08-27
cgc ucc cua cug cau ggg gac uuc cac gcg uuc ucc gcu ggg ccu gga 1344
Arg Ser Leu Leu His Gly Asp Phe His Ala Phe Ser Ala Gly Pro Gly
435 440 445
cuc uuc ucc uau auc cgc cac ugg gac cag aau gag cgu uuu cug gua 1392
Leu Phe Ser Tyr Ile Arg His Trp Asp Gln Asn Glu Arg Phe Leu Val
450 455 460
gug cuu aac uuu ggg gau gug ggc cuc ucg gcu gga cug cag gcc ucc 1440
Val Leu Asn Phe Gly Xaa Val Gly Leu Ser Ala Gly Leu Gln Ala Ser
465 470 475 480
gac cug ccu gcc agc gcc agc cuc cca gcc aag gcu gac cuc cug cuc 1488
Asp Leu Pro Ala Ser Ala Ser Leu Pro Ala Lys Ala Asp Leu Leu Leu
485 490 495
agc acc cag cca ggc cgu gag gag ggc ucc ccu cuu gag cug gaa cgc 1536
Ser Thr Gln Pro Gly Arg Glu Glu Gly Ser Pro Leu Glu Leu Glu Arg
500 505 510
cug aaa cug gag ccu cac gaa ggg cug cug cuc cgc uuc ccc uac gcg 1584
Leu Lys Leu Glu Pro His Glu Gly Leu Leu Leu Arg Phe Pro Tyr Ala
515 520 525
gcc uga 1590
Ala
530
<210> 29
<211> 529
<212> PRT
<213> Homo sapiens
<400> 29
Met Ser Gln Asp Thr Glu Val Xaa Met Lys Glu Val Glu Leu Asn Glu
1 5 10 15
Leu Glu Pro Glu Lys Gln Pro Met Asn Ala Ala Ser Gly Ala Ala Met
20 25 30
Ser Leu Ala Gly Ala Glu Lys Asn Gly Leu Val Lys Ile Lys Val Ala
35 40 45
Glu Asp Glu Ala Glu Ala Ala Ala Ala Ala Lys Phe Thr Gly Leu Ser
50 55 60
Lys Glu Glu Leu Leu Lys Val Ala Gly Ser Pro Gly Trp Val Arg Thr
65 70 75 80
Arg Trp Ala Leu Leu Leu Leu Phe Trp Leu Gly Trp Leu Gly Met Leu
85 90 95
Ala Gly Ala Val Val Ile Ile Val Arg Ala Pro Arg Cys Arg Glu Leu
100 105 110
Pro Ala Gln Lys Trp Trp His Thr Gly Ala Leu Tyr Arg Ile Gly Asp
115 120 125
Leu Gln Ala Phe Gln Gly His Gly Ala Gly Asn Leu Ala Gly Leu Lys
30/32
CA 02341777 2001-08-27
130 135 140
Gly Arg Leu Xaa Tyr Leu Ser Ser Leu Lys Val Lys Gly Leu Val Leu
145 150 155 160
Gly Pro Ile His Lys Asn Gln Lys Xaa Xaa Val Ala Gln Xaa Asp Leu
165 170 175
Leu Gln Ile Asp Pro Asn Phe Gly Ser Lys Glu Xaa Phe Asp Ser Leu
180 185 190
Leu Gln Ser Ala Lys Lys Lys Ser Ile Arg Val Ile Leu Asp Leu Xaa
195 200 205
Pro Asn Tyr Arg Gly Glu Asn Ser Trp Phe Ser Xaa Gln Val Asp Xaa
210 215 220
Val Ala Thr Lys Val Lys Xaa Ala Leu Glu Phe Trp Leu Gln Ala Gly
225 230 235 240
Val Xaa Gly Phe Gln Val Arg Asp Ile Glu Asn Leu Lys Xaa Ala Ser
245 250 255
Ser Phe Leu Ala Glu Trp Gln Asn Ile Thr Lys Gly Phe Ser Glu Asp
260 265 270
Arg Leu Leu Ile Ala Gly Xaa Asn Ser Ser Asp Leu Gln Gln Ile Leu
275 280 285
Ser Leu Leu Glu Ser Asn Lys Asp Leu Leu Leu Xaa Ser Ser Tyr Leu
290 295 300
Ser Xaa Ser Gly Ser Xaa Gly Glu His Thr Lys Ser Leu Val Thr Gln
305 310 315 320
Tyr Leu Asn Ala Xaa Gly Asn Arg Trp Cys Ser Trp Ser Leu Ser Gln
325 330 335
Ala Arg Leu Leu Xaa Ser Phe Leu Pro Ala Gln Leu Leu Arg Leu Tyr
340 345 350
Gln Leu Met Leu Phe Thr Leu Pro Gly Thr Pro Val Phe Ser Tyr Gly
355 360 365
Xaa Glu Ile Gly Leu Xaa Ala Ala Ala Leu Pro Gly Gln Pro Met Glu
370 375 380
Ala Pro Val Met Leu Trp Xaa Glu Ser Ser Phe Pro Asp Ile Pro Gly
385 390 395 400
Ala Val Ser Ala Asn Met Xaa Val Lys Gly Gln Ser Glu Asp Pro Gly
405 410 415
Ser Leu Leu Ser Leu Phe Arg Arg Leu Ser Asp Gln Arg Ser Lys Glu
420 425 430
Arg Ser Leu Leu His Gly Asp Phe His Ala Phe Ser Ala Gly Pro Gly
435 440 445
Leu Phe Ser Tyr Ile Arg His Trp Asp Gln Asn Glu Arg Phe Leu Val
31/32
CA 02341777 2001-08-27
450 455 460
Val Leu Asn Phe Gly Xaa Val Gly Leu Ser Ala Gly Leu Gln Ala Ser
465 470 475 480
Asp Leu Pro Ala Ser Ala Ser Leu Pro Ala Lys Ala Asp Leu Leu Leu
485 490 495
Ser Thr Gln Pro Gly Arg Glu Glu Gly Ser Pro Leu Glu Leu Glu Arg
500 505 510
Leu Lys Leu Glu Pro His Glu Gly Leu Leu Leu Arg Phe Pro Tyr Ala
515 520 525
Ala
530
32/32
